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α-Isopropylmalate synthase (IPMS) catalyses the first committed step in the leucine biosynthesis 
pathway in microorganisms and some plants. It catalyses the condensation of ketoisovalerate 
(KIV) and acetyl-coenzyme A (AcCoA) to form isopropylmalate and coenzyme A (CoA). IPMS is 
allosterically inhibited by the product of the pathway, L-leucine. Structurally, IPMS is a homodimer, 
and each chain consists of a N-terminal (α/β)8 barrel where the active site is located, a catalytic 
accessory unit formed of subdomain I and subdomain II, and a C-terminal regulatory domain that 
binds L-leucine. Truncation of IPMS that removes subdomain II or part of subdomain II abolishes 
catalysis.1, 2 
Of particular interest in this thesis is IPMS from Neisseria meningitidis (NmeIPMS). Although this 
enzyme has been extensively studied, there is no full-length crystal structure available, although 
there are several of a related enzyme, IPMS from Mycobacterium tuberculosis (MtuIPMS), with KIV, 
and with L-leucine, bound. There is no substantial conformational change observed when the 
substrate-bound crystal structure is compared to the structure with L-leucine bound. Untangling 
the dynamic nature of allostery, and how it has evolved, in these proteins is a particular focus of 
this thesis.  
There are also structurally similar proteins that catalyse similar reactions that are also of interest. 
Citramalate synthase (CMS) is structurally similar to IPMS but catalyses the reaction of pyruvate 
and AcCoA to form citramalate and CoA in an isoleucine biosynthesis pathway and is inhibited by 
L-isoleucine. Homocitrate synthase (HCS) functions in a lysine biosynthesis pathway in some 
organisms and utilises ketoglutarate and AcCoA to form homocitrate and CoA. HCS contains a 
homologous catalytic domain and catalytic accessory unit as IPMS but lacks a regulatory domain 
and is competitively inhibited by lysine. The similarities, differences, and modularity of these 
proteins is explored using computational methods and also by the construction of truncated and 
fusion proteins. 
Chapter 2 utilises a computational method, statistical coupling analysis, to identify a potential 
network in NmeIPMS-like IPMS proteins. Subsequent alanine mutations in NmeIPMS 
demonstrated that mutating charged residues in this proposed network can abolish or attenuate 
the allosteric signal, suggesting that the network identified may represent a way the allosteric signal 
is transferred from the allosteric site to the active site. Isothermal titration calorimetry is also used 
to explore the thermodynamics of L-leucine binding to the wild-type NmeIPMS and to the L-
leucine insensitive alanine mutants. 
Chapter 3 broadens the scope of statistical coupling analysis (SCA) and also uses another 
computational method, mutual information (MI), to investigate how structurally similar 
subdomains facilitate catalysis in the presence and absence of a regulatory domain. A population 
of proteins that contain a regulatory domain, and a population that do not, were assessed using 
SCA and MI to determine whether there were differences, particularly in the subdomains, that may 
provide information about maintenance of the balance of flexibility and stability that is crucial to 
catalysis in these proteins.  
Chapter 4 uses an active, truncated, form of NmeIPMS to compare and contrast with the wild-type 
protein. The kinetics of both the truncated NmeIPMS and the wild-type NmeIPMS are investigated 
under crowded conditions to explore the impact that viscosity has on these dynamic proteins. 
Alanine mutations are also made in subdomains I and II to investigate the role of particular 
residues in catalysis and allostery, and these allow comparison with previous work done on 
MtuIPMS that highlights the difference between two structurally similar groups of IPMS proteins.  
Chapter 5 describes the cloning, expression, and partial purification of an HCS, SsoHCS, from 
Sulfolobus solfataricus that appears to have a different type of regulatory domain to the canonical 
IPMS/CMS regulatory domain. The partial characterisation of this protein suggests that an 
allosterically regulated HCS has been identified. Chapter 5 also describes the construction of 
several fusion proteins, where parts of IPMS, HCS, and CMS, are fused to together to explore the 
modularity of these proteins. Catalysis was preserved in some of the fusions although allostery was 
not preserved in any so far investigated.  
The final chapter includes a broad summary of the work in this thesis as well as ideas for future 
research. This chapter also contains a discussion about the considerable differences between some 
IPMS enzymes that, although they catalyse the same reaction, are considerably different 
taxonomically. Additionally, the important role of networks of residues that facilitate catalysis and 
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Chapter 1: Introduction  
 
1.1 Protein dynamics and their importance  
 
Proteins were once thought to be static entities, an idea propagated by the fixed models produced 
by X-ray crystallography that did not represent the dynamic nature of proteins in the cellular 
context. It is now apparent that proteins are inherently conformationally flexible through a 
combination of thermodynamic movement and coordinated motion that can be crucial for 
processes such as catalysis and allostery.3-6 Intrinsic protein dynamics can also be important for 
protein-protein interaction.7  
 
1.1.1 Types of protein motion 
 
The time scale upon which proteins move can vary depending on the nature of the motion (Figure 
1.1). At the fastest extreme of currently investigated motion is local flexibility, which is typically 
on the femto-second to pico-second timescale.8 This type of motion can be revealed via the B-
factors in high-resolution X-ray crystallography and by nuclear magnetic resonance (NMR).9 Local 
flexibility can be described as highly localised, low energy, movement of the backbone atoms, 
particularly the Cα-Cβ bond, to allow for plasticity in side-chain movement. Moving further down 
the time scale includes loop motions that can occur over a longer timescale than local flexibility. 
The movement of flexible loops can be crucial for catalysis, as observed in dihydrofolate reductase 
from Escherichia coli where the movement of the loop region plays a key role in switching between 
the five kinetic intermediate states during catalysis.10 Loop regions can have additional roles, such 
as in the M2 muscarinic acetylcholine receptor, a G-protein coupled receptor, where a flexible loop 
acts as a gatekeeper for both the allosteric and orthosteric ligands.11 
 
Multi-domain proteins can also undergo domain motions where domains, typically attached by 
flexible loops or linkers, can move relative to each other. These motions can be important for 
allosteric regulation. One example is found in the 3-deoxy-D-arabino-heptulosonate 7-phosphate 
synthase from Thermotoga maritima, where the regulatory domains shift upon binding of the 
allosteric inhibitor, tyrosine, to physically block access to the active site.12 The motion of MurD, 
part of the peptidoglycan biosynthesis pathway in some bacteria, also demonstrates large scale 
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domain motion that was previously thought to be tied to ligand binding but may also be 




Figure 1.1: A timescale of the types of motion observed in proteins. 
 
1.1.2 Methods used to study protein dynamics 
 
The biophysical study of protein dynamics is intricate and difficult. One of the most successful 
techniques uses nuclear magnetic resonance, or NMR, in a variety of ways to uncover how proteins 
move in solution. Backbone dynamics can be investigated using amide 15N and 1H  order 
parameters as this provides information about interactions such as hydrogen bond formation, 
while spin-lock and Carr-Purcell-Meiboom-Gill methods can provide information about slower 
motion such as the movement of loops.13, 14 Relaxation dispersion techniques are commonly used 
to study dynamics in proteins typically in the micro-millisecond timescale.15 One recent example 
used 15N and 1H relaxation dispersion measurements to investigate the motion of a “dynamic 
mutant” of E. coli dihydrofolate reductase with different ligands bound, demonstrating that the 
two types of measurements can provide different information about protein motion.16  
 
Molecular dynamics simulations (MD), a computational tool that meshes chemistry and physics to 
simulate the movement of proteins at the atomic level, has been used extensively to probe how 
proteins move and to predict changes in conformation and dynamics upon ligand binding.17 In 
one recent example, cryo-electron microscopy (cryo-EM) and large-scale molecular dynamics were 
combined to provide all-atom models for the HIV-1 capsid in several morphologies, 
demonstrating how MD can complement static methods, such as cryo-EM or X-ray 
crystallography, to provide a more complete picture of how a protein functions.18 Covariance 
analyses, such as statistical coupling analysis, has also been combined with MD to investigate how 




Fluorescence resonance energy transfer (FRET) has been used to study large-scale domain 
rearrangements. FRET utilises donor and acceptor molecules that have been covalently linked to 
the protein of interest, and, if the molecules are close enough to one another, upon excitation of 
the donor molecule, the acceptor molecule fluoresces, which enables the measurement of 
conformational dynamics and distances in the protein.20 Typically, this is achieved using an 
averaged population which presents difficulty in interpretation, but single molecule FRET, where 
the FRET signal of one molecule can be resolved, has been developed to overcome the problems 
of ensemble FRET.20     
1.1.3 Dynamics and drug development 
 
The study of protein dynamics is crucial for the development of new drugs. Mauldin et al.21 used 
NMR spectroscopy to demonstrate that the binding of two inhibitors to dihydrofolate reductase 
altered the dynamics of a region distant to the active site, where the cofactor, NADH, binds. This 
prevented the interchange between NADH and NAD+, and thus disrupted enzyme catalysis. This 
demonstrates how drug binding may have wide ranging impacts on a protein that are not easily 
detectable by techniques that directly investigate drug binding, such as fragment-based lead 
discovery or isothermal titration calorimetry (ITC), a point echoed by Peng et al.22 who suggested 
that flexibility-function studies may provide new opportunities for drug design.  
 
The role of protein dynamics in drug resistance is also becoming increasingly apparent. Podust et 
al.23 determined the structure of Mycobacterium tuberculosis cytochrome P450 14α-sterol demethylase 
(MtuCYP51) with azole inhibitors bound. CYP51 is an anti-fungal drug target, but mutations in 
this protein in clinically relevant species such as Candida albicans have led to drug resistance. In the 
above study, the authors mapped mutations from naturally occurring azole resistant strains from 
C. albicans onto the MtuCYP51 structure and showed that the mutations that conferred resistance 
to the drugs were in regions that allowed CYP51 to move through its dynamic catalytic cycle. Drug 
resistance in HIV protease also developed at sites distant from the inhibitor binding site that affect 
protein dynamics.24 Mutations conferring resistance occur in a region that is important for the 
large-scale conformational changes of the catalytic cycle of the HIV protease, and these mutations 
disrupt the motion of the enzyme, favouring the open and un-liganded conformation. This 
increases the off-rate of a competitive inhibitor, allowing the substrate sufficient time to bind and 




1.1.4 The evolution of protein dynamics 
 
Protein dynamics are also critical for the evolution of new functions. One example of the 
essentiality of the evolution of dynamics is shown by the somatic evolution of antibodies. Affinity 
maturation, a process of somatic hypermutation and clonal selection, produces antibodies with 
increased affinity for an antigen.25 Zimmerman et al.26 explored the evolution from germ-line to 
mature antibodies in terms of the dynamics of the antibodies themselves. Mature antibodies tended 
to have mutations that induced hydrogen-bonding as well as packing interactions in particular 
locations. This leads to the rigidification of the combining site aiding the specificity and affinity of 
the antibody binding to the antigen. Adhikary et al.27 also investigated the dynamics of antibodies, 
specifically in terms of their evolution. They showed that there were similarities in dynamics in 
most of the mature antibodies that came from different germ-line precursors, suggesting that 
altering the dynamics of the antibody is key for their evolution to be more specific, and to show 
more affinity, for a particular antigen. Additionally, a pair of antibodies from the same germ-line 
precursor produced one flexible and one significantly rigid pair of antibodies, and the rigid 
antibody bound the antigen with considerably higher affinity.  
 
Another example of how protein dynamics can tune the evolution of new functions can be found 
in malate dehydrogenase and lactate dehydrogenase from Apicomplexa.28 Although malate 
dehydrogenase and lactate dehydrogenase in Apicomplexa are similar in structure and catalyse the 
same type of chemistry, there is strict substrate specificity in their respective active sites. Through 
ancestral protein reconstruction and structural characterisation, it was shown that protein 
dynamics were key in evolution of malate dehydrogenase function from that of lactate 
dehydrogenase, as epistatic mutations far from the active site altered the dynamics of the active 




1.2 Allosteric regulation 
 
Allostery is simply defined as the process by which ligand binding at one site affects the function 
at a distant site.29 Allosteric regulation is found in all types of self-replicating organisms.30 Allosteric 
regulation of enzyme function by products of a metabolic pathway can commonly be found at 
control points. These points are typically near the start of a pathway, and can provide feedback 
regulation to the pathway.31  Regulation of metabolism is key to organismal survival but flux-
balance analysis, a computational approach, suggests that near-optimal survival bacterial growth 
can be achieved by simple product feedback inhibition or activation.32 This demonstrates that 
allosteric control by feedback inhibition is both key to organismal survival, and part of a fascinating 
evolutionary process.  
Three ways proteins can develop allosteric regulation have been proposed.30 The first involves 
utilisation of loops or other dynamic parts of a protein that can form new binding sites for allosteric 
effectors. This was demonstrated by Mathonet et al.33 where allosteric regulation by transition 
metal ions was introduced into an unregulated monomeric protein by insertion of random peptides 
into flexible loops followed by rounds of selection. The second is the formation of multi-subunit 
proteins, which allows communication between subunits and the potential for formation of 
binding sites for allosteric effectors.30 The third way that proteins may evolve allosteric regulation 
is by domain swapping, caused by gene fusion events, where an unregulated enzyme recruits a 
domain that can bind a small molecule and interact with the catalytic domain.34 Allosteric control 
can be introduced to unregulated enzymes by domain fusion events.35, 36  
Guntas et al.37 demonstrated the ease by which an allosteric enzyme could form by domain 
insertion of TEM-1 β-lactamase fragments into E. coli maltose binding protein (MBP), in which 
the β-lactamase activity was modulated by the ligand of the MBP protein. A domain insertion 
library was constructed in which a fragment of the lactamase gene was randomly inserted into a 
vector containing the malE gene, and selection was performed using an MBP auxotroph E. coli 
strain. Bi-functionality, followed by allostery, was then assessed. There were several allosteric 
enzymes identified, for example, an essentially end-to-end fusion that exhibited approximately 
50% increased lactamase activity in the presence of maltose, as well as several mutants where the 




1.2.1 The evolution of allosteric regulation 
 
The evolution and conservation of allosteric regulation is a topic of hot debate. Allosteric 
mechanisms across a protein family may or may not be conserved depending on the protein family. 
Flock et al.38 determined that, although there has been significant divergence in the GPCRs and 
their associated Gα proteins, there is a conserved mechanism of allostery that GPCRs utilise, and 
the authors identified key residues for allostery. A mutant analysis of Langerin, a C-type lectin 
receptor, discovered a network of evolutionarily conserved residues that are associated with Ca2+ 
binding, an essential co-factor that binds allosterically in a pH-dependent manner.39 A 
computational approach looking at three bacterial CheY structures determined there was both 
conservation and variability in the allosteric response.40 Indeed, although the E. coli and Salmonella 
typhimurium CheY sequences and structures share close similarity, there is a substantial difference 
in the identified hydrogen-bond network, suggesting that the underlying thermodynamic 
mechanism of allostery has evolved differently in the two examples. Clearly, further research is 
needed to understand the mechanisms of allostery in a variety of systems, especially with the advent 
of computational tools and the availability of sequence information. 
1.2.2 Allostery and dynamics  
 
Allosteric regulation and protein dynamics are intimately entwined. There are numerous examples 
of proteins that have altered dynamics in the presence of an allosteric ligand, sometimes in the 
absence of a conformational change. Tsai et al.29 suggests that there are three types of allostery: 
one governed by entropy, one by both enthalpy and entropy, and one by predominantly by 
enthalpy, and the different types of allostery can  produce different dynamics.  
The first type of dynamics-driven allostery defined by Tsai et al.29 is entropy-driven and is tied to 
a change in the overall dynamics of the system, such as increased rigidity or flexibility. There are 
numerous examples of purely entropy-driven allostery, but one key example is the binding of 
cAMP (cyclic AMP) to catabolite activator protein (CAP).41 CAP is dimeric with two cAMP active 
sites, and the binding of cAMP to one active site alters the binding of a second cAMP to the other 
active site, an example of negative cooperativity. Two cAMP molecules bound to CAP increase 
the affinity of the protein to DNA, thus acting as allosteric effectors.41 Popovych et al.41 
demonstrated that the negative cooperativity demonstrated by the binding of cAMP was solely as 
the result of changes in conformational entropy, namely the rigidification of CAP that negatively 




Figure 1.2: The three broad categories of changes in dynamics caused by allosteric ligand binding. 1. represents an overall change 
in dynamics without conformational change, while 2. represents changes in both dynamics and conformation, and 3. represents 
only a change in conformation 
 
The second type of dynamic allostery combines both largely enthalpy-driven conformational 
change and changes to the intrinsic dynamics of the system that are entropically driven. One 
interesting example of this type of allostery is protein kinase A.42 This protein exists in three major 
conformations depending on nucleotide binding. The overall energy landscape of protein kinase 
A is fairly broad, while the binding of allosteric inhibitors locks the protein into defined 
conformations, demonstrating changes in both wide-scale conformation and local dynamics.  
The third type of allostery is characterised by large scale conformational change that alters the 
conformation of or access to the active site. One example is mammalian glutamate dehydrogenase 
(GDH) where the allosteric inhibitor GTP binds near a hinge region that separates the cofactor 
and substrate binding domains and traps the enzyme in a conformation that prevents opening of 
the catalytic cleft.43  
Dynamically-driven allostery shows that allostery may still be occurring, even though a 
conformational change may not be detectable by methods such as X-ray crystallography.29  Indeed, 
Gunasekaran et al..44 argue that all dynamic proteins may be allosteric. This underlies the growing 
importance of dynamics in understanding allosteric regulation, and also how little is known about 
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how changes in conformational states can alter catalytic activity, especially upon binding of 
allosteric ligands at a distance from the active site. 
1.2.3 Allosteric sites as drug targets 
 
Conventionally, the active site has been the primary target of drug design. These compounds are 
termed orthosteric drugs. However, allosteric sites have also been proposed as drug targets. There 
are some advantages to allosteric drugs over orthosteric drugs. One key area in research into 
allosteric drugs is G-protein coupled receptors.45, 46 As allosteric sites are typically less conserved 
than the active site, this can aid in the specificity of drug design to target a particular protein 
family.47 Two types of G-protein coupled receptors, M2 and M3, showed a response to a particular 
drug, either inhibitory (M3) or activating (M2). A third type of receptor, M4, does not show an 
allosteric response even though it was shown that the receptor was binding the drug.47 This 
demonstrates how one allosteric drug can produce a different response depending on the target. 
A study into the G-protein coupled receptor GLP-1 also showed what is termed ligand-induced 
stimulus bias, where different ligands binding to the receptor cause the receptor to adopt different 
conformations, and therefore produce different downstream signalling profiles.48 The difference 
in response to the same drug shows how allosteric drugs could be used to mediate a specific 
downstream response. Allosteric sites can also be used to alter the activity at the active site, while 
orthosteric drugs typically abolish catalytic activity.49 Allosteric and orthosteric drugs can also be 
used in combination to elicit the response required.50 
There are several disadvantages to allosteric drug design, both biological and technical. As 
mentioned above, allosteric sites may be subjected to increased evolved resistance as the allosteric 
sites are typically less conserved.  Also, small chemical differences in allosteric ligands can cause a 
major difference in allosteric response and subsequent downstream signalling, as found in the 
mGluR G-protein coupled receptors, where different allosteric drugs cause major differences 
downstream, complicating allosteric drug design.51 Additionally, allosteric sites can be shallow, 
which provides challenges for the rational design of inhibitors due to problems with binding 
affinity of the allosteric ligand.49 
Although there are significant issues to overcome in the development of allosteric inhibitors, they 
provide a new avenue to pursue in the development of new drugs. One particularly interesting 
example is the allosteric inhibition of the penicillin-binding protein 2 (PBP2a) from methicillin-
resistant Staphylococcus aureus (MRSA).52 This enzyme provides antibiotic resistance to β-lactam 
antibiotics (such as methicillin) to MRSA, and it was discovered that it is also allosteric, as 
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peptidoglycan binds at a site distant from the active site, that allows opening of the active site to 
facilitate substrate binding.53, 54 In silico docking studies identified a class of compounds, the 
quinazolinones, that have potent activity against MRSA.55 Further investigation into allosteric drug 
targets may provide additional weapons to fight the growing threat of antimicrobial resistance.   
Although there is an intimate link between protein dynamics in various forms and allosteric 
regulation, there is a lack of knowledge about how such allosteric pathways have evolved, and how 
dynamics can drive evolution in different types of systems under varied evolutionary pressures. If 
allosteric drugs are going to provide an alternative to traditional orthosteric drugs, more research 
is needed to understand the evolution of protein dynamics, especially in relation to allosteric 
regulation. One such enzyme, where allostery appears to be driven by dynamics in the absence of 





1.3 Isopropylmalate synthase (IPMS) 
 
 
Figure 1.3: The chemical reaction catalysed by IPMS. 
 
α-Isopropylmalate synthase (IPMS) catalyses the first committed step of leucine biosynthesis in 
microorganisms, utilising ketoisovalerate (KIV) and acetyl co-enzyme A (AcCoA) to form 
isopropylmalate (IPM) and CoA (Figure 1.3). The leucine biosynthetic pathway is essential to the 
proliferation of microorganisms, and its absence in higher eukaryotes, makes IPMS is a promising 
target in the search for new antibiotics.56 Leucine auxotrophy in Mycobacterium tuberculosis (Mtu) 
reduces virulence and, when immune deficient mice have been infected with a leucine auxotroph 
strain of M. tuberculosis, this infection provides protection against subsequent infection.57 As with 
most pathogens, macrophages engulf Mycobacteria upon infection. Mycobacteria can then alter the 
environment of the phagosome, allowing for bacterial replication inside the macrophage.58 Bange 
et al.59 determined that a leucine auxotrophic Mycobacterium bovis BCG strain could not replicate 
inside cultured macrophages, showing why this strain could not grow within mice. The essentiality 
of leucine biosynthesis has also been demonstrated in E. coli, and in Methanococcus maripaludis, where 
it was shown that leucine auxotrophy can be produced by knocking out the leuA gene that codes 
for IPMS.60, 61 IPMS has thus been proposed as a putative drug target, especially in M. tuberculosis.62 
IPMS catalyses a Claisen-like condensation reaction between KIV and AcCoA to produce 
isopropylmalate (Figure 1.3).63 All IPMS enzymes  characterised thus far require a divalent metal 
ion for catalysis.64 As with many metabolic pathways, as IPMS catalyses the first committed step 
of the pathway, it is feedback inhibited by L-leucine, the end-product of the pathway.  IPMS is 
allosterically regulated by L-leucine binding to the C-terminal regulatory domain, inhibiting 
catalysis. IPMS is also inhibited by CoA, a product of the reaction, in organisms such as 
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Saccharomyces cerevisiae.65 The gene that encodes IPMS, leuA, is also under transcriptional control by 
L-leucine, as demonstrated by experiments in both E. coli and Salmonella typhimurium.66  
1.3.1 The crystal structure of Mycobacterium tuberculosis IPMS 
 
The crystal structure of IPMS from M. tuberculosis (MtuIPMS) has been solved, and this provides a 
basis for further study of this type of enzyme.67 However, this is the only full-length IPMS structure 
that has been solved, and there are significant phylogenetic differences between the ‘IPMS2’ 
(MtuIPMS-like IPMSs) and the ‘IPMS1’ (NmeIPMS-like IPMSs) groups.68, 69 There may be 
differences in dynamics between the two groups that are not apparent from the overall structure. 
 
 
Figure 1.4: The structure of MtuIPMS (PDB: 1SR9). The N-terminal extension is shown in purple, the catalytic domain in green, 
subdomain I in blue, subdomain II in red, and the regulatory domain in teal in Chain B. The essential metal ion (spheres) and the 






Figure 1.5: KIV binding in MtuIPMS (PDB: 1SR9). The metal ion and KIV are shown in black. 
 
MtuIPMS is a domain-swapped homodimer with the subunit structure comprised of three main 
components: The N-terminal catalytic domain, which is a triosephosphate isomerase (TIM) (β/α)8-
barrel, two subdomains (subdomains I and II) that form a catalytic accessory unit between the 
catalytic domain, and the C-terminal regulatory domain (Figure 1.4).67 Structures of MtuIPMS with 
bound substrate KIV (PDB: 1SR9) and inhibitor L-leucine (PDB: 3FIG) have been solved, as well 
as several with other non-natural ligands bound in the active site. As of yet, no structure of an 
IPMS has been solved with either CoA or AcCoA bound, nor has the apo structure of MtuIPMS 
been solved. The catalytic domain of MtuIPMS also has an N-terminal extension that contributes 
to dimerization.67 The active site, as with many TIM barrels, is at the C-terminal end of the barrel.70 
C-terminal to the catalytic domain is subdomain I, the first part of the catalytic accessory unit. 
Subdomain I is formed from one long and two short α-helices. The long helix sits across over the 
active site of the other chain and contributes residues to the active site of the opposite chain. 
Subdomain II, the second part of the catalytic accessory unit, is composed of three α-helices that 
form a tight bundle and is connected to subdomain I by a flexible linker that is disordered in both 
the L-leucine bound and KIV bound structures of MtuIPMS. Subdomain II also forms a close 
interaction with the C-terminal regulatory domain, that is formed of a novel (βββα)2 fold, where 
L-leucine binds in the interface of the regulatory domain dimer. In the active site, the essential 
metal ion is co-ordinated by two conserved histidine residues (His285 and His287) and an aspartic 
acid (Asp81) from the conserved LR(D/E)G motif (Figure 1.5). KIV forms interactions with 
Arg80 and Thr254 as well as with the metal ion. Glu218, and Tyr410 and His379 from the other 
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chain also contribute to the active site, and are strongly or completely conserved in IPMS.67 In 
related enzymes, the smaller substrate binds first followed by AcCoA in an ordered fashion, and 
this is likely to occur in IPMS as well.71 There is some capacity in the MtuIPMS active site to bind 
alternative substrates – α-ketobutyrate, α-ketovalerate, and pyruvate have been shown to act as 
poor substrates for the condensation reaction72. Unlike the smaller substrate, MtuIPMS shows 
specificity for AcCoA as the larger substrate.56 
 
Figure 1.6: The kinetic mechanism of MtuIPMS as determined by de Carvalho et al..56 A, B1 and B2 are acidic (A) and basic (B) 
residues in the enzyme active site that are involved in the reaction. 
 
The kinetic mechanism of MtuIPMS has been studied in detail using a variety of techniques (Figure 
1.6).56 These experiments suggested that MtuIPMS uses a non-rapid equilibrium, random, bi-bi 
kinetic mechanism and that there are likely two catalytic bases - one that deprotonates and enolises 
AcCoA and another that hydrolyses the isopropyl-CoA intermediate into the two products. 
Interestingly, solvent isotope labelling experiments suggest that the chemistry of the reaction is 
not the rate-limiting step, and further study suggests that product release may be the rate 





Figure 1.7: The structure of MtuIPMS (PDB: 1SR9).Chain A (left) and Chain B (right) showing the structural asymmetry of the 
dimer. The N-terminal extension is shown in purple, the catalytic domain is shown in green, subdomain I is shown in blue, 
subdomain II is shown in red, and the regulatory domain is shown in teal 
 
The crystal structure of MtuIPMS is asymmetric, meaning that the two chains superimpose poorly 
(Figure 1.7).67 The linker region between subdomains I and II was not resolved in any crystal 
structure of MtuIPMS thus solved. This asymmetry may play important roles in catalysis and the 
allosteric communication pathway between the regulatory domain and the active site.67 It is not 
clear whether the asymmetry is due in part to crystal packing constraints, although it is a 
conformation that is accessible by the protein.74 
 
Figure 1.8: The crystal structure of MtuIPMS (PDB: 1SR9) highlighting residues Arg97 and Asp444. 
 
Point mutations in MtuIPMS at Arg97 and Asp444, located in the catalytic domain and subdomain 
II respectively, were made to investigate the domain-swapped dimer interfaces (Figure 1.8).74 These 
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protein variants both adopted similar solution structures to that of wild-type MtuIPMS in the 
presence and absence of L-leucine, as determined by small angle x-ray scattering (SAXS), but had 
increased catalytic activity and decreased sensitivity to L-leucine compared to the wild-type protein. 
It was suggested that these mutations increased the flexibility at one interface formed by the 
catalytic domain of one chain and subdomain II from the other chain. In the other half of the 
structure, the two residues are approximately 31 Å apart. The increase in flexibility at this interface 
may allow regions important for AcCoA interaction and binding to sample conformations that 
allow AcCoA to bind more readily, thus showing increased catalytic activity compared to the wild 
type protein. The decrease in inhibition by L-leucine may also occur due to the increase in flexibility 
at the interface in this mutant protein.74 
1.3.2 Structures of other IPMSs 
 
Several partial structures of IPMS enzymes have been solved, including the IPMS from Neisseria 
meningitidis (NmeIPMS) (Figure 1.9) truncated at residue Glu365 in subdomain II (PDB 3RMJ), and 
MtuIPMS, which was truncated at residue Val425 in subdomain II (PDB 3U6W).64 The truncated 
enzymes had structurally similar catalytic barrels, both to each other and to the respective full 
length protein, but the structures of the partial subdomains showed substantially more flexibility 
than that of the full-length protein. Neither of these truncated proteins was catalytically active, 
although it was shown that both truncated enzymes could bind KIV.64 
 
Figure 1.9: The structure of a truncation of NmeIPMS (PDB: 3RMJ).The protein was truncated at position Glu365. The metal 
ion is shown in black, denoting the location of the active site, while the catalytic domain is shown in green and part of subdomain 




A full length, but naturally truncated, IPMS structure has also been solved (Figure 1.10).2 The 
‘short form’ IPMS from Leptospira biflexa (LbiIPMS2) does not possess the C-terminal regulatory 
domain, but maintains catalytic activity, although not allosteric regulation by L-leucine. Structurally, 
the TIM barrel is similar to that of MtuIPMS, with KIV bound in a similar position, making the 
same contacts seen in the MtuIPMS active site. Subdomain II adopts a different conformation in 
LbiIPMS2 compared to subdomain II in MtuIPMS. Unlike the asymmetry seen in MtuIPMS, the 
two chains in LbiIPMS2 are symmetrical in the crystal structure. Subdomain II appears to adopt a 
similar conformation to that of Chain A of the MtuIPMS structure but is substantially different to 
that of Chain B of MtuIPMS. Truncations of subdomain II in both the long form (LbiIPMS1) and 
short form (LbiIPMS2) enzymes demonstrated that while the absent C-terminal regulatory domain 
is not required for catalysis, an intact subdomain II is.2  
 
Figure 1.10: The structure of LbiIPMS2 (PDB: 4OV4).One chain is shown in grey. The catalytic domain is shown in green, 
subdomain I is shown in blue, and subdomain II is shown in red. 
 
LbiIPMS1 and LbiIPMS2 also showed cooperativity with regards to the substrates. LbiIPMS2 
demonstrated positive cooperativity towards both KIV and AcCoA, although the cooperativity 
was much more pronounced with AcCoA than KIV.2 Positive cooperativity was less pronounced 
in the long form LbiIPMS1 for which no structure has yet been solved. Cooperativity has also 








Figure 1.11: The position of L-leucine bound to the regulatory domain of MtuIPMS (PDB 3FIG).The N-terminal extension is 
shown in purple, catalytic domain is shown in green, subdomain I is shown in blue, subdomain II is shown in red, and the 
regulatory domain is shown in teal. The black sphere denotes zinc bound in the active site while L-leucine is shown bound in the 
regulatory domain as black sticks. 
 
As mentioned above, IPMS is allosterically regulated by the end product of the pathway, L-leucine. 
L-Leucine binds at the dimer interface between the regulatory domains (Figure 1.11) and thus 
mediates catalysis at the active site, with two molecules of L-leucine bound per homodimer. 
Interestingly, crystal structures of both apo and L-leucine-bound MtuIPMS have the same overall 
conformation, including the structural asymmetry discussed previously, which suggests that L-
leucine binding may alter the molecular dynamics of the IPMS protein, rather than cause a discrete 
conformational change upon binding.67 However, it is also plausible that there are more localised 
conformational changes that are not revealed by X-ray crystallography due to effects such as crystal 
packing.77  Small-angle X-ray scattering data of MtuIPMS also suggest that there is no gross 






Figure 1.12: The structure of MtuIPMS (PDB: 1SR9) highlighting the location of Tyr410.Tyr410 is shown in Chain A (black 
circle) and chain B (blue circle). Chain A is shown in grey while the catalytic domain of Chain B is shown in green, subdomain I 
is shown in blue, subdomain II in red, and the regulatory domain is shown in teal. The active site is denoted by the substrate, 
KIV (black stick) and the metal ion (black sphere). 
 
 
Although the crystal structures with and without L-leucine have been solved, there is very little 
difference between the two structures.63 De Carvalho et al.63 constructed point mutations in the 
region of the protein where subdomain I interacts with the catalytic barrel to investigate how 
allosteric inhibition by L-leucine functioned in the absence of conformational change. Residue 
Tyr410 (Figure 1.12), that resides in subdomain I and thus crosses over to form part of the active 
site with the other chain, was mutated to Phe, and the Tyr410Phe mutant was entirely insensitive 
to L-leucine even though this residue is far from the allosteric site. This result suggests that there 
is a communication network extending through the subdomains that is important for allosteric 
communication.  
Although the precise mechanism of allostery remains elusive, it has been shown that dynamics are 
critically important to this enzyme for catalysis. Frantom et al.78 utilised hydrogen/deuterium 
exchange (HDX) to explore the mechanism by which the allosteric signal is transferred from the 
regulatory domain to the catalytic domain. In wild-type MtuIPMS, the comparison of HDX in the 
apo and L-leucine-bound MtuIPMS showed a reduction in exchange in residues that surround the 




interacts with the regulatory domain as part of an allosteric network that transmits the signal to 
the catalytic domain. There was also reduced exchange in part of the catalytic barrel that is 
important for KIV binding, suggesting a potential mechanism by which L-leucine binding affects 
catalysis. 
 
Figure 1.13: The diversity of the IPMS and IPMS-like protein family based on Kumar et al..69 The colours indicate the different 
groups of proteins. 
 
There appear to be different mechanisms of allostery in different IPMS enzymes. V-type allostery, 
where binding of the allosteric inhibitor affects the maximum activity, is seen in LbiIPMS1 towards 
KIV upon binding of L-leucine, whereas a mixed V/K-type allostery is shown towards AcCoA.2 
K-type allostery occurs when binding of the inhibitor affects the affinity of the enzyme towards a 
substrate. MtuIPMS has a different form of allosteric regulation, showing slow-onset inhibition 
that is not seen in other examples of IPMS.79 Also, MtuIPMS solely demonstrates V-type allostery 
towards both substrates.73 NmeIPMS demonstrates mixed, non-competitive inhibition for both 
KIV and AcCoA.1 The differences in mechanism of allosteric regulation towards the substrates 
may represent phylogenetic differences, as MtuIPMS is phylogenetically distinct from the other 
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two IPMS enzymes (Figure 1.13).69 However, Kumar et al.80 showed that both Methanococcus 
jannaschii IPMS (MjaIPMS) , a IPMS1 IPMS, and MtuIPMS, a IPMS2 IPMS, demonstrate V-type 
allostery that targets the hydrolytic step of the chemical mechanism. Kumar et al.80 suggest that 
although they are phylogenetically different and only share ~20% sequence identity, the allosteric 
mechanism has been conserved or has shown convergent evolution. Dong et al.8 argues that 
allosteric mechanisms can be transmitted through multiple, different pathways that pre-exist in the 
protein. The binding of an allosteric inhibitor creates strain in the dynamic protein, and this strain 
dissipates through these extended pathways, altering the ensemble population, producing different 
effects. The difference in mechanism by which allostery occurs, and that this is not tied directly to 
phylogeny, suggests that the different enzymes may individually utilise different pre-existing 
pathways to facilitate allosteric regulation.  
The dynamics of IPMS are intricate and show significant differences between individual proteins. 
The dynamics of IPMSs are tied to both the enzyme activity and allostery. This group of enzymes 
present a fascinating picture of how dynamics can be acted upon by evolutionary processes in both 




1.4 Evolution of amino acid biosynthesis pathways 
 
This project focuses on three amino acid biosynthetic pathways in prokaryotes: the leucine 
biosynthetic pathway, the threonine-independent isoleucine biosynthetic pathway (termed the 
isoleucine biosynthesis pathway in this thesis), and the α-aminoadipate pathway for lysine 
biosynthesis (the lysine biosynthesis pathway) (Figure 1.15). The leucine biosynthetic pathway is 
found in most Bacteria, Archaea, and Fungi, as well as green plants.81 The threonine-independent 
pathway for isoleucine biosynthesis is only found in a subset of bacteria such as Geobacter 
sulfurreducens and Leptospira interrogans (Lin), and is common in Archaea.82, 83 The α-aminoadipate 
pathway for lysine biosynthesis is common in Fungi, but a variation of this pathway is also found 
in Thermus-Deinococcus bacteria as well as some Archaea.84, 85 
The first enzymes in the pathways detailed above, IPMS, homocitrate synthase (HCS), which is 
present in the lysine biosynthetic pathway, and citramalate synthase (CMS) in the isoleucine 
biosynthetic pathway, are structurally homologous to each other. Gene duplication, or horizontal 
gene transfer, and functional divergence of an ancestral, promiscuous, IPMS, may have given rise 
to these enzymes.86-88 The leucine biosynthetic pathway is the only known pathway for the 
biosynthesis of L-leucine, suggesting that the ancestral protein was an IPMS, as there are alternative 
pathways for the synthesis of isoleucine and lysine that do not rely on enzymes with structural 
homology to an IPMS.88 
Drevland et al.89 suggests that the evolution of the pyruvate pathway for isoleucine biosynthesis 
occurred via gene duplication and divergence of the leucine biosynthesis pathway, and that this 
occurred at least twice, producing the Leptospira interrogans (Lin)-like CMSs (CMS3) and Mja-like 
CMSs (CMS1) identified by Kumar et al..69 There also appear to be multiple origins of the IPMS 
from a zygomycete fungus, Phycomyces blakesleeanus, where the leuA gene is more closely related to 
plants and cyanobacterial leuA genes than it is to other fungal homologues.90 In a study examining 
the effects of a feedback-insensitive IPMS in wild and cultivated tomatoes, it was also suggested 
that there were independent and lineage-specific gene duplication and diversification events from 
IPMS to produce either the methylthioalkylmalate synthase (MAM synthase), another paralogue 
of IPMS, in Brassicaceae and the feedback insensitive IPMS in tomato and related plants.91 The 
similarity in substrate selectivity in these enzymes is demonstrated in Figure 1.14. This 
demonstrates another instance of gene duplication and divergence in the IPMS and IPMS-like 





Figure 1.14: The similarity in substrate between IPMS and three homologues.All four enzymes are metalloenzymes and utilise 






Figure 1.15: Biosynthetic pathways of interest from different organisms.The leucine biosynthetic pathway, the threonine-independent isoleucine biosynthetic pathway, and the two 
variants of the aminoadipate pathway for lysine biosynthesis from Fungi, and from thermophilic bacteria, showing the homology with the arginine biosynthesis pathway from 
bacteria. Colours represent homology (e.g. IPMS and IPMS-like proteins are in red. Whited/black circles represent where no homology is observed. 
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1.4.1 Substrate promiscuity in Claisen-condensation-like enzymes 
It has been shown that there is some degree of substrate promiscuity in the IPMS and IPMS-like 
enzymes.72 MtuIPMS, as discussed above, can catalyse the condensation reaction using alternative 
ketoacid substrates, albeit poorly. Although MjaCMS appears to show no activity with alternative 
substrates, LinCMS can utilise ketobutyrate and glyoxylate.92, 93 Homocitrate synthase from Thermus 
thermophilus can use oxaloacetate as a substrate, instead of the natural substrate α-ketoglutarate, in 
the presence of potassium chloride.94 This suggests that, although the active sites of the enzymes 
are tailored towards a specific substrate, there is some flexibility as to which substrate can be 
bound.  
There is preliminary evidence for a bifunctional, or promiscuous, IPMS/HCS in Pyrococcus 
horikoshii, a thermophilic archaeon.95 Only one copy of the genes coding for the first three steps in 
either lysine or leucine biosynthesis has been identified in the genome even though both lysine 
biosynthesis via the AAA pathway and leucine biosynthesis are thought to occur.85 Interestingly, 
the other pathway for lysine biosynthesis, the L,L-diaminopimelate (DAP) pathway, is paralogous 
to an arginine biosynthesis pathway, thus suggesting a common ancestor for these pathways as 
well, demonstrating how a biosynthetic pathway can be built modularly from existing pathways.  
In Thermus species, the first half of the pathway to produce aminoadipate is analogous to the fungal 
AAA pathway (Figure 1.15). From there, however, the pathways diverge. The fungal AAA pathway 
utilises two reductase enzymes and a dehydrogenase enzyme to form lysine, whereas in Thermus 
species, there has been a gene duplication event involving elements of the arginine biosynthesis 
pathway, and the latter half of the Thermus AAA lysine biosynthesis pathway shares common 
ancestry with arginine biosynthesis (Figure 1.15).95 This was demonstrated by Miyazaki et al.96 who 
characterised LysJ, the protein product of the lysJ gene, a homologue of argD, from Thermus 
thermophilus, that is essential for lysine biosynthesis. Fondi et al.95 also demonstrated that the Thermus 
AAA pathway for lysine biosynthesis was only present in a small subset of organisms, namely 
Sulfolobus and Pyrococcus archaea and very few bacteria. The DAP pathway is well represented by 
other bacterial species, whereas the fungal AAA pathway is, as of yet, the only lysine pathway seen 
in fungi. This suggests there may be two potential evolutionary origins of the AAA pathway, 
utilising different gene duplication events.  
Interestingly, homocitrate synthase also appears to have other roles outside of amino acid 
biosynthesis. It has been shown that homocitrate synthase, of which there are two isoforms coded 
by the lys20 and lys21 genes, in Saccharomyces cerevisiae, can be localised to the nucleus and has a role 
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in DNA damage repair.97 This appears to be independent of the homocitrate synthase catalytic 
function that is present in both Lys20 and Lys21.  It also appears that the Lys20 isoform of HCS 
in S. cerevisiae may have weak histone acetyltransferase (HAT) activity while also interacting with 
other HATs, namely Gnc5 and Esa1. Furthermore, homocitrate synthase and two other enzymes 
that catalyse the first three steps of the AAA lysine biosynthesis pathway have also been implicated 
in methane production in methanogenic archaea.98 In the typical AAA pathway reaction, 
homocitrate synthase utilises α-ketoglutarate and acetyl CoA to produce (R)-homocitrate (Figure 
1.15).99 Homoaconitase then dehydrates homocitrate to produce cis-homoaconitate before 
homoaconitate hydratase activity of homoaconitase utilises the product to form homoisocitrate 
(Figure 1.15). Homoisocitrate dehydrogenase acts on homoisocitrate to form 2-oxoadipate.  
However, in the production of coenzyme B which is essential for methane production in 
methanogenic archaea, instead of conversion of oxoadipate to L-2-aminoadipdate as in AAA-
pathway catalysed lysine biosynthesis, 2-oxoadipate is extended to form, finally, 2-oxosubterate, 
required to form the final product, 7-mercaptoheptanoylthreonine phosphate or coenzyme B.100  
Homocitrate synthase has also been implicated in a third pathway, the production of an iron-
molybdenum cofactor that plays a critical role in nitrogen fixation by bacteria. The cofactor 
contains one molecule of (R)-homocitrate produced by homocitrate synthase coded for by the so-
called nifV gene in organisms such as Azotobacter vinelandii.101 The diverse roles of homocitrate 
synthase in pathways beyond lysine biosynthesis in some organisms demonstrate how some 
enzymes can be utilised in vastly different pathways depending on the needs of the organism.  
IPMS, CMS, and HCS are related through structure and catalytic activity, even though the primary 
amino acid sequences have diverged significantly. All three enzymes are key catalytic steps in three 
distinct pathways that have likely diverged at some point from an original common, promiscuous, 





1.5 Citramalate synthase 
 
Citramalate synthase (CMS) catalyses the first committed step in the synthesis of L-isoleucine in 
one of two pathways utilised by, primarily methanogenic, microorganisms.89 CMS, like IPMS, 
utilises AcCoA as a substrate, but uses pyruvate as the α-ketoacid ̛substrate to produce citramalate 
(Figure 1.16). 
 
Figure 1.16: The reaction catalysed by citramalate synthase. 
 
A full crystal structure of CMS has not yet been solved, but two partial structures of the catalytic 
domain and regulatory domain of CMS from Leptospira interrogans (LinCMS), have been solved 
(Figure 1.17).78, 92 LinCMS is very similar in structure to MtuIPMS, despite there being only 
approximately 30% sequence similarity between the two proteins. IPMS and CMS are the only 
characterised enzymes to bear the unique fold of the regulatory domain.  
1.5.1 The structure of Leptospira interrogans CMS (LinCMS) 
 
 
Figure 1.17: Two structures of LinCMS (PDB: 3BLI, PDB: 3F6G).The catalytic domain is shown in green, a partial subdomain I 
is shown in red, and the regulatory domain (PDB: 36FG) is shown in teal. The substrates AcCoA and pyruvate, and the metal ion 




LinCMS is dimeric, and the monomeric structure is made of a catalytic (β/α)8-barrel barrel, two 
subdomains, and a C-terminal regulatory domain that is very similar in structure to the IPMS 
regulatory domain.  Crystal structures of the catalytic domain with malonate, pyruvate, and with 
pyruvate and AcCoA have been solved (PDB codes 3BLE, 3BLF, 3BLI). The TIM barrel is very 
similar to that of MtuIPMS and other IPMS structures solved, with a root mean square deviation 
(RMSD) of 1.8 Å between the LinCMS and the MtuIPMS barrels.92 The substrate, pyruvate, is 
bound in a similar position to that of KIV in IPMS. A hydrogen bond is formed from pyruvate to 
a conserved threonine residue in the LinCMS structures and to the metal ion that is coordinated 
to conserved histidine and aspartate residues, as in the MtuIPMS crystal structures.  Although the 
binding mode of the substrate is similar to that of KIV in the MtuIPMS structure, the residues that 
comprise the active site differ between MtuIPMS and LinCMS to allow for control of substrate 
specificity. LinCMS shows strong substrate specificity towards pyruvate, although it demonstrates 
some limited activity with other keto-acids such as ketobutyrate and ketoisovalerate.102 
 
Figure 1.18: Allosteric ligand binding to the regulatory domain of MtuIPMS .L-Leucine (blue) is bound in the interface of the 
regulatory domain of MtuIPMS (PDB: 1SR9, light blue). L-Isoleucine (pink) is shown bound in the interface of the regulatory 
domain of LinCMS (PDB: 3F6G, light pink) 
 
CMS is allosterically regulated by L-isoleucine, which binds in the dimer interface of the regulatory 
domains as L-leucine does in IPMS (Figure 1.18).78 It has been suggested that the mechanism of 
allosteric inhibition is similar between IPMS and CMS.78  LinCMS demonstrates K-type allostery 
towards both substrates, whereas MtuIPMS demonstrates V-type allostery towards both 
substrates.79, 103 However, there appears to be different mechanisms of allostery amongst the 
different IPMS proteins, suggesting that these enzymes may use a variety of mechanisms of 
allosteric regulation . The crystal structure of the regulatory domain of LinCMS has been solved, 
showing L-isoleucine binding in a similar site to that of L-leucine in MtuIPMS (Figure 1.18).  
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1.6 Homocitrate synthase 
 
Homocitrate synthase (HCS) represents the first committed step in the AAA pathway, one of the 
pathways utilised by microorganisms to synthesise lysine.71 Like both IPMS and CMS, the 
substrates for HCS are AcCoA and an ketoacid, in this case, ketoglutarate (Figure 1.19).84  
 
Figure 1.19: The reaction catalysed by homocitrate synthase. 
 
HCS is structurally similar to both IPMS and CMS. Several full-length crystal structures of HCS 
have been solved from two organisms, the yeast Schizosaccharyomyces pombe, (SpoHCS) (PDBs 3IVT, 
3IVS, 3IVU, and 3MI3) and a thermophilic bacterium, Thermus thermophilus, (TthHCS) (PDBs 
2ZAF, 3A9I, 2ZTJ, and 2ZTK).104-106 These structures show that both SpoHCS and TthHCS HCS 
have a very similar catalytic barrel to that of CMS and IPMS, and possess the corresponding 
subdomains attached to the barrel, although the structure of subdomain II could not be resolved 
in TthHCS. Unlike the majority of IPMS enzymes, no HCS enzyme identified thus far has a 
canonical regulatory domain.106  Instead, kinetic studies have shown that these HCS proteins are 




1.6.1 The structures of HCS from Schizosaccharomyces pombe and Thermus thermophilus 
 
 
Figure 1.20: The structure of SpoHCS (PDB: 3IVT).The catalytic domain is shown in green, subdomain I in blue, and 
subdomain II in red. Chain A is shown in grey. The substrate, ketoglutarate, and the metal ion are shown in black. The right-
hand image shows the enzyme rotated 180° compared to the left-hand image to highlight the contribution of chain A to the 
active site of chain B.  
 
The structure of HCS from Schizosaccharyomyces pombe (SpoHCS) has been solved in the apo form, 
in two conformations with the natural substrate ketoglutarate (KG) bound in the active site (Figure 
1.20), and with the competitive inhibitor, lysine, bound.104, 105  The catalytic domain appears very 
similar to that of the MtuIPMS and LinCMS, although there is a short N-terminal extension that 
is disordered in the apo structure of SpoHCS, but forms a short β-strand and a 310 helix in the 
ketoglutarate-bound structures. The subdomains are fully resolved in all four structures of 
SpoHCS. As observed in MtuIPMS, subdomain I of SpoHCS crosses over to form part of the active 
site with the opposing chain, creating a domain-swapped homodimer. In one of the two KG-
bound structures, the so-called ‘closed lid’ structure (PDB: 3IVT), two 310 helices form the lid that 





Figure 1.21: The movement of Asp123 in SpoHCS.Asp123 (cyan) when lysine (blue) is bound to the active site is compared the 
binding of ketoglutarate (Asp123 is shown in purple, KG in green). 
 
In SpoHCS, there is a switch that allows acidic residues Asp123 and Glu222 to form interactions 
with the ε-ammonium group of lysine, the competitive inhibitor of HCS (Figure 1.21). In the 
ketoglutarate bound form, Glu222 facilitates the salt bridge formation of the side chain of Arg163 
with the C5 carboxylate of ketoglutarate, and His103 additionally forms a hydrogen bond with the 
substrate. The aspartic acid is conserved in HCSs that lack a regulatory domain and thus are 
regulated by competitive inhibition.69 Upon binding of lysine, there is also a slight conformational 
shift of the lid motif described above, where the lid motif moves away from the active site 
compared to the apo form, suggesting that the ligand bound in the active site can affect the 
conformation of the subdomains. Lysine is a competitive inhibitor towards ketoglutarate but a 
mixed inhibitor towards AcCoA, reaffirming the role of the subdomains in AcCoA interaction and 
binding105. 
 
Figure 1.22: The crystal structure of TthHCS (PDB: 2ZYF).Chain A is shown in grey. The catalytic domain is shown in green, 
and subdomain I is shown in blue. The metal ion and ligand, KG, are shown in black. The right-hand image is a rotation of the 




The crystal structure of TthHCS has also been solved with ketoglutarate (Figure 1.22), lysine or the 
product, homocitrate, bound in the active site.106 Unlike the crystal structures of SpoHCS, 
subdomain II in the TthHCS structures was unable to be resolved, suggesting that it is very mobile. 
As with the previous structures, TthHCS forms a domain-swapped homodimer, with the TIM 
barrel forming the catalytic domain, while subdomain I from the adjacent monomer contributes 
residues to the active site (Figure 1.22, right). The residues that contribute to ligand binding and 
specificity are similar to those in SpoHCS as described above, and as with SpoHCS, the binding of 
the inhibitor to the active site appears to rearrange the subdomains.   
 
Figure 1.23: The structure of the catalytic domain of LinCMS showing the binding of substrates.LinCMS (light blue, cartoon, 
from PDB: 3BLI) showing AcCoA (blue), pyruvate (green), and the metal ion (black sphere). The zoomed circle shows 
interactions formed between AcCoA and Arg53 (black stick) and Phe83 (black stick). 
 
A comparison was made between the pyruvate and AcCoA bound structures of LinCMS and the 
ketoglutarate-bound structure of TthHCS.106 Although a large number of residues that are involved 
in AcCoA binding in the LinCMS structure are conserved in TthHCS, residues involved in 
recognition of the adenine ring and 3’-phosphoribosyl parts of AcCoA in LinCMS are not 
conserved in TthHCS, suggesting that there is a different binding mode for this large substrate in 
the different homologues. In LinCMS, the adenine ring forms a π-π stacking interaction with Phe83 
while the 3’-phosphate group of the adenine ribose forms an interaction with Arg53 (Figure 
1.23).102 By comparison, in TthHCS, these residues are a leucine and a valine respectively. 
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1.6.2 Competitive inhibition in HCS 
 
The regulatory domain of IPMS/CMS may be a comparatively new evolutionary addition, and the 
ancestral protein may have been unregulated or competitively inhibited as opposed to allosterically 
regulated. Due to the structural similarity between HCS and the allosterically regulated IPMS and 
CMS, the absence of a regulatory domain on characterised HCS enzymes suggests that IPMS and 
CMS may be able to perform catalysis without a regulatory domain, and indeed, this has been 
shown both in artificially truncated IPMS and CMS, and in the naturally truncated form.2, 108 There 
is no alternative pathway for leucine biosynthesis, which suggests that an IPMS was the ancestral 
enzyme that was duplicated to allow for the evolution of CMS and HCS. As modern IPMS and 
CMS enzymes maintain the ability to catalyse reactions with the regulatory domain removed, it 
suggests that the ancestral protein did not maintain a regulatory domain. Drevland et al.89 suggests 
there were two duplication events leading to the phylogenetically distinct types of CMS, and the 
difference in lysine inhibition and the great species difference between the Thermus-Deinococcus 
group of thermophilic bacteria and the fungi and yeast that utilise HCS and the α-aminoadipate 
pathway suggests there have also been multiple gene duplication events to produce two distinct 
types of HCS.  Additionally, many organisms appear to maintain multiple copies of the leuA gene, 
with and without a regulatory domain, which suggests multiple gene duplication events.2, 90  
Larson and Idnurm90 demonstrated that the leuA gene from Phycomyces blakesleeanus was 
evolutionarily closer to those from plants and photosynthetic bacteria than it was to leuA genes 
from other fungi, although the gene product can complement a leu3 (isopropylmalate synthase) 
Schizosaccharyomyces pombe knockout. As this species diverged early from other fungi during 
evolution, the gene in these organisms may be an ancestral variant while other organisms have 
acquired the gene more recently, or horizontal gene transfer events may have occurred, either to 
provide Phycomyces blakesleeanus with a leuA gene from a more modern cyanobacteria or plant, or to 
provide both lineages with different genes. This suggests another mechanism by which these genes, 
and pathways, can be transferred between organisms, and may suggest a mechanism by which 
diverse organisms such as thermophilic bacteria and fungi appear to have similar genes. These 
enzymes present an interesting picture of divergent and convergent evolution across both 
prokaryotes and eukaryotes.  
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1.7 Modular domain evolution 
 
As more sequence and structural information becomes available, it has become apparent that non-
homologous proteins can be built with domains common to multiple proteins, suggesting that the 
part of a gene that codes for a common domain can move through the genome as a modular 
unit.109 There are numerous examples, particularly in eukaryotes where domains involved in 
protein-protein interactions and cell signalling appear in different proteins, yet fulfil the same 
role.110 Additionally, there are examples where the same domain can perform different roles, for 
example, domains catalysing different chemical reactions, while retaining the same tertiary 
structure.  The most ubiquitous example of this is the TIM barrel that makes up the catalytic barrel 
of the enzymes detailed above, and is the most common fold that has been structurally 
characterised.111 The TIM barrel can catalyse a variety of different reactions, including the 
eponymous triose phosphate isomerisation of dihydroxyacetone phosphate and D-glyceraldehyde 
3-phosphate.70 Another example of a domain found in different contexts in a variety of proteins 
is the ACT domain.112 Large scale domain rearrangements may have occurred in numerous 
different ways, from short duplications, to large, disruptive, chromosome mutations.113   
1.7.1 The modularity of the IPMS and IPMS-like enzymes 
 
Although the TIM barrel represents a common structural module in a variety of proteins and 
organisms, in the context of IPMS and IPMS-like enzymes, the catalytic module of these proteins 
contains the TIM barrel as well as subdomain I and subdomain II. Zhang et al.2 argued that the 
catalytic and functional module of IPMS is the catalytic domain and the subdomains, due to the 
essentiality of the subdomains in facilitating catalysis. Interestingly, the fold that makes up the 
regulatory domain of IPMS has only been identified in IPMS and CMS to date. There is some 
evidence via databases such as Pfam114 that it is also present in threonine synthase from Francisella 
species, but as of yet, these have not been characterised.115 Moore et al.113  suggests that these 
domains either emerged very recently, and thus have not spread through the genome, or have 
diverged so significantly in sequence that the current tools for identifying these domains are unable 
to identify them. It is interesting that this fold has been retained during the gene duplication events 
leading to the two phylogenetically distinct CMS enzymes, but was not in the HCS genes, although 
as discussed above, these genes may have been transferred through evolution by a variety of 
mechanisms that may account for this. Regardless, the idea of modular domain rearrangement 
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provides an interesting evolutionary tactic and a potential way to explore evolution of regulation 
in metabolic pathways.  
Additionally, protein modularity presents an interesting way to investigate dynamics. In these 
proteins, the catalytic module includes two subdomains for which mobility is critical for catalysis, 
but these subdomains can bear the burden of a regulatory domain, and indeed, if this regulatory 
domain is removed, the proteins still facilitate catalysis.2, 108 Therefore, studying how these proteins 
fluctuate in the presence and absence of the regulatory domain, both in the natural protein and in 
artificial constructs, may provide some clues as to how, during evolution, a highly dynamic protein 
has evolved to maintain a regulatory domain that restricts the conformations that the subdomains 
can form.  
1.8 Summary 
 
The study of protein conformation and dynamics is a field of increasing interest and importance. 
Investigating how proteins move is beginning to solve some of the mysteries that could not 
previously be solved with static techniques such as X-ray crystallography, and the study of 
dynamics is providing new insight into old conundrums such as allosteric regulation in the absence 
of a detectable conformational change. Understanding how proteins move, and how evolution 
mediates and shapes these movements, will be invaluable information for the design of 
antimicrobials, especially allosteric drugs.  
IPMS, CMS, and HCS present an interesting evolutionary picture where dynamics plays a key role 
in both allosteric regulation and catalysis. The combination of allosterically and non-allosterically 
regulated proteins allows the exploration of how dynamics have evolved to mediate the burden of 
the regulatory domain while still facilitating catalysis, and how the dynamics of the subdomains 
can be altered in the presence of the allosteric inhibitor to attenuate catalysis at the distant active 
site.  
A crystal structure of MtuIPMS with L-leucine bound has been solved, and there is no significant 
conformational change when compared to the crystal structure without L-leucine bound. The lack 
of change suggests that a change in dynamics is of importance in transmitting the allosteric signal 
from the binding site in the C-terminal regulatory domain to the active site in the N-terminal 
catalytic domain. However, in the absence of crystallographic data, investigating the potential 
change in dynamics in phylogenetically diverse proteins such as NmeIPMS is difficult. A technique 
called statistical coupling analysis, that utilises sequence information, was used to investigate 
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whether a network of coevolved residues may contribute to the transmission of the allosteric signal 
in NmeIPMS-like IPMS proteins. The evolution of allosteric regulation was further explored by 
the construction of fusion proteins using the regulatory domains from LinCMS and SsoHCS to 
investigate whether the allosteric network could be preserved even with a different regulatory 
domain. 
Subdomain II of the IPMS and IPMS-like proteins, including HCS that lacks a regulatory domain, 
is critically important for catalysis, as removal of part of subdomain II renders the protein 
catalytically inactive.  The structural similarity between the regulatory domain containing proteins 
and the proteins without a regulatory domain suggests that the overall mechanism of catalysis, of 
which subdomain II is a part, is similar. A previous truncation of NmeIPMS removed part of 
subdomain II as well as the regulatory domain and rendered the truncated protein inactive. To 
investigate whether a truncation that encompasses all of subdomain II can produce a truncated 
active NmeIPMS, the protein was truncated at the C-terminal end of subdomain II.  
As extant IPMS enzymes have been found with and without a regulatory domain, it suggests that 
the dynamic subdomains can function under both structural constraints. However, the differences 
in dynamics between the two structural populations, especially in the subdomains, are of 
considerable interest, but structural information for both populations is lacking, making techniques 
such as molecular dynamics simulations difficult. Sequence information was also utilised to 
investigate coevolved residues in both populations to determine whether there may be a different 
network of coevolved residues that enable catalysis in both structural populations.     
Therefore, in this study, the evolution and regulation of these three enzymes was investigated using 












Coevolution can be defined as two things affecting the evolution of each other. It is seen in a wide 
biological sense in things like the parasite-host interaction. Zaman et al.116 discussed how the 
competition between parasite and host drives both parasite and host to evolve more complex 
functions, thus driving evolution of both species.  
Coevolution, and covariation, can also be observed at the protein level. A change in residue or 
chemistry at one position may alter the local protein environment sufficiently to, upon random 
mutation at a second position; change the chemical environment acceptable in that second 
position.117 Thus, a change in amino acid population at one position alters the amino acid 
population at another position. This is one way that antibiotic resistance can proliferate. Typically, 
the initial mutation selected for to confer resistance to the antibiotic can be harmful to the 
organism, causing a decrease in fitness.117 However, the mutation can be maintained in the 
population if there is a compensatory mutation that may be deleterious by itself but is neutral or, 
less commonly, advantageous when combined with the first mutation, thus stabilising the 
resistance mutation in the bacterial population.117 Therefore, the identification of coevolving 
networks in proteins is of importance to understanding antibiotic resistance and the development 
of new antimicrobial drugs.  
Atchley et al.118 describe potential sources of covariation in proteins. These include covariation 
with a phylogenetic basis, structural or functional covariation, and stochastic covariation. 
Stochastic covariation may include elements such as fluctuations in dynamics. Sfriso et al.119 
identified residue pairs that displayed coevolution but were not close structurally. They then 
utilised molecular dynamics and connected these residue pairs to other conformations of the 
protein, displaying that dynamics can also be a driver of coevolution.  
Many different algorithms have been developed to detect coevolution in multiple sequence 
alignments. This project focuses on the most common methods: statistical coupling analysis (SCA) 




2.1.1 Introduction to statistical coupling analysis (SCA) 
 
Figure 2.1: A theoretical protein demonstrating the difference between residues that show coevolution and those that do 
not.Position l, that is not involved in protein structure or function, position k, that is conserved but not coevolved with these 
residues, and positions i and j, that show coevolution 
 
SCA allows the identification of networks of coevolved residues amongst evolutionary noise. An 
example is displayed in Figure 2.1, where a protein contains four generic residues named i, j, k, and 
l.120 If the amino acid distribution at l is superfluous to both structure and function, then the amino 
acid frequency at this position should approximate the mean of all amino acid frequencies in all 
proteins. However, if residues, such as i, j, and k have a functional role, then the amino acid 
distribution at these positions should be different from the mean. This can be identified by simple 
conservation of residues at positions important for catalysis, for example, as represented by 
position k. However, if two residues are coevolved, they may not be absolutely conserved, but the 
distribution of residues at one site is affected by the distribution at another site. The degree to 
which one residue is affected by another can represented by a numerical score. The higher the 
score, the more coevolution shown by two residues. In this example, these residues are represented 
by i and j. Conversely, if the population of residues at position k is not affected by the population 
at either i or j, these residues have not coevolved even though position k shows significant 
conservation. 
SCA was first pioneered by Ranganathan et al..121 The technique was demonstrated using a multiple 
sequence alignment (MSA) of the PDZ domain family. SCA applied to this MSA identified a 
network of coupled residues that extended from the peptide ligand binding site through the 
domain to surface residues. The pathway identified using this technique was confirmed by 
thermodynamic mutant cycle analysis, as well as a binding energy assay. It was suggested that this 
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pathway represented a way by which the domain could alter its energetic connectivity in response 
to ligand binding.  
SCA has also been used to determine which residues are necessary for maintaining functionality in 
a protein fold.122 A SCA was performed on a MSA of WW domain family sequences, and through 
this, a group of coevolved residues was identified. Protein sequences were designed based on this 
SCA analysis, and the artificial proteins were then tested for activity. The structural and thermal 
properties of the artificial proteins were also explored. These artificial proteins were functionally 
indistinguishable from native sequences, suggesting that the function of the protein was 
fundamentally encoded in these coevolved residues, even though some were quite distant from 
the ligand binding site.  
Investigating allosteric communication pathways has been a major focus of SCA, as allosteric 
pathways can be very difficult to discern from sequence or structure alone. One example is the 
allosteric communication pathway in haemoglobin.120 A SCA was performed on a MSA of 800 
globin family sequences. Following hierarchical clustering of scores determined by SCA, two 
overlapping groups of statistically coupled residues were identified. The first of these groups, once 
mapped onto the 3D structure of haemoglobin, included residues that interacted with heme and 
those that formed part of the tetramer interface. Based on experimental data, these regions were 
known to be important for the switch from the T to R state in response to O2.  This analysis 
demonstrates that SCA can be used to identify allosteric networks that have already been validated 
by experimental data.  
Not only can SCA be utilised to explore allosteric pathways already known, but it can also be used 
to identify novel allosteric pathways. A MSA of cysteine peptidases was used in SCA to identify 
groups of coevolved residues, termed sectors.123 These residues surrounded the active site, and 
extended through the protein as a network. A known ligand, chondroitin sulfate, was shown to 
form multiple contacts with sector residues. Putative allosteric binding cavities were identified 
utilising other software. These binding pockets also included sector residues, and of these, ‘site 6’ 
as it was termed, was shown to bind a novel allosteric ligand.  
IPMS, as discussed above, is allosteric and the mechanism for allostery is not well understood but 
may involve the control of dynamics of the protein. It is, therefore, plausible that there is a network 
of residues that may not be absolutely conserved themselves that control the dynamics of the 
protein in response to L-leucine binding. SCA was used to try to identify this potential network. 
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2.2 Statistical coupling analysis of isopropylmalate synthases 
 
2.2.1 Multiple sequence alignment construction 
 
The initial sequence population and the final curated multiple sequence alignment are critical to 
the efficacy of covariance analyses such as SCA.124 The population needs to be of substantial 
diversity so subpopulations, where there is substantial variation from the main population in terms 
of sequence at any particular site, do not dominate the alignment and thus skew the results of the 
SCA towards that subpopulation. Thus, positions in the MSA that do not show conservation 
should have an amino acid distribution approximately equal to the mean amino acid distribution 
for all proteins. This means that there has been sufficient evolution to allow for statistical deviation 
from the mean amino acid distribution at any position to be significant. In addition, the alignment 
needs to be of sufficient size that random removal of some members of the sequence population 
does not alter the amino acid distribution at sites where there is not conservation. 
To obtain sequences for SCA, IPMS sequences were obtained using PSI-BLAST (Position-Specific 
Iterative Basic Local Alignment Search Tool) in an iterative fashion using the protein sequence of 
Neisseria meningitidis IPMS (NmeIPMS) as the input sequence.101 The genus Neisseria was excluded 
from this search as otherwise the results were overwhelmed with results from this genus, and this 
would mean that the results were skewed towards this subpopulation of sequences. Following 
acquisition of sequences, the collection of sequences was run through the CD-HIT webserver to 
eliminate sequences that had a greater than 90% similarity to other sequences in the sequence set.125  
2.2.2 Cluster Analysis of Sequences 
 
CLANS (Cluster Analysis of Sequences) was then performed on the sequence pool, containing 
approximately 1500 protein sequences, and a single cluster was selected for further analysis (Figure 
2.2).126  CLANS uses an all-versus-all BLAST search to calculate pairwise attraction values. These 
attraction values are then used to produce a force-directed graph that allows visualisation of the 
sequence space. In the case of this sequence population, there is a single cluster, and the sequences 
cluster more tightly in the centre of the cluster. This is similar to the clustering seen when sequence 




Figure 2.2: The graphical output of the CLANS analysis of the NmeIPMS-like IPMS sequence pool. This shows the clustering of 
the sequence population into a single cluster. 
 
2.2.3 Multiple sequence alignment  
 
The representative sequences of the CD-HIT and CLANS clusters, including NmeIPMS, were then 
used to perform an alignment using MAFFT.92 MAFFT is a multiple sequence alignment 
programme that utilises fast Fourier transform (FFT) to perform alignments.92, 127 The FFT-NS-2 
algorithm was used for construction of the alignment; as of the algorithms available in MAFFT, 
this gave the best trade-off between relative speed and accuracy. In this heuristic method, a series 
of short ‘words’ of a defined length is identified in the sequence, and a distance matrix is computed 
based on the number of ‘words’ shared between any two pairs of sequences. The distance matrix 
is essential for the construction of a rough guide tree, from which an alignment can be constructed. 
In the FFT-NS-2 method, this alignment is then improved on by re-construction of the guide tree, 
followed by a second alignment that is typically more accurate than the first. MAFFT was selected 
as the programme used to construct the MSA as it performs well with different sequence 
populations.128 
Following construction of the alignment, sequences that were less than 350 amino acids or more 
than 700 amino acids were removed. Sequences less than 350 amino acids typically were partial 
proteins, and as the typical length of an IPMS without a regulatory domain is 380 – 400 amino 
acids long, they were unlikely to be functional IPMS. Sequences of greater than 700 amino acids, 
of which there were very few, appeared to have additional domains or lacked a stop codon and 
were therefore not of interest for this study. Sequences that lacked the essential ‘DRE’ motif were 
also removed. This motif, consisting of Asp – Arg – Glu in a helix in the active site, has been 
shown to be essential for catalysis and is characteristic of the IPMS and IPMS-like proteins.68. 
41 
 
Finally, sequences that lacked the regulatory domain were also removed as the interest in this 
particular analysis lies in proteins that display the canonical regulatory domain. 
Iterative cycles of sequence removal and re-alignment to restrict the sequence alignment to 
proteins that are homologues of NmeIPMS was then performed. Those sequences with 
appropriately conserved residues at positions known to be important for substrate selectivity and 
inhibitor selectivity were maintained, based on residues identified by Hunter and Parker72 and 
Kumar et al.69 Active site residues, such as His204 and His206 that are critical for coordinating the 
metal ion, and Tyr313, known to be important for catalysis, show substantial conservation, while 
regions that do not appear to have a role in ligand binding or allostery do not show conservation. 
This gives confidence that the alignment accurately represents the pattern of conservation seen in 
IPMS sequences, including known regions of importance. A total of 584 sequences made up the 
final alignment, with a pairwise percentage identity of approximately 60%.  
2.2.4 Removal of gaps and alignment with a known structure or model 
 
The alignment was truncated in Matlab so any sequence position with a gap frequency of greater 
than 20% was removed. This prevented the trivial over-representation of gaps in the alignment in 
the final calculations. The sequence from the NmeIPMS PDB file was then aligned with the 
NmeIPMS sequence in the multiple sequence alignment. This produced a file that relates alignment 
numbering to structural numbering to allow for ease of later analysis.  
2.2.5 Analysing sequence similarity and conservation 
 
A matrix (S) was constructed comparing the similarity of pairs of sequences. Within the matrix, 
each position is the fraction of residues that are similar between two sequences in the multiple 
sequence alignment. The matrix can be represented in the form of histograms (Figure 2.3, left), or 
as a heat map (Figure 2.3, right). These suggest that the population is not completely homogenous 
with some obvious grouping. This is also reflected in the CLANS results, where there was a tight 
group of sequences in the centre, but the sequences clustered tightly together without additional 





Figure 2.3: The similarity of sequences in the MSA used for the SCA. 
The degree of conservation at each position was also assessed (Figure 2.4).120 This was used 
primarily to assess how well the alignment matched with what is already known about the system, 
for example assessing whether conservation at key residues such as the histidines responsible for 
metal binding, His204 and His206, had been preserved in the alignment. The positional correlation 
was measured by a statistical quantity, D, which is the probability of observing the frequency of 
an amino acid at a position in an alignment of M number of sequences, given a specific background 
probability that has been computed from the mean frequency of all protein sequences in non-
redundant databases.120 D is also known as the Kullback-Leibler relative entropy.120 The positional 
correlation scores were then mapped onto the homology model of NmeIPMS (Figure 2.4, bottom). 
The positional correlation scores matched well with previous alignments and what is known about 
the system. The conserved histidine residues at positions 204 and 206 show a high score for 
positional correlation, as do other conserved residues in the active site. Conversely, regions without 
substantial conservation, such as parts of subdomain II, have comparatively low positional 




Figure 2.4: Positional correlation in the NmeIPMS-like IPMS used for the SCA.The positional correlation based on an entropy 
score is shown as a histogram (top) and mapped onto the homology model of NmeIPMS (bottom) where the highest entropy 
scores are shown in red and the lowest in blue. 
 
2.2.6 SCA calculations 
 
The SCA programme (sca5.m) was used to produce a positional correlation matrix (Cp), which 
numerically demonstrates the correlated evolution of all pairs of positions, and a sequence 
correlation matrix (Cs), which shows the pattern of similarity between all pairs of sequences. Unlike 
the sequence similarity matrix described in 2.2.5, these matrices are weighted based on 
conservation, so a change in a more conserved residue is weighted higher than one in a very 
variable position. The weighting provides the benefit of reducing noise. Residues that abut each 
other typically show coupling to maintain essential structural and functional features, such as 
correct protein fold and level of hydrophobicity or hydrophilicity in that region, and this low-level 
coupling can present as significant noise in the analysis. However, conservation weighting can bias 
the result by a phylogenetically related group. For example, if a particular group of sequences 
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within the MSA shows a change in residues involved in substrate binding that by nature are highly 
conserved, these residues will be statistically coupled based on this analysis, even though the 
grouping is tied more specifically to phylogeny. This phylogenetic bias can effectively drown out 
signals that are not related to phylogeny and limit the usefulness of the analysis. Although this 
technique was used with this caveat in place, a limited phylogenetic pool was selected for this 
analysis. This substantially limits the impact of conservation weighting, and thus provides more 
widely meaningful results.  
2.2.7 Principal component analysis 
 
Principal component analysis was used to determine which residues form ‘sectors’ in the protein. 
This involves the deconstruction of the data into eigenvalues and eigenvectors. An eigenvector is 
a direction and an eigenvalue provides information on how varied the data is in that direction. 
Every eigenvector has an eigenvalue.  In this analysis, the eigenvector (otherwise known as an 
‘eigenmode’) is a weighted combination of residues, whereas the eigenvalue of that eigenvector 
indicates how statistically important that eigenvector is. 
 
Figure 2.5: The eigenspectra of the principal component analysis of the NmeIPMS-like IPMS SCA. The arrows show the top 
three eigenmodes. 
The eigenspectra, or distribution of eigenmodes by eigenvalue, was plotted (Figure 2.5). The 
alignments were also scrambled, with amino acids distributed at random in the columns of the 
MSA. This allowed ‘randomised’ alignments (red line, Figure 2.5) to be used to assess the degree 
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by which eigenvalues of eigenmodes could be explained by chance, as there is substantial 
stochasticity due to the nature of the data examined, and the number of sequences in the alignment 
is not significantly larger than the number of positions in the alignment. The top three eigenmodes 
are statistically significant, and the top eigenmode has a substantially larger eigenvalue than the 
others.  
 
Figure 2.6:  Scatter plot of the top three eigenvectors of the NmeIPMS-like IPMS SCA. The numbers represent the residue 
number from NmeIPMS. 
 
The top 3 eigenmodes are represented as scatter plots in Figure 2.6, and show that most residues 
are not statistically coupled, and thus have small eigenvalues close to 0. However, some have 
comparatively large eigenvalues, and thus are residues of interest. To define the sectors, the 
eigenvalues in the top eigenmode were fitted to a lognormal distribution, and a cumulative density 
function was made from this (Figure 2.7). A cut-off was made at 70%, which meant the output 
represents residues in the top 30% of the cumulative density function, which form the tail. These 





Figure 2.7:  The eigenvalues of the top eigenmode of the NmeIPMS-like IPMS SCA(histogram) fitted to a lognormal distribution 
(red line).  The blue dashed line shows the cut-off in the tail in the cumulative density function (CDF). 
 
Additionally, positional correlation can be related to sequence correlation using single value 
decomposition to determine whether the sector residues were related to a phylogenetic group. 
Figure 2.8 shows that there is no particular definition of the sequence correlation, suggesting that 
there is only one relatively homogeneous sequence population. This suggests that the sector 
identified in Figure 2.7 is a global property of this sequence family, and not related to phylogenetic 
subsets. If there was a relationship between phylogeny and positional correlation, the results would 
look similar to those found in Halabi et al.129, where several independent sectors were identified 
and these were directly related to phylogenetic relationships.  
 




2.2.9 The structural and dynamic basis of the sector identified by SCA 
 
A single sector, that does not appear to have a phylogenetic bias in this sequence population, was 
identified by principal component analysis. This sector was then mapped onto the homology 
model of NmeIPMS (Figure 2.9) and compared to results from molecular dynamics simulations 
that were performed by Dr. Wanting Jiao (personal communication, May 2014).  
 
Figure 2.9: The single sector identified by PCA of the SCA mapped onto the NmeIPMS homology model. 
 
The sector appears to contain residues spanning from the N-terminal catalytic barrel to the 
regulatory domain at the C-terminal end of the protein. Residues within the sector appear to form 
a network of interconnected residues that link the active site with the allosteric site in the interface 
between the two regulatory domains. The sector contains a large number of residues in the flexible 
subdomains, suggesting a potential mechanism by which the allosteric signal is transferred to the 




Table 2.1: Table of residues identified in the NmeIPMS SCA, as well as MD experiments performed on NmeIPMS (performed by 






















































































































































































































































373 Subdomain II Interactions broken in Leu bound MD 
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Hydrogen-deuterium exchange (HDX) studies in the presence and absence of L-leucine in 
MtuIPMS identified several parts of the protein that undergo decreased exchange in the presence 
of L-leucine.78 These regions include part of the regulatory domain surrounding the L-leucine α-
amino group (residues 617 – 632, MtuIPMS numbering), a group of residues in the regulatory 
domain that contact subdomain II (residues 488 – 495), a hydrophobic patch in subdomain II 
(residues 453 – 457), and conserved residues implicated in substrate and metal binding in the active 
site (residues 78 – 87) (Figure 2.10, Table 2.1). As the residues identified by HDX in the catalytic 
domain are conserved, they will not be identified by statistical coupling analysis, but if there is 
variation in the other residues, there could be statistical coupling identified in NmeIPMS using SCA 
if this is an allosteric path that is conserved between all IPMSs.  
 
Figure 2.10: The structure of MtuIPMS (PDB: 3FIG), residues identified by H/D exchange as showing a change in dynamics in 
the presence of L-leucine (spheres). Chain A is shown in grey, the catalytic domain is shown in green, subdomain I in blue, 
subdomain II in red, and the regulatory domain in teal. The Zn ion in the active site is shown as a black sphere. L-Leucine bound 
to the regulatory domain is shown as black sticks. 
 
The residues 617 – 632 (MtuIPMS numbering), identified by HDX of MtuIPMS, that surround the 
α-amino group of L-leucine in the regulatory domain, and additionally form contacts with 
subdomain II, do show statistical coupling in the NmeIPMS-like IPMS SCA (residues 477 – 492, 
NmeIPMS numbering), but the other groups of residues identified by the hydrogen-deuterium 
exchange do not show statistical coupling. In the NmeIPMS-like IPMS alignment, the region 
spanned by residues 386 – 389 (NmeIPMS numbering), that corresponds to residues 488 – 495 in 
MtuIPMS in subdomain II, has a considerable number of gaps, suggesting that this region is not 
highly conserved in length or sequence even in sequences closer in phylogeny than MtuIPMS and 
NmeIPMS.  
The region of subdomain II (residues 356 to 360, NmeIPMS numbering) of NmeIPMS that 





particularly at residue 360 (NmeIPMS numbering), but none of the residues show statistical 
coupling in the NmeIPMS SCA. This suggests that, if this set of statistically coupled residues 
identified in the NmeIPMS-like IPMS SCA forms an allosteric network, there is a difference in 
allosteric networks between MtuIPMS and the NmeIPMS-like IPMS.  
A difference in allosteric network between MtuIPMS and NmeIPMS corresponds well with reports 
of different modes of allosteric inhibition in different branches of the phylogenetic tree of these 
enzymes. LbiIPMS2, an NmeIPMS-like IPMS, shows V-type allostery towards KIV but a mixed 
V/K-type allostery towards AcCoA, while MtuIPMS shows V-type allostery towards both 
substrates and slow-onset inhibition not seen in other IPMSs, while MjaIPMS shows V-type 
allostery towards both substrates and a similar mode of action to MtuIPMS, that is altering the 
rate-determining hydrolytic step of the enzymatic reaction.2, 78  The difference in the mode of 
allostery displayed by different populations of IPMS enzymes suggests that there may be a 
phylogenetic basis to the difference in allosteric networks and modes of regulation. 
 
Figure 2.11: The NmeIPMS homology model with Arg310 highlighted as spheres.Chain A is shown in grey, Chain B is shown in 
colour: the catalaytic domain is shown in green, subdomain I in blue, the linker in orange, subdomain II in red, and the regulatory 
domain in teal. The active site is highlighted by KIV (black spheres) and the metal ions (black spheres). 
 
Another residue identified in the sector identified by the NmeIPMS SCA is Arg310 which is 
located in subdomain I (Figure 2.11).  An Arg310Ala mutation has been made in NmeIPMS, and 
this mutant shows a comparable response to L-leucine as that observed in wild type NmeIPMS, 
but Arg310Ala had a significantly higher Km for AcCoA of 750 µM ± 260 compared to the wild-




substantially to ligand binding.130 However, substrate binding, especially AcCoA interaction and 
binding, are intimately linked with both allosteric regulation and movement of the subdomains 
so this residue may be statistically coupled to those involved in allosteric signal transmission 
without being involved itself. 
To investigate the nature of this statistical coupled sector further, additional alanine mutations 
were made in NmeIPMS. These residues were chosen as they were identified in the MD simulations 
as forming potentially interesting interactions. Additionally, they also appear in the SCA, suggesting 





2.3 Mutants in NmeIPMS based on MD and SCA 
 
Several residues identified by the SCA of NmeIPMS-like IPMSs are particularly interesting. MD 
simulations conducted and analysed by Dr. Wanting Jiao (personal communication, May 2014) on 
the apo NmeIPMS homology model, and the model with L-leucine bound, were performed, and 
changes in hydrogen-bonding networks in the presence of L-leucine were identified. The only 
overlap between residues identified from the SCA and residues identified from the MD analysis 
are Arg470, Arg32, Glu298, Ser453 and Asn455 (Figure 2.12).  
 
Figure 2.12: Residues identified in the SCA and in the MD simulation shown on the homology model of NmeIPMS. Chain A is 
shown in grey. The catalytic domain of chain B is shown in green, subdomain I in blue, the linker in orange, subdomain II in red, 
and the regulatory domain in teal. The residues of interest are shown as spheres. The active site is denoted by KIV (black stick), 
and the metal ion (black sphere). 
 
In the MD simulations, both with and without L-leucine, Ser453 and Asn455 form a cross-chain 
interaction in the regulatory domain. When MD simulation was performed, potentially interesting 
residues, some of which showed a change in interaction in the apo simulation compared to the L-
leucine bound simulation, were highlighted. In the MD simulations, Arg470 forms an interaction 
with either Glu353 or Glu349 in both the presence and absence of L-leucine, but is the only 
positive charge on the bottom of the regulatory domain, suggesting a potential role in allosteric 
regulation (Figure 2.14). Arg32 from chain A, in both the ligand free and L-leucine bound 
simulation, forms an interaction with Asp375 from chain B, making a potentially important link 
between subdomain II and the catalytic domain. Previous work has shown that mutation of 
Glu353 or Asp375, neither of which were identified in the SCA, to alanine only had a mild or no 
effect on L-leucine sensitivity.130, 131  
55 
 
The lack of change in response to L-leucine seen in the Glu353 and Asp375 mutants suggests that 
there are multiple factors in play when assessing the validity of both the MD simulations and the 
SCA analysis.  
 
Figure 2.13: The structural alignment of the partial NmeIPMS crystal structure (PDB: 3RMJ) and a MtuIPMS crystal structure 
(PDB: 1SR9)(left, transparent)and the NmeIPMS homology model(right, transparent).The catalytic domain is in green, subdomain 
I in blue, the linker in orange, subdomain II in red, and the regulatory domain in teal. Chain A is shown in grey. KIV (black stick) 
and the metal ion (black sphere) are shown in the left hand figure and denote the active site. 
 
The MD simulations are limited as there are no structural data for the full-length NmeIPMS. The 
homology model used as the starting point for the MD simulation was constructed based on the 
MtuIPMS crystal structure. The catalytic domain of the homology model, however, does 
structurally align with the partial crystal structure of NmeIPMS that has been solved (Figure 2.13) 
(RMSD: 1.96 Å). The partial crystal structure of NmeIPMS also aligns structurally with the 
MtuIPMS crystal structure (Figure 2.13, RMSD: 1.51 Å). Additionally, the crystal structures of 
MtuIPMS are the only full-length structures of IPMS, and, as discussed above, MtuIPMS is 
evolutionarily distant from NmeIPMS, meaning that conformations that NmeIPMS adopts may not 
be observed in MtuIPMS and vice versa. 
The limitations of crystallography are also a problem as the conformation MtuIPMS adopts in the 
crystal structure, which the NmeIPMS homology model is based off, may not be catalytically or 
allosterically relevant. Small-angle X-ray data suggests that MtuIPMS adopts multiple 
conformations in solution74. This may mean that the initial conformation used for the NmeIPMS 
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MD simulations may not reflect the conformations adopted by the protein during the catalytic 
cycle.  
There are also limitations of the SCA. SCA detects the change in distribution of amino acids at 
one residue position in response to the change in distribution of amino acids at another position. 
If a position is highly, or absolutely, conserved, even if it is biologically relevant and involved in 
the network, it may not show statistical coupling. Asp375, for example, is almost absolutely 
conserved in this alignment, so is unlikely to show statistical coupling. Additionally, SCA looks at 
the broader protein group to identify potential networks, but NmeIPMS may have undergone 
additional evolutionary pressures that affected the network, meaning the residues identified in the 
network may not entirely overlap with residues identified in the MD simulation that looks at only 
NmeIPMS.  
 
Figure 2.14: The homology model of NmeIPMS showing the locations of Arg32 and Arg470(spheres). Chain A is shown in grey, 
Chain B is shown in green (catalytic domain), blue (subdomain I), red (subdomain II), and teal (regulatory domain). The active 
site is denoted by the black spheres (metal ions) and the black sticks (KIV). 
 
2.3.1 NmeIPMS Arg470Ala and Arg32Ala  
 
Alanine mutants have been made for Arg470 and Arg32 in NmeIPMS.132 The two mutants had 
been partially characterised previously.131 Both Arg470Ala and Arg32Ala display similar Michaelis-
Menten kinetics to the wild type protein (Table 2.2), although Arg470Ala showed a slight increase 
in Km for both AcCoA and α-KIV compared to the wild type protein. Both mutants showed an 
approximately 2-fold decrease in kcat compared to the wild type protein. Both mutant proteins 
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were insensitive to L-leucine inhibition up to 10 mM, suggesting that the connection between the 
regulatory domain and the catalytic domain had been severed, or that L-leucine was no longer 
binding the regulatory domain. 
Table 2.2: Kinetic parameters for NmeIPMS wild type, NmeIPMS Arg32Ala, and NmeIPMS Arg470Ala. *Kinetic characterisation 
of the arginine mutants was performed by Matthew Plowman-Holmes 
 
 




36 ± 3 35 ± 3 7.2 ± 0.1 
NmeIPMS 
Arg32Ala* 
44 ± 4 39 ± 4 3.1 ± 0.1 
NmeIPMS 
Arg470Ala* 







Figure 2.15: ITC data for NmeIPMS (100 µM) using L-leucine (400 µM) as the ligand.The data are fitted with an independent 
model (top) and a multiple site model (bottom). The thermodynamic parameters determined from these models are shown in 
Table 2.3. 
 
Table 2.3: Thermodynamic parameters of the independent model and multiple site model fitted to the NmeIPMS wild-type ITC 
data 
Model type Kd (M) n ΔH (kJ/mol) ΔS (J/mol.K) 
Independent 
2.06 x 10-6 ± 3.21 x 
10-6 































2.3.1.1 Isothermal titration calorimetry of Arg470Ala and Arg32Ala  
 
Isothermal titration calorimetry was used to assess whether leucine was still binding the protein. 
Isothermal titration calorimetry (ITC) is a technique used to assess the binding of a ligand, in this 
case L-leucine, to a protein by measurement of the heat produced or absorbed by the protein upon 
ligand binding.133  
A model could not be reliably fitted to the ITC data obtained for the binding of leucine to 
NmeIPMS, although an independent model and a multiple site model were both fitted to the data 
using NanoAnalyze (Figure 2.15, Table 2.3). 
As the binding of leucine by NmeIPMS is endothermic, where ΔH is unfavourable but ΔS is 
favourable, heat is absorbed by the protein upon ligand binding. The increase in entropy implies 
an increase in flexibility in all or part of the protein, as well as a potential partial desolvation effect 
when leucine interacts with the protein.  The binding curve of leucine binding to wild-type 
NmeIPMS matches well with previously reported ITC data of leucine binding to MtuIPMS.63 This 
similarity suggests that, although the absolute residues involved in the allosteric pathway are 
different, there may be a similar thermodynamic mechanism of allostery.63 Interestingly, the 
Tyr410Phe MtuIPMS mutant that is not inhibited by leucine, displays a similar binding curve to 
that of the wild-type protein, although there is a considerable increase in enthalpy upon leucine 
binding to the mutant compared to the wild type protein. 
Popovych et al.41 studied the binding of cyclic adenosine monophosphate (cAMP) to catabolite 
activator protein (CAP) using ITC. Although binding of cAMP to the dimeric CAP is negatively 
cooperative, binding of the first molecule of cAMP does not adversely affect the conformation of 
the second subunit but instead alters the dynamics of the protein, creating the negative 
cooperativity. Although cooperativity has not been suggested in the binding of leucine to 
NmeIPMS, the binding curve suggests that, in contrast to the canonical sigmoidal binding curve, 




Figure 2.16: Isotherms of NmeIPMS Arg32Ala (top) and NmeIPMS Arg470Ala (bottom). A protein concentration of 150 µM 
and a ligand concentration of 2 mM was used for the Arg32Ala titration, and a protein concentration of 140 µM with a leucine 
concentration of 600 µM was used for the Arg470Ala titration. 
 
Table 2.4: Thermodynamic parameters and stoichiometry of the NmeIPMS leucine insensitive mutants determined by ITC. 





Independent 0.9 ± 0.8 
3.148x10-5 ± 1x10-4 
 
-3 ± 50 75.90 
NmeIPMS 
Arg470Ala 
Independent 0.5 ± 0.3 3.145x10-6 ± 2 x 10-4 -3 ± 20 165 
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Isothermal titration calorimetry was also performed for the two mutants that were not inhibited 
by leucine (Figure 2.16, Table 2.4). These mutants appear to bind leucine, although the binding 
curves are very different to that of wild type NmeIPMS. The ITC binding curve for both Arg470Ala 
and Arg32Ala is weakly exothermic as opposed to the endothermic binding curve of the NmeIPMS 
wild-type protein, demonstrated by the change from positive enthalpy in the binding of leucine to 
wild-type NmeIPMS to negative enthalpy in the binding leucine to both the mutants. Both mutants 
display much lower heats of binding than the wild type protein. As some form of binding is 
observed, it suggests that the two mutant proteins appear to be binding leucine, albeit, potentially, 
in a different way to the way NmeIPMS wild-type binds leucine. Other factors, such as changes in 




2.3.2 NmeIPMS Glu298Ala 
 
 
Figure 2.17: The location of Glu298 in the NmeIPMS homology mode. The residue is shown as spheres, and in Chain B (blue 
sphere) the active site is shown by KIV (black sticks) and the metal ion (black sphere), demonstrating the proximity of Glu298 to 
the active site 
 
Glu298 is another residue of interest (Figure 2.17). As with Arg470 and Arg32, Glu298 was 
identified in both the SCA and in the MD simulations when performed both with and without 
leucine. In the ligand free MD simulation, Glu298 from chain A was predicted to form interactions 
with Ser20 of chain B and Gln19 in both monomers. As with the potential interaction partners of 
Arg470 and Arg32, the residues predicted to interact with Glu298 do not appear in the SCA. Both 
Gln19 and Ser20 are absolutely or highly conserved in the alignment (Figure 2.18). The residues 
may have additional roles aside from allostery, and the level of conservation may reflect this.   
 
Figure 2.18: A LOGO diagram of the MSA used for the SCA showing the conservation of Gln19 and Ser20. 
 
The equivalent to Gln19 in MtuIPMS, Gln84, demonstrates a change upon L-leucine binding in 
one chain of the protein (Figure 2.19). In the allosteric ligand-free structure of MtuIPMS, Gln84 
forms an interaction with Arg427, and this interaction is broken in the leucine-bound structure, 




was made in MtuIPMS, and this caused a large increase in the Km for AcCoA and a substantial 
decrease in kcat, but a more moderate impact on the Km for KIV
68. This mutation did not cause a 
significant impact on inhibition by leucine, suggesting that in MtuIPMS, Gln84 is not involved in 
allosteric regulation by leucine.  
 The NmeIPMS Glu298Ala mutant was made to assess the impact of removing this charge on the 
kinetics of the enzyme but more specifically on the inhibition by leucine.  
 
Figure 2.19: The interaction between Gln84 and Arg427 in MtuIPMS in the absence of leucine(orange - Arg427, black - Gln84, 
PDB: 1sr9), and the presence of leucine (yellow - Arg427, grey – Gln84, PDB: 3fig) 
 
2.3.2.1 Production of NmeIPMS Glu298Ala by site-directed mutagenesis 
 
Whole circle site-directed mutagenesis was used to create the Glu298Ala mutant. The template 
used was the wild type NmeIPMS that had previously been cloned into pET151 via TOPO 
cloning.64 Therefore, the expressed protein contained a N-terminal His6 tag and a TEV protease 
site. The protein was expressed as soluble protein and was purified by IMAC followed by size-
exclusion chromatography. The N-terminal His6 tag was not removed, as discussed in Chapter 4.  
2.3.2.2 Kinetic analysis of NmeIPMS Glu298Ala 
 
The kinetic parameters of NmeIPMS Glu298Ala were determined using a chemically coupled assay, 
where the chemical couple, 4’-4’-dithiopyridine (DTP), interacts with the free thiol of CoA, the 






Figure 2.20: Michaelis-Menten kinetics of NmeIPMS E298A.When obtaining the apparent Km for one substrate, the other 
substrate was held at a saturating concentration of 250 µM. 
 
The Km values for AcCoA for NmeIPMS Glu298Ala have not changed substantially compared to 
the wild type NmeIPMS, suggesting that this mutation does not affect the interaction of the protein 
with AcCoA (Figure 2.20, Table 2.5). The Km for KIV has increased, from 36 ± 3 for the wild-type 
protein to 51 ± 5 for the Glu298Ala mutant. As Glu298 is in subdomain I, which contributes 
residues to the active site, altering the interactions that subdomain I makes with the barrel or within 
the active site may cause an increase in Km for KIV. The kcat has decreased compared to the wild 
type protein, causing a substantial decrease in kcat/Km. Although this mutation does impact 
catalysis, there is a less than two-fold reduction in activity, suggesting that the residue does not 
contribute significantly to catalysis, but may play a role in anchoring subdomain I to the catalytic 
barrel to facilitate catalysis. The mutation of Glu298 to Ala has a similar effect on catalysis to the 
Arg470Ala and Arg32Ala mutations.  
2.3.2.3 Leucine inhibition of NmeIPMS Glu298Ala 
 
The IC50 for leucine for wild type NmeIPMS and NmeIPMS Glu298Ala were determined (Figure 
2.21, Table 2.5). The IC50 for leucine for wild type NmeIPMS was similar to previous 
characterisations of untagged protein, suggesting that the addition of the His6 tag does not 
adversely impact leucine inhibition.1, 64, 130 The IC50 was determined at saturating AcCoA and KIV 




Figure 2.21: The IC50 for leucine for NmeIPMS wild-type, and NmeIPMS Glu298Ala.The IC50 for NmeIPMS wild-type (blue) and 
NmeIPMS Glu298Ala (purple) were determined at an AcCoA of 230 µM and a KIV concentration of 210 µM. 
 
The IC50 for leucine for NmeIPMS Glu298Ala has increased from 50 µM to 220 µM ± 20 µM. This 
analysis was performed at saturating AcCoA and KIV substrate concentrations, as with the wild 
type protein IC50 determination. This suggests that although the mutation has a limited effect on 
catalytic activity, there is an almost four-fold increase in IC50, suggesting that the protein is less 
inhibited by leucine than its wild type counterpart. Additionally, the residual activity for the wild 
type protein, at a high concentration of leucine, has been determined at between approximately 
14% residual activity.  To further investigate the inhibition profile of the NmeIPMS Glu298Ala 
mutant, the effect of leucine at several concentrations while the substrate is varied could be 
investigated. This was not performed due to time restraints. 
The residual activity for the Glu298Ala mutant is higher than that of the wild type protein at 30%, 
suggesting that inhibition by leucine is less complete in this mutant compared to the wild type. De 
Carvalho et al.63 determined the inhibition by leucine of a number of mutants in MtuIPMS, and 
MtuIPMS His379Ala showed increased residual activity in the presence of leucine compared to the 
wild type protein although there was no change in the Ki or Ki* values for this mutant. The authors 
suggested that the binding of L-leucine was not affected by this mutation, but the active site was 
less altered in the mutant when leucine is bound compared to the wild type protein, allowing for 




Product release is thought to be a key, and possibly rate determining, step in the IPMS reaction 
cycle, as this may involve a large-scale movement of the subdomains to facilitate release of 
products and subsequent binding of substrates.56 The asymmetry noted in the MtuIPMS structures 
is suggestive of a ‘closed’ and ‘open’ active site, and MD simulations on NmeIPMS have suggested 
that AcCoA can be more readily recruited to the open active site. Therefore, the increased residual 
activity may be because the active site may not remain closed efficiently as Glu298 is in subdomain 
I and forms an interaction at the top of the barrel that may help to anchor subdomain I to the top 
of the barrel. In the absence of this interaction when Glu is mutated to Ala, substrate binding and 
release may occur more readily in the presence of the inhibitor than in the wild type protein.  
Although the Glu298Ala mutation did not abolish leucine sensitivity as the Arg470Ala and 
Arg32Ala mutants did, it did have a substantial impact on inhibition by leucine. This suggests that 
this residue may form part of the allosteric network that alters the active site in response to leucine.  
Table 2.5: A summary of the kinetic and inhibition parameters of NmeIPMS wild type and several alanine mutants. * denotes 
parameters determined by Plowman-Holmes131. N/A stands for not applicable. 
 
2.4 Summary  
 
With the massive increase in sequence data available, techniques to identify patterns and provide 
meaning to that data are becoming increasingly available and sophisticated. Covariance analyses, 
such as statistical coupling analysis, present a way to explore protein evolution in a new light. Such 
techniques do require knowledge of the system they are analysing, and structural and functional 
information is required for further investigation of the system. Additionally, these types of analyses 
require a thoroughly curated multiple sequence alignment, and, particularly for SCA, an 
understanding and analysis of the phylogenetic basis of the sequence population. If little is known 
about the system, it can be difficult to produce an accurate sequence alignment, especially if the 
alignment contains regions with significant gaps.  
Protein Km (KIV) 
µM 
Km (AcCoA) µM kcat (s-1) L-Leu IC50 (µM) Residual 
activity 
(%) 
Wild type NmeIPMS 36 ± 3 35 ± 3 7.2 ± 0.1 53 ± 5 17 
NmeIPMS R470A* 55 ± 3 58 ± 6 2.8 ± 0.1 N/A N/A 
NmeIPMS R32A* 39 ± 4 44 ± 4 3.1 ± 0.1 N/A N/A 
NmeIPMS E298A 51 ± 5 39 ± 4 4.7 ± 0.1 220 ± 20 30 
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Covariance analyses provide a way to explore sequence space that is not reliant on absolute 
conservation. Residues that may not be conserved but are important for protein function can be 
readily identified, and aspects of protein behaviour such as protein-protein interaction, functional 
dynamics, and allosteric regulation, can be explored more broadly if the pathways that underline 
these aspects can be identified and modulated. Covariance analyses also provide opportunities to 
explore enzyme evolution in the context of drug resistance, as identifying regions of the protein 
that are key for catalysis or allosteric regulation that are not binding sites may provide additional 
targets or ways to modulate functionality and suggest how organisms have evolved, or may evolve, 
to evade drugs.  
The NmeIPMS-like IPMS were chosen as the target for this investigation, as this group of enzymes 
provide an interesting picture of a very dynamic protein in which the mechanism of allostery is 
not well understood. Also, it is difficult to study this protein by purely biophysical or structural 
means as it does not readily crystallise, and protein stability can also be problematic. Therefore, 
covariance analyses provide a different way to investigate the important residues controlling 
protein motion that facilitate catalysis and allosteric regulation. As IPMS is found almost invariably 
in bacterial species, a wide phylogenetic net can be cast to limit the impact of a narrow phylogenetic 
or environmental niche on the covariance analyses that may provide less information about the 
protein motion as a whole.  
The SCA identified one sector that spanned from the N-terminal catalytic domain to the C-
terminal regulatory domain of NmeIPMS. The sector contained numerous residues in the dynamic 
subdomains, as well as ones surrounding the leucine binding site, suggesting a potential role for 
this sector in the transmission of allostery through the subdomains that are so critical for AcCoA 
binding to the catalytic domain.  
In light of the identification of this sector, several mutations were made in NmeIPMS to assess the 
character of this pathway. Some of these residues had also been identified through other means, 
such as MD simulations, that provide further evidence for the importance of these residues in 
protein function. One mutation, Glu298Ala, had a limited impact on catalytic activity, but 
attenuated allosteric inhibition substantially, while two other mutations, Arg470Ala and Arg32Ala, 
also had limited impact on catalysis, but completely abolished allosteric inhibition by leucine. Both 
Arg470Ala and Arg32Ala did still bind leucine, as evidenced by isothermal titration calorimetry. 
This evidence suggests that residues in this SCA sector do contribute to the allosteric network. It 
also suggests that SCA, as discussed previously, may provide a way to identify these networks that 
are not apparent by simple multiple sequence alignment, is not reliant on structural information, 
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and is less expensive computationally than MD simulations. SCA also does not rely on structural 
information.  
This analysis demonstrates the power of covariance analyses such as SCA to identify networks that 
are not apparent from other types of analyses. It provides additional insight into the complex 
mechanism by which this group of enzymes perform their function and how this catalytic activity 





Chapter 3: Covariation analysis of IPMS, CMS, and 




The statistical coupling analysis of the NmeIPMS-like IPMS group demonstrates that this type of 
analysis can provide promising leads and valuable information about this very dynamic system. 
However, Kumar et al.69 suggest that there are evolutionarily distinct versions of IPMS, CMS, and 
HCS (Figure 3.1). What was termed IPMS1 is characterised by IPMS from Methanocaldococcus 
jannaschii (MjaIPMS) and NmeIPMS, while IPMS2 was typified by MtuIPMS. IPMS1 are 
phylogenetically close to CMS1, including MjaCMS, while LinCMS-like CMS fall into a discrete 
group termed CMS3. The HCS group also divides along phylogenetic lines. As different members 
of these groups can show allostery affecting different parts of the catalytic cycle, as discussed in 
Chapter 1, it suggests that the mechanism of allostery may be tied to phylogeny, or at least is not 
conserved through all the diverse groups. Therefore, to explore the underlying mechanisms of 
catalysis and regulation more widely, a broader phylogenetic approach must be taken.  
One interesting feature of this broad group of proteins is the presence and absence of the 
regulatory domain. Additionally, the subdomains appear to be of critical importance in the 
recruitment of AcCoA and facilitation of catalysis in both the regulatory domain present (RDP) 
and the regulatory domain absent (RDA) proteins. This suggests that there must be coevolution 
of residues to facilitate sufficient flexibility and stability in the subdomains to allow for catalysis in 
the presence or absence of a regulatory domain.  
There are similarities in structure between the two populations that suggest that they have a similar 
mechanism for binding AcCoA. The loop that connects the subdomains contains residues that are 
critically important for AcCoA recruitment, although Okada et al.106 suggest that the groove in 
which the adenosine portion of AcCoA is proposed to bind in Thermus thermophilus HCS (TthHCS) 
is a different shape to that in Leptospira interrogans CMS (LinCMS), suggesting that there is 
potentially a difference in absolute substrate recognition between the two populations.  
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Therefore, coevolution analyses were used to probe these broad protein populations to investigate 
whether there is coevolution in the subdomains that may facilitate catalysis in the presence or 
absence of a regulatory domain.  
 
 







3.2 Statistical coupling analysis of Claisen condensation-like enzymes  
 
3.2.1.1 Multiple sequence alignment construction 
 
A pool of sequences containing the LeuA Dimer motif was obtained from Pfam.114 As with the 
NmeIPMS-like sequence pool described in Chapter 2, sequences were removed from the 
population if they were less than 300 amino acids, greater than 700 amino acids, or lacked key 
conserved residues or motifs. An initial multiple sequence alignment of 888 sequences of 
NmeIPMS-like IPMS, LinCMS-like CMS, and MjaCMS-like CMS sequences was obtained using 
MAFFT, seeded by a structural alignment performed by PROMALS3D.92, 134  
 
 
Figure 3.2: MSAs showing the region around the conserved tyrosine in subdomain II known to be important for catalysis. The 
tyrosine of interest (Tyr410 in MtuIPMS, Tyr313 in NmeIPMS) is shown in the red boxes. When MtuIPMS and related species are 
present in the alignment, this region is mis-aligned in this region, while when MtuIPMS-like IPMS are not present, this region is 
not mis-aligned. 
 
MtuIPMS-like IPMS sequences were not used in this analysis due to problems with producing an 
accurate alignment (Figure 3.2). The MtuIPMS-like IPMS sequences form a separate cluster in the 
protein similarity network constructed by Kumar et al. and in the CLANS analysis discussed in 
Chapter 3.2.1.1.1.69 The length of the IPMS-like IPMS sequences is also considerably longer, for 
example, the average length of the MtuIPMS-like IPMS sequences was approximately 590 amino 
acids while NmeIPMS-like IPMS sequences have an average length of approximately 515 amino 
acids. The structural alignment between the LinCMS and MtuIPMS structures was inaccurate as 
the extension in the middle of the MtuIPMS sequence and the lack of structural information for 
subdomain I and II in the LinCMS structures meant that the MSA was mis-aligned if MtuIPMS-
like IPMS sequences were present.  
The structural alignment was performed using the PROMALS3D web-server, with the homology 
model of NmeIPMS, and one of the structures of LinCMS (PDB: 3BLF) as input.134 The RMSD 
of the NmeIPMS homology model and the partial structure of NmeIPMS (PDB: 3RMJ) is 1.96 Å, 
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suggesting that, based on the structural evidence available, it provides an adequate representation 
of the protein structure. As the structure of LinCMS is not complete, this structural alignment only 
aligned the catalytic barrels of both proteins. This structural alignment was then used as a ‘seed’ 
for a large-scale multiple-sequence alignment in MAFFT. If the structural alignment was not used 
as a seed, the multiple sequence alignment was mis-aligned based on a comparison with a structural 
alignment produced in PyMol using the super alignment tool.  
MAFFT is a multiple sequence alignment programme that utilises fast Fourier transform (FFT) to 
perform alignments.92, 127 The structural alignment produced by PROMALS3D was used as a ‘seed’. 
This means that the aligned ‘letters’ (i.e. the residues) are preserved, but gaps are not. The 
additional sequences were added as full sequences, and MAFFT FFT-NS-2 was used to produce 
a final multiple sequence alignment. Due to the nature of the gap penalties with this algorithm, 
and the lack of structural information at this position from the LinCMS crystal structures, the 
conserved Tyr in subdomain I that is equivalent to NmeIPMS Tyr313 in the LinCMS-like sequences 
was manually aligned. This final, curated, alignment of 888 sequences was then used as input for 
SCA. 
Alternative methods of sequence alignment were also considered. PRANK, a phylogeny-aware 
sequence alignment method, the EXPRESSO variant of T-COFFEE, and DECIPHER, a new 
multiple sequence alignment method that uses secondary structure prediction and gap penalties 
relevant to the local environment of each amino acid, were also tested for this sequence pool.135-
137 However, MAFFT, when seeded with the PROMALS3D structural alignment of the known 
enzymes, produced a reliable alignment as alignments produced by other methods mis-aligned 
conserved regions known to be important for catalysis.  
As the output of the SCA is absolutely dependent on the quality of the alignment, an external 
method of validating the alignment was required. The LoCo tool was also used to assess the 
multiple sequence alignment by analysing local co-variance in the alignment.138 There was limited 
local co-variance at most positions, aside from ones with biological relevance, such as those 
conveying specificity of the ketoacid substrate to the active site, suggesting that there was not 
significant mis-alignment within the alignment.  
Pfam was also mined for a sequence population of Claisen condensation enzymes that did not 
contain regulatory domains. This sequence population was then manually edited to remove 
aberrant sequences and similar enzymes that bind other substrates, based on criteria established 
by Casey et al.68  Fungal HCS sequences were not used in this alignment as they formed a discrete 
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phylogenetic group. A structural alignment between a structure of LbiIPMS (PDB: 4OV4), an 
IPMS lacking a regulatory domain, and TthHCS (PDB: 2ZTJ), a bacterial HCS, was performed 
using PROMALS3D and this was used to seed a multiple sequence alignment, performed in 
MAFFT. This alignment of 488 sequences was then manually assessed and used as the basis for 
the SCA of the RDA alignment.  
3.2.1.1.1 CLANS of the sequence populations 
 
Figure 3.3: CLANS analysis of the sequence populations of interest including the MtuIPMS-like IPMS sequences (green), 
NmeIPMS-like and MjaCMS-like IPMS and CMS (blue), TthHCS-like HCS (red), SpoHCS-like HCS (purple), and LinCMS-like 
CMS (teal). 
 
All sequences obtained for this analysis were investigated using CLANS (Figure 3.3). This included 
MtuIPMS-like IPMS sequences and fungal HCS sequences as CLANS does not require a MSA as 
input. This showed a similar pattern to that observed by Kumar et al.69 with MtuIPMS-like IPMS 
forming a discrete group away from the other sequences. 
CLANS was also performed using only the RDP sequence population, and this demonstrated that 





Figure 3.4: CLANS analysis of the RDP sequence population.The definition between the NmeIPMS-like IPMS (blue) and the 
MjaCMS-like CMS (orange) population is shown although it is absent in Figure 3.2.  The LinCMS-like CMS population forms a 
separate cluster. 
 
3.2.2 Regulatory-domain present sequence SCA (RDP-SCA) 
 
3.2.2.1 Sequence similarity in the RDP sequence alignment  
 
Figure 3.5: Sequence similarity in the RDP alignment from a matrix of similarity. 
Sequence similarity in the RDP sequence alignment was assessed (Figure 3.5). The heat map 
(Figure 3.5, right) shows a matrix of similarity, the fraction of amino acids that are the same 
between two sequences. This shows that the sequence population is not homogeneous, as would 




3.2.2.2 Conservation in the RDP sequence alignment 
 
The positional conservation was also assessed by determining the relative entropy of each position 
(Figure 3.6). This shows that there is considerable conservation at similar positions to that of the 
NmeIPMS-like IPMS sequence population, for example the conserved histidine residues His204 
and His206 important for metal ion coordination. There is less conservation overall in the RDP 
sequence alignment compared to the NmeIPMS sequence alignment, which correlates with the 
increased phylogenetic distance between the sequences of interest. 
 
  
Figure 3.6: Positional correlation in the RDP alignment.Highlighted are absolutely conserved residues known to be important 
for catalysis. The residue numbers are from NmeIPMS. 
 
3.2.2.3 SCA-PCA of the RDP sequence alignment  
 
The positional correlation matrix of the RDP alignment was calculated using SCAv5.m as 
described in Chapter 2. The matrix (Figure 3.7) demonstrates the small amount of absolute 
conservation in the matrix (dark blue) but shows that there is considerable positional correlation 




Figure 3.7: Positional correlation matrix from the SCA calculation of the RDP alignment.The colour gradient shows the degree 
of statistical coupling from blue (low) to red (high). 
 
The eigenspectrum was also plotted (Figure 3.8). As described in Chapter 2, the red line denotes 
the randomised alignments that allow determination of the significant eigenmodes. The top three 
eigenmodes are statistically significant, and the top eigenmode has a substantially larger eigenvalue 
than the others, as observed in the NmeIPMS SCA. The top eigenmodes were also assessed by 
scatter plot. The scatter plots suggest that there are potentially at least two ‘independent’ sectors 
within the data (Figure 3.10). As it was known that multiple different phylogenetic groups were 
used in the construction of the alignment, independent component analysis (ICA), as opposed to 
the PCA used in the NmeIPMS SCA,  was utilised to investigate the identity of these sectors.  
 
Figure 3.8: The eigenspectrum of the matrix produced by SCA after PCA for the RDP alignment.The black box indicates those 
eigenmodes of interest. The red line indicates the distribution of randomised matrices. 
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3.2.2.4 Independent component analysis (ICA) of the RDP-SCA  
 
 
Figure 3.9: The top three independent components of the RDP SCA. 
 
Independent component analysis (ICA) is a way of repositioning the data to explore the presence 
or absence of independent sectors within the SCA matrix.  Principal component analysis 
determines the independent variable that best describes all of the data, while independent 
component analysis is used to extract the underlying components involved in producing the data. 
An example commonly used to describe independent component analysis is the “cocktail party 
problem” where several people are talking at once, so the resulting principal component is a 
mixture of all of the voices. If independent component analysis is used, the noise can be separated 
into individual voices again. In this analysis, the top 3 eigenmodes were selected for analysis, and 
the eigenmodes were transformed into independent components (Figure 3.9, Figure 3.10). Singular 
value decomposition of the sequence correlation matrix from the initial SCA was also performed 
to allow for identification of independent sectors that also displayed sequence correlation, i.e. 





Figure 3.10: Scatter plot of the first and second eigenmodes demonstrating the potential two sectors within the data in the red 
and green boxes 
 
When the top three independent components are plotted and compared to the pattern of sequence 
divergence, it is obvious that the residues with a high score for the second independent component 
(IC2) is due to the phylogenetic relationship in the sequences (Figure 3.11). Based on the multiple 
sequence alignment, this cluster of sequences is likely from the LinCMS-like CMS group of 
sequences, and this reflects the CLANS analysis that clustered these sequences apart from the 
NmeIPMS-like IPMS group and the MjaCMS-like CMS group. 
 Upon further analysis of the residues in this IC, it appears that IC2 includes residues that are 
involved in AcCoA interaction. IC2 was also mapped onto the NmeIPMS homology model (Figure 
3.12). This IC includes residue Arg77 (NmeIPMS numbering), which corresponds to Phe83 from 
LinCMS. In the AcCoA-containing structure of LinCMS (PDB: 3BLI), Phe83 a forms 
hydrophobic interaction with AcCoA in the LinCMS structure, and Phe is conserved in the 
LinCMS-like CMS sequences at this position, whereas Arg is conserved in the MjaCMS/NmeIPMS 
population in the alignment. Additionally, this IC contains residues such as Lys112, Lys364, and 
Arg371 that have been predicted to be involved in AcCoA interaction with NmeIPMS by docking 
studies performed by Dr. Wanting Jiao (personal communication, May 2014). This suggests that 
LinCMS may have a different way of binding AcCoA to the other RDP proteins, and other residues 
that may be involved in AcCoA interaction show statistical coupling in these populations to 




Figure 3.11: Scatter plots of the top three independent components (top, left), and the sequence space mapped to the 
independent component matrix (top, right). The blue spheres denote IC2 (top, left) and the sequence space that corresponds to 
IC2 (top, right). The histogram (bottom) indicates the scores for residues in IC2 plotted with a lognormal distribution (red line). 
The blue dashed line denotes the cut-off in the tail. 
 
 
Figure 3.12: The residues with significantly high scores from IC2 mapped onto the homology model of NmeIPMS. Chain A is 
shown in grey, Chain B is coloured. The catalytic domain is shown in green, subdomain I in blue, the linker in orange, subdomain 
II in red, and the regulatory domain in teal. 
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Residues with a high score for the first IC (IC1) do not appear to have the same phylogenetic basis 
as IC2, as residues in IC2 showed statistical coupling due to the change in AcCoA interaction in 
the LinCMS-like CMS group, and this was observed by comparing the sequence space with the 
independent components (Figure 3.11). The absence of a relationship with sequence suggests the 
residues in this independent component may provide more broad information about coevolved 
residues in the RDP population than IC2. IC1 contains residue Phe101, the only residue of those 
making contact with the ketoacid substrate that is different between all three broad phylogenetic 
groups involved in this analysis69, further suggesting that this IC may give a broader picture of 
coevolved residues in these proteins than IC2. 
 
 
Figure 3.13: The residues with significantly high scores from IC1 mapped onto the homology model of NmeIPMS.Chain A is 
shown in grey, Chain B is coloured. The catalytic domain is shown in green, subdomain I in blue, the linker in orange, subdomain 
II in red, and the regulatory domain in teal. 
 
When the residues in IC1 are highlighted on the homology model of NmeIPMS (Figure 3.13), they 
appear to show a network of interconnected residues that span the catalytic domain and 
subdomains, with a few residues in the regulatory domain. This suggests that this IC may represent 
a network of residues that are involved in controlling the motion of subdomain II to facilitate 
catalysis. IC1 also contains residue 336, which is an arginine in NmeIPMS. An alanine mutant of 
Arg336 in NmeIPMS has been made, and this change had a substantial impact on AcCoA 





Figure 3.14: The residues with significantly high scores from IC3 mapped onto the homology model of NmeIPMS.Chain A is 
shown in grey, Chain B is coloured. The catalytic domain is shown in green, subdomain I in blue, the linker in orange, subdomain 
II in red, and the regulatory domain in teal 
 
The third independent component of interest (IC3) has a number of residues with significant 
scores. These appear to be primarily located in regions of flexibility such as loops at the end of 
helices in the catalytic barrel, suggesting a potential role for the residues in this IC in maintaining 





3.2.3 Regulatory domain absent SCA  
 
As with the RDP sequence population, the regulatory domain absent (RDA) sequence 
population was obtained from Pfam and was edited as described above. The fungal HCS 
sequences were removed as they skewed the sequence population significantly, so the sequence 
population, as with the RDP population, was made up of bacterial sequences.  The fungal HCS 
sequences formed a distant group in the initial CLANS analysis (Figure 3.3), and when an 
alignment was constructed using these sequences, an initial attempt at using independent 
component analysis was performed. However, the differences between the bacterial and fungal 
RDA sequences were unable to be resolved. To investigate the similarities and differences 
between co-evolved residues in the two different populations, a further analysis using only fungal 
HCS sequences could also be performed although this was not done due to time constraints.   
3.2.3.1 CLANS analysis of the RDA sequence population 
 
CLANS analysis was also performed on the RDA sequence population to assess the sequence 
space (Figure 3.15). This suggested that, although there were several clusters, they were interlinked 
and there were no outlying clusters as seen in the RDP sequence population. The multiple 
sequence alignment was performed as described above.   
 
Figure 3.15: CLANS output for the RDA sequence populations.The different clusters identified by the program are shown in 
different colours. The clusters denote different clusters of proteins lacking regulatory domains. These clusters are not well 









3.2.3.2 SCA analysis of the RDA alignment  
 
This, along with analyses of the sequence similarity and positional correlation, was performed as 
described above for the RDP sequence alignment. The sequence similarity showed a similar pattern 
to that of the RDP alignment (Figure 3.16), although as with the CLANS pattern, there is closer 
sequence similarity amongst this RDA population than there is amongst the RDP population due 
to the outlying LinCMS-like sequence group in the RDP population.  As with the RDP sequence 
group, there is positional correlation at residue positions of significance, such as conserved 
histidines involved in metal ion coordination, and the conserved tyrosine in subdomain I (Figure 
3.16).  
 





The matrix obtained from the SCA calculations demonstrates a similar pattern to that of the RDP 
sequence alignment. Principal coupling analysis was performed on the matrix obtained from the 
SCA calculations, producing the eigenspectrum (Figure 3.17, top). There does not appear to be a 
substantial phylogenetic component to the coupling values observed in the matrix (Figure 3.17) so 
the top eigenmode was further investigated, as opposed to the RDP sequence alignment where 
there was an obvious phylogenetic component to the top eigenmodes. 
 
 
Figure 3.17: The eigenspectra (top) and the top three eigenmodes (bottom) of the RDA SCA. 
 
The top eigenmode was fitted with a lognormal distribution, and the independent sector in the 
RDA matrix was defined by the construction of a cumulative density function and cutting off this 
so only residues in the tail were selected as sector residues. When these residues were plotted onto 
the homology model of NmeIPMS, they form a network spanning the subdomains and the catalytic 
domain (Figure 3.18). This network includes residues known to be involved with substrate 
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selectivity in the active site, such as Phe101, His99, and Leu75, (NmeIPMS numbering) suggesting 
that there may be a phylogenetic basis to the coupling observed or that when there is a change in 
these residues, there is a change in other residues to compensate for the altered shape or charge in 
the active site.  
This sector also includes residues thought to be important for AcCoA interaction. The positive 
charge in the linker region between subdomain I and subdomain II is thought to be critical for the 
recruitment of AcCoA, and residues in this linker region show statistical coupling, suggesting that 
maintaining the charge in this position is important for facilitation of catalysis in the absence of 
the regulatory domain. Residue Glu298 was also identified in the NmeIPMS-like IPMS SCA 
(Chapter 2) but not in the RDP SCA analysis, suggesting that this residue may have different roles 
in the NmeIPMS-like IPMS population in allosteric regulation but yet not in facilitation of catalysis 
in the broader group, demonstrating the interconnectedness of residues involved in both catalysis 
and allosteric regulation in these proteins.  
 
Figure 3.18: The network of residues identified as the sector by principal component analysis of the RDA SCA matrix. 
 
There are several residues that also appear in the SCA of the RDP group. Phe360 (NmeIPMS 
numbering), located in subdomain II, shows statistical coupling in both the RDP and RDA SCA, 
implying that this residue has a critical role in catalysis in both populations regardless of the large 
structural change between the two populations. Phe360 in the RDP population is predominantly 
phenylalanine while in the RDA, this residue position is predominantly leucine, suggesting a 
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change from a large to small hydrophobic residue. In the NmeIPMS homology model, this residue 
is in the middle of the three-helix bundle that comprises of subdomain II (Figure 3.19, left).  
A change in this position may substantially change the structure of the helices that make up 
subdomain II, that could stabilise or destabilise the subdomains, altering the recruitment of AcCoA 
and subsequently, catalysis. Asn169 (Figure 3.19, right), which also shows statistical coupling in 
both analyses, is found inside the active site, suggesting that a change in this position could be 
coupled to changes in the active site in response to substrate selectivity changes in the active site. 
 
 
Figure 3.19: The location of Phe360 in subdomain II, and Asn169 in the active site of NmeIPMS. Phe360 is shown as red 
spheres, and Asn169 is shown as green spheres. The metal ion (sphere) and KIV (stick) are shown in black. 
 
3.3 Summary  
 
The comparison of the two statistical coupling analyses presents an interesting picture of these 
two groups of structurally similar proteins. There is a number of differences between the two 
populations. The RDP alignment could be best explored using independent component analysis 
as there was a phylogenetic bias to the alignment. This bias was not apparent in the RDA 
alignment, so principal coupling analysis could be used to investigate the presence of sectors. Both 
SCA produced sectors that spanned the catalytic domain and subdomains, suggesting coupled 
residues that control the motion of the subdomains are critical for catalysis. Very few residues in 
the regulatory domain in the RDP SCA were coupled, suggesting that there is not a conserved 
pathway of allosteric regulation amongst those proteins containing a regulatory domain. This 
correlates with differences in mechanism of allostery observed between the different populations.  
There are a number of residues that show statistical coupling in both groups. Some of these 





maintaining the structure or dynamics of the subdomains in the presence or absence of the 
regulatory domain. As demonstrated by Phe360, there appears to be a difference in the size of 
residue in that position in the RDA compared to the RDP, suggesting that although this residue 
shows statistical coupling in both populations, there is also significant differences in the two 
alignments.  
Some of these residues are involved in substrate selectivity, suggesting that in both proteins, there 
is possibly a functional basis to the coupling, although it is reasonable to presume that changes in 
the active site to accommodate other substrates are accompanied by changes in other regions of 
the protein regardless of specific phylogenetic changes. However, one way to explore this would 
be to use a method that is not influenced by phylogeny. As discussed above, the influence of the 
weighting of the SCA matrix by conservation can cause a bias in the subsequent analysis. If a 
substantial subset of the sequence population is from a different phylogenetic group and has 
significant changes in residues that are well conserved such as the LinCMS-like CMS group, 
principal component analysis cannot be used to analyse that matrix. Although the RDA sequence 
population has substantial phylogenetic differences, ICA failed to identify these, suggesting that 
principal component analysis is sufficient to analyse this population. 
This phylogenetic bias in SCA was also noted by Colwell et al.139 who explored the statistical 
coupling analysis performed by Halabi et al.129 on a group of serine proteases, and compared it to 
a covariance analysis performed by Skerker et al.140 who used mutual information (MI) to 
investigate the interaction between histidine kinases and their response regulators. Colwell et al.139 
demonstrated that, although the algorithms used in the analyses were similar, they were not 
interchangeable in that if the MI algorithm was used on the serine protease sequence alignment, 
the results were considerably different and vice versa. They identified that the major difference 
between the two algorithms was the conservation weighting function used in SCA, and if this was 
used with the MI algorithm, then the results were comparable to the results from the SCA 
algorithm, and conversely, the SCA algorithm in the absence of the conservation weighting 
function produced similar results to the MI algorithm, which does not have a similar weighting 
function. This demonstrates clearly that the clusters identified by SCA are dependent on the 
conservation weighting function, and thus phylogenetic bias. This is particularly evident when 
there are changes in conserved residues and can skew the results significantly. Teşileanu et al.141 
also argued the same point, demonstrating that the functional sectors identified in prior SCAs may 
actually be identifiable through conservation, if single-site statistics are used to identify them.  
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As the residues identified by SCA in these two analyses present a potentially interesting picture of 
how these proteins may be able to bear the burden of the regulatory domain and still allow catalysis 
using the dynamic subdomains. However, the significant phylogenetic bias to the results by the 
conservation weight matrix used in the SCA becomes problematic as there are significant 
phylogenetic differences particularly in the RDP sequence population. Therefore, mutual 
information was also used to explore the same sequence alignments to compare and contrast the 
results as done by Colwell et al.139 to explore the potential network of residues controlling the 




3.4 Identification of covariance in IPMS and IPMS-like enzymes using mutual 
information 
 
Mutual information, in this context, was adapted from information theory, and is a measure in the 
uncertainty about a position, in this case a residue in an MSA, given information about another 
position (residue).142 It can vary from 0 to 1, with 1 indicating complete knowledge. MI is calculated 
based on the Shannon entropy (H), a measure of how random the residue population is in a 
particular column of a MSA.143 Formerly, MI was a relatively imprecise way of detecting covariation 
in an MSA, as factors such as the number of sequences, the sequence diversity, and phylogenetic 
biases all hindered the usefulness of the algorithm.  
Dunn et al.143 developed a new metric, MIp, that utilises MI, but can accurately and quickly identify 
coevolved residues without the limiting factors of phylogeny. This technique uses a correction, 
termed the average product correction (APC), which determines the background mutual 
information of a particular alignment, which includes random noise and phylogenetic effects, and 
is used to correct that alignment so that only the residues that show mutual information related to 
structure and function, as opposed to background or phylogenetic aspects are identified. The 
difference between total MI, and MI when corrected, is presumed to be MIsf, or mutual 
information due to structural or functional restrictions on the protein, and thus are of interest. 
Dickson144 then developed an efficient way of calculating mutual information using C and Perl-
based programmes to calculate MI, MIp, and a variety of other statistics. This was implemented in 
Linux as the MIp Toolset. The MIp Toolset was utilised in the following analysis to obtain 
information about the mutual information of various groups of residues in alignments of subsets 
of the Claisen condensation-like enzymes. 
3.4.1 Sequence populations and alignments 
 
Buslje et al.124 assessed the size of sequence alignments needed for effective predictability from the 
MI algorithm, with and without the average productive correction discussed above. They 
determined that an alignment size of over 400 sequences, where the sequences contained within 
are less than 62% identical, was required to provide sufficient numbers and variability of sequence 
to sufficiently reduce the impact of random noise and phylogenetic relationships so the output 
provides sufficient predictive performance.  The RDP and RDA sequence alignments used in the 
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MIp analysis therefore remained the same as in the SCA analysis as both alignments fall within 
these parameters.  
3.4.2 Mutual information analysis  
 
The analysis was performed as described above, utilising the MIp Toolset that contains multiple 
programmes including the MIp.pl programme used for determining mutual information within a 
MSA. The output of this programme consisted of a large table of information, and a .dot file for 
easier viewing. One other programme within the MIp Toolset is dist_pdb that allows distances 
between Cα carbons to be determined from a PDB file. Chain A and Chain B from the NmeIPMS 
homology model, discussed previously, were independently used as an input for this programme.  
Gloor et al.145 noted that mutual information identified two types of co-evolving residues, residues 
that coevolved with only one or a small subset of other residues, termed single pairs, and those 
that form larger networks of residues and are typically at an active site or regions essential for 
protein function. They suggest that single pairs are typically important for local structure and the 
amino acid sidechains involved in such pairs are in contact, while the large group of residues are 
more likely to have a broader functional impact.  
BioPython was used to produce contact maps for the NmeIPMS homology model, both within a 
chain and between the two chains. This allowed assessment of the single pair residue groups 
identified in the MIp analysis (Figure 3.22) to determine whether these single pairs showed the 
same pattern identified by Gloor et al..145 Onto the NmeIPMS contact map, the residues with 
significant Z scores from either the RDP MIp analysis (Figure 3.20, top), or the RDA MIp analysis 
(Figure 3.20, bottom) were mapped. The single pairs of residues that share mutual information in 
both the RDP and RDA MIp analyses appear to be related to local structure, and also are typically 




Figure 3.20: Contact maps of the NmeIPMS homology model. Chain A is shown in blue, Chain B is shown in green, and cross-
chain contacts in purple. The contact maps show the single pair interactions identified by MIp in orange/red. The interactions 
identified by the RDP MIp analysis are in the top figure, and the interactions identified by the RDA analysis are in the bottom 
figure. 
 
   
In the RDP MIp analysis, there is one single pair that does not form close structural contacts, 
residues 281 and 451 (NmeIPMS numbering). Plausibly, these residues may be closer in space in 
the dynamic protein, or during the catalytic cycle, and thus share mutual information. In the RDA 
MIp analysis, several single pairs cannot be accounted for by close structural contacts. This is likely 
because the NmeIPMS homology model was used to construct the contact map, and this contains 













3.4.2.1  RDP sequence population MIp analysis 
 
The so-called ‘group’ residues (Figure 3.21) are of particular interest as they form a network of 
mutual information that provides insight into the functioning of the protein.145 The network can 
be narrowed down to ‘nodes’ of residues that show the highest mutual information in relation to 
each other (Figure 3.23). These residues are from the catalytic domain, subdomain I, and 
subdomain II.  None of the residues appears in the molecular dynamics simulations or docking 
studies. This could be due to the nature of the sequence alignment, or because the molecular 
dynamics simulations did not fully account for the natural behaviour of the protein. 
 
Figure 3.23: The node residues from the RDP MIp analysis that share the highest Z scores.The residue numbering is from 
NmeIPMS. 
  
Interestingly, several of the residues were very close in sequence to highly conserved parts of the 
protein that are known to be important for catalysis. Residue Tyr176 falls just after a group of 
highly conserved residues (Pro171-Gly175) that include Thr173, known to be important for 
catalysis. Residue Ile315 also falls just after a highly conserved residue, Tyr313, which is also 
important for catalysis. Tyr176 and Ile315 also appear to form a cross-chain hydrophobic 
interaction in the NmeIPMS homology model that may restrain subdomain I. If a structural 
alignment of the L-leucine bound conformation of MtuIPMS (PDB: 3FIG) against the homology 
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model of NmeIPMS is performed, the two comparable residues, Met257 and Pro412 (MtuIPMS 
numbering) are also in close proximity in the MtuIPMS L-leucine bound structure (PDB: 3FIG), 
due to the domain swap that occurs in the homodimeric structures. In the L-leucine absent 
structure (PDB: 1SR9), the region containing Met257 is disordered. Tyr176 and Ile315 (NmeIPMS 
numbering) do not show significant mutual information in the regulatory domain absent analysis, 
suggesting that this interaction may be particularly important for those sequences that contain a 
regulatory domain. 
As with the example above, residue Phe363 and Ala367 are also in a region of high conservation, 
although neither residue themselves is particularly highly conserved. This suggests that the 
interactions and positions surrounding conserved regions may show mutual information to allow 
for preservation of the contacts or interactions that those residues within the conserved region. 
Molecular dynamics simulations suggest that residue Lys364 in NmeIPMS forms a hydrogen bond 
with Glu503 in the presence of AcCoA, suggesting that the interactions adjacent to this conserved 
residue are important for maintaining its ability to interact with other residues to facilitate AcCoA 
binding and subsequent catalysis. Phe363 also forms the centre of the node residues, having 
significant mutual information with 6 other residues. This residue appears to form part of the 
hydrophobic ‘core’ of the alpha helical bundle that makes up the subdomains, and thus may be 
crucial for maintaining proper tertiary structure in that region. The presence and stability of 
subdomain II has shown to be critical for catalysis, potentially due to subdomain II’s role in 
limiting the conformations formed by the linker region between subdomain I and II that is 






Figure 3.24: The location of residues 135, 136, and 167, in the NmeIPMS homology model.KIV and the metal ion are shown in 
black 
 
Interestingly, the residues Thr135, Asp136, and Thr167, that also form part of the group residues 
identified by MIp, are on the opposite face of the protein to where subdomain I interacts and to 
where the active site is located (Figure 3.24). However, they may have a role in aiding the inherent 
flexibility of the catalytic site to facilitate substrate binding and catalysis, and thus share mutual 
information with other residues important for facilitation of catalysis.  
 
Figure 3.25: The node residues identified by MIp from the RDP alignment mapped onto the homology model of NmeIPMS. 
The homology model is rotated by 180˚. 
 
As a whole, the group residues identified in this analysis form a network of interactions from the 
catalytic domain to the regulatory domain (Figure 3.25), which implies that maintenance of these 
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interactions has been preserved through evolution. Providing sufficient flexibility to allow for the 
large-scale dynamic movements predicted to play a role in catalysis yet maintaining enough rigidity 
and structure to limit the number of conformations the protein can form, particularly in the 









Figure 3.27: The single pairs from the RDA MIp analysis. 
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3.4.2.2 RDA sequence population MIp analysis  
 
As with the RDP sequence population, there was a mixture of single pairs sharing mutual 
information and a group of residues that share mutual information with each other (Figure 3.26). 
The single pairs are predominantly close in sequence and structure, and thus probably are key for 
maintaining local tertiary structure or dynamics (Figure 3.27).  
The main group of residues that share mutual information (Figure 3.26), and the ‘nodes’ of this 
group (Figure 3.28), are different to that of the RDP sequence population. The RDA node residues 
identified by MIp include a number that are known to be important for substrate selection in the 
active site, namely residues Phe101, Leu75, Glu139, His99, and Ser141.69, 72 There is a phylogenetic 
basis to these residues appearing, as substrate selectivity is phylogenetic, but these residues do 
show mutual information as knowledge of one residue provides information about other residues 
important for substrate selectivity in the active site. This mutual information may not have been 
apparent in the RDP population as Ser141 is also a serine in the MjaCMS-like population although 
not the LinCMS-like population, which may reduce the mutual information in these residues. 
 
 
Figure 3.28: The node residues from the MIp analysis of the RDA alignment (NmeIPMS numbering). 
 
Residue 364 is also in this group of node residues, and this residue, as discussed above, may form 
a hydrogen bond with Glu503 in NmeIPMS in the absence of leucine. This interaction is broken 
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in the presence of leucine in the MD simulations. The appearance of residues such as this and 
Glu298 in the regulatory domain absent, but not regulatory domain present mutual information 
analysis is somewhat unexpected, but it does suggest that the interactions that are potentially key 
for allostery, that were identified in the NmeIPMS SCA, may also be key for control of the 
subdomains, and thus may be key for catalysis in the regulatory domain absent population and 
therefore share mutual information.  
Only one residue is found in the ‘node’ residues of both populations in the MIp analysis, residue 
Thr167 (NmeIPMS numbering). In NmeIPMS, this residue is a threonine, while in SpoHCS, and 
LinCMS, it is an arginine. In the structures available of SpoHCS, Arg191, the equivalent of Thr167 
in NmeIPMS, forms different interactions depending on the substrate bound to the active site. In 
the apo structure of SpoHCS, Arg191 forms interactions with Glu222 and Glu161, whereas in the 
KG-bound structure of SpoHCS, the arginine residue forms an interaction with Glu222 and 
Asp123 (Figure 3.29, top). Arg191 is known to be important for binding of the competitive 
inhibitor, lysine, and indeed in the lysine-bound structure, Arg191 is forming an interaction with 
Glu161, allowing Asp123 to flip into the active site to form a hydrogen bond with lysine (Figure 
3.29, bottom). In the structures available of LinCMS, the equivalent to Thr167 in this enzyme, 
Arg173, forms an interaction with Glu9 and Asn142 (LinCMS numbering). The latter residue is 





Figure 3.29: The interaction of Arg191 in SpoHCS. In the apo structure (PDB: 3IVS, top left), with the substrate ketoglutarate 
bound (PDB: 3IVT, top right), and with the competitive inhibitor, lysine, bound (PDB: 3MI3, bottom). The metal ion is shown 
as a black sphere, and the substrate and inhibitor are shown in black. 
 
The comparable residue to Asn142 from LinCMS in MtuIPMS, Glu214, forms a direct interaction 
with the ketoacid substrate. In the structure of TthHCS with ketoglutarate bound, Arg160, the 
Thr167 equivalent, forms interactions with Glu193 and Asp92 (Figure 3.30, left). These are 
equivalent to Ser202 and His99 from NmeIPMS, and Glu222 and Asp123 in SpoHCS.  In the lysine-
bound structure of TthHCS (Figure 3.30, right), Arg160 forms interactions with Glu193 and 
Glu131, allowing, as with SpoHCS, the aspartate residue to form interactions with lysine in the 




Figure 3.30: The change in hydrogen bond interaction of Arg160 in TthHCS with ketoglutarate (left) and lysine (right) bound. 
 
As the residue in the Thr167 position appears to have a significant influence over the character of 
the active site, it seems reasonable that it forms substantial mutual information with other residues, 
especially those involved with substrate or inhibitor binding or selectivity, in both sequence 
populations under investigation. Additionally, the strong mutual information between Thr167 and 
Ser202 in the RDA alignment can be rationalised as those residues form interactions in the 
structures available of the regulatory domain absent population.  
 
Figure 3.31: The small group of residues in the MIp analysis of the RDP alignment showing residues that share mutual 
information with Asn169 
There are substantial differences in both the ‘node’ residues in the two populations, as well as the 
group residues as a whole. In the RDP alignment, Gln303, Ile176, Ile135, Phe363, and Ala367 are 
all part of the ‘node’ residues. In the regulatory domain absent population, although Gln303, 
Phe363, and Thr135 are present in the results of the analysis, they do not form significant MI with 
each other or other residues as seen in the regulatory domain present population. Conversely, in 
the regulatory domain absent population, Asn169 is present in the regulatory domain present 
analysis, but forms a small network alone with Phe140, Gly465, Ala103, and Val160 (Figure 3.31). 
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Phe140 forms part of the node residues along with Asn169 in the main group in the RDA 
alignment, suggesting that these residues are important for local interaction in the RDP population.  
There is a considerable amount of conservation at position Gln303 in the regulatory domain 
present population, with approximately 62% having Q at that position. There is much more limited 
conservation at that position (30% Ala 30% Val) in the regulatory domain absent population. This 
residue is additionally next to an absolutely conserved histidine (His302 in the NmeIPMS 
sequence). In the KIV bound structure of MtuIPMS, the only full length regulatory domain 
containing structure available, the equivalent of Gln303, Gln380, forms a sidechain interaction 
with solvent in both chains. In the leucine bound structure, Gln380 forms an interaction with 
Gln438, which is equivalent to Lys364 in NmeIPMS. Lys364 is found in the node residues of the 
regulatory domain absent population, and the residue next to it, Phe363, is one of the node residues 
in the regulatory domain present population.  
At position Phe363, there is considerable conservation in the regulatory domain present 
population with approximately 60% having Phe at that position, and at position 362, nearly ¾ of 
sequences have either Arg or Lys, while in position 364, 86% have a lysine. This regulatory domain 
containing population, as mentioned above, does not include MtuIPMS-like sequences due to 
problems with sequence alignments. In the regulatory domain absent population, the majority of 
sequences have V or I at position 363, whereas position 364 has approximately 80% of sequences 
having Arg or Lys at that position. There is almost no sequence conservation at position 362. This 
suggests that position 363 may be key for control of the subdomains in the regulatory domain 
containing population, but not in the regulatory domain absent population.  
The comparison of the two populations demonstrate that although there are similarities, namely 
in the catalytic domain, there are considerable differences, especially in the subdomains, as to 
which positions share substantial mutual information. Interestingly, although there is a major 
difference in structure between the RDP and RDA populations, and the relative flexibility or 
inflexibility, of the subdomains appears to be key for the catalytic function in both populations, 
there is a limited number of positions that share substantial mutual information in either 
population, although there are considerable differences between the two populations. However, 
both populations produce a group of positions that share mutual information that form a network 
from the catalytic barrel through the subdomains, and to the regulatory domain in the population 
that has one. Additionally, a limited number of residues in either population is identified by the 
molecular dynamics simulations. This may indicate that there are considerable, potentially 
phylogenetic, differences in dynamics between groups of sequences, and that the interactions 
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involved in maintaining dynamics may not share substantial mutual information with other 
residues, i.e. they evolve independently. However, the presence or absence of positions in either 
population, particularly in subdomain II, sharing mutual information demonstrates that there are 
considerable differences between the two structural populations, and these can be used to 
hypothesise about the roles of these residues in maintaining the catalytic function of the enzyme 




3.5 Comparison of MIp and SCA results 
 
In this study, both SCA and MIp used the same multiple sequence alignment for each sequence 
population and there were a number of similarities in the results. The results of MIp are displayed 
as a network diagram, with a mixture of single pairs of residues sharing mutual information as well 
as a group of networked residues that share mutual information amongst themselves, while the 
results of SCA are a single sector of residues that show statistical coupling. Of the residues in IC1 
from the RDP SCA, several were also found in the group residues from the MIp analysis for the 
same alignment (Figure 3.32). These residues are of particular interest as they comprise of residues 
from the catalytic domain and the subdomains (Figure 3.32). As these residues are in both IC1 and 
the MIp analysis, it suggests that the network of these residues show coevolution and may be 
important for the control of the subdomains to facilitate catalysis.  
 
 
Aside from one residue, that also appears in IC3, no residues from IC2 are present in the MIp 
analysis. As discussed above, this IC includes residues that show statistical coupling due to the 
LinCMS-like CMS group showing substantial phylogenetic distance from the other sequences in 












Figure 3.32: Residues identified by both covariance analyses 
methods performed on the RDP alignment mapped onto the 
NmeIPMS homology model. 
Table 3.1: Residues identified by both covariance 
analyses performed on the RDP alignment 
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the population. As MIp is phylogeny independent, it stands to reason that this group is not 
represented in the MIp analysis. IC3 is comprised of a number of residues that also appear in the 
MIp analysis. These residues are predominantly from the single pairs in the MIp analysis, 
suggesting that these couple independently of the group residues.  
As with the RDP alignment, there are several residues in the RDA alignment that show both 
statistical coupling and mutual information (Figure 3.33). As with IC1, these residues show a 
network of residues that are present in the catalytic and subdomain II, suggesting that these 
residues are important for the facilitation of catalysis. The only residue that shows mutual 
information and statistical coupling in both populations is Asn169, suggesting that this residue is 
crucial for catalysis in both populations. 
  
 
Although some residues are similar in the two populations, there are also substantial differences, 
especially with the residues that show lower levels of either statistical coupling or mutual 
information, demonstrating the difference between the two algorithms. The purpose of the 
conservation weighting in the SCA is to reduce the amount of noise in the alignment by weighting 
by conserved residues, with the rationale being that changes in conserved residues are more likely 
to have an influence on the functionality of the protein. There are substantially fewer residues 
showing statistical coupling than those showing mutual information, suggesting that the weighting 
does highlight more important residues, although whether up-weighting conserved residues means 
Residues that were identified by both 












Table 3.2: Residues identified by both 
covariance analyses performed on the RDA 
alignment 
Figure 3.33: Residues from the RDA alignment that show both mutual 
information and statistical coupling (spheres) mapped onto the 




that residues that are not conserved but are coupled are missed by the SCA remains to be seen. 
These analyses suggest that both algorithms could be used to identify coevolved residues, although 
more work would be needed to assess which provides the better information for these proteins. 
This could be achieved by site-directed mutation followed by kinetic analysis to assess the validity 
of the networks, or specific residues in the network, in relation to their role in catalysis.  
Although most of the network was not identified by both techniques, in both populations, a group 
of residues were identified by both techniques. These residues that demonstrate both statistical 
coupling and mutual information appear to be a network that may be involved in conveying 
catalysis. The networks in each population, aside from residue 167, are different, suggesting a 
mechanism by which the separate structural groups control the subdomains in the presence and 
absence of the regulatory domain.  
3.6 Overall discussion  
 
Probing sequence information for coevolution information has been a technique that has 
undergone many changes over the years. There is some debate about the validity of particular 
analyses and algorithms, but there is debate also about whether coevolution can even be detected 
by analysis of multiple sequence alignments. Talavera et al.146 posits the “coevolution paradox” 
that states that coevolution would need to be sufficiently strong to cause coordinated changes, and 
this strength would reduce the evolutionary rate to such a level that they are unlikely to happen. 
However, Avila-Herrera et al.147 suggests that a neutral mutation or one mildly harmful to fitness 
could occur, and alter the fitness landscape in such a way to increase the likelihood of a 
compensatory mutation occurring to maintain structure or function. Both mutual information and 
statistical coupling analysis have been used in numerous studies where experimental evidence that 
these algorithms and the subsequent analysis of the results can provide information about 
structure-function relationships in a protein that other analyses cannot.120-122, 124, 129, 143, 145, 148, 149   
As discussed above, the conservation weighting function used in SCA can bias the results of the 
algorithm particularly when there are very different phylogenetic groups as there were in this 
analysis. This presents an obvious problem when searching for coevolved, yet not coevolved and 
conserved, residues and one that could be worked around  by changing the weighting function, as 




Mutual information, in its MIp form, was therefore employed to assess whether there is substantial 
coevolution that was not tied to phylogeny. However, MIp is not without its flaws. Some of these, 
such as sequence alignment errors, are fundamental to any of these analyses that are dependent on 
an accurate sequence alignment to represent evolution. Additionally, indirect coevolution in 
mutual information analyses, where a pair of residues appears to have higher mutual information 
due to their high mutual information with another partner, can skew analyses by making long-
distance contacts appear to have high MI, when indeed it is their interaction with closer structural 
partners, also with high MI, that is actually correct. To combat this issue, a Bayesian network model 
has been produced to attempt to sort direct from indirect dependencies.150 Additionally, a new 
approach called Bayesian Partitioning with Pattern Selection has been pioneered, which may 
present a way forward to improved techniques for coevolution analysis.151  
In these analyses, the goal was to identify residues that contribute to the overall function of the 
protein, particularly with regards to the very flexible subdomains that have a crucial role in catalysis 
and can bear the burden of an additional structural element present in some proteins but not 
others. The two analyses produced similar results with differences that can be accounted for by 
the difference in the way the output of the algorithm is weighted with regards to conservation. 
However, both analyses produced results that correspond well with information already known 
about the protein, and a considerable number of residues is found in both MIp and SCA analyses. 
These analyses identified some residues that could be of considerable interest going forward that 
would not have been otherwise apparent by analysis of the alignments in light of conservation. 
Additionally, these results can later be mined for information that correlates with other knowledge 
about the proteins, such as point mutations and subsequent characterisation, to continue to build 








The role of the regulatory domain in the IPMS and CMS proteins is clear: the allosteric inhibitor 
is bound by this domain and the allosteric signal is somehow transmitted to the distant active site. 
However, the proposed evolutionary trajectory suggests that the ancestral IPMS did not have a 
regulatory domain. It is not clear, therefore, how the very flexible subdomains, whose motion is 
critical for catalysis, can compensate for the comparative burden of the regulatory domain in some 
of the extant proteins. The information obtained in Chapter 3 about the difference in coupled 
residues in the subdomains in the presence or absence of a regulatory domain highlights some 
similarities and considerable differences between the two populations of proteins. However, the 
relative flexibility and stability of the subdomains has been shown to be critically important in both 
structural populations. It has, however, been shown that IPMS and CMS proteins that have 
evolved to bear the burden of the regulatory domain can provide catalysis in the absence of a 
regulatory domain.2, 108  
It was reported previously that NmeIPMS could not perform catalysis without a C-terminal 
regulatory domain.1, 64 However, it has since been determined that the truncation used in these 
analyses was also missing a considerable part of subdomain II as well as the regulatory domain, as 
the location of the truncation was at residue Glu365, and more recent homology model 
construction and sequence alignments have suggested that subdomain II of NmeIPMS 
encompasses residues up to residue Lys395. To explore further how the subdomains facilitate 
catalysis in the presence and absence of the regulatory domain, a truncation of NmeIPMS was 
made at a different location to that previously reported to encompass all of subdomain II.  
This truncated protein provides insight into the evolution of these proteins, as the catalytic module 
of the catalytic domain and subdomains exist in contemporary proteins in both allosterically 
regulated, that also have a C-terminal regulatory domain, and unregulated forms. Additionally, this 
truncated and active enzyme permits the study of the subdomains in the absence of their role in 





4.1.1 Truncation of NmeIPMS by site-directed mutagenesis 
 
The location of the point at which to truncate NmeIPMS to ensure all of subdomain II was included 
within the truncated protein was determined using multiple sequence alignments, pairwise 
sequence alignments, and structural alignments with known structures (Figure 4.1). The precise 
residue that was changed to a stop codon was selected as it was in a short region that did not show 
substantial conservation in the MSA, suggesting that that particular region was not of particular 
importance for allostery or catalysis. The residue selected, Lys395, is also located after the end of 
subdomain II in the MSA with a short form IPMS (LbiIPMS short) and the SpoHCS, suggesting 
that subdomain II in the truncated NmeIPMS would be intact. 
 
Figure 4.1: A MSA showing the position of the Lys395 residue in NmeIPMS. The MSA was a structural alignment constructed 
using Promals3D and a structure of the short form of LbiIPMS (PDB: 4OV4), SpoHCS (PDB: 3VIS), and MtuIPMS as well as 
the sequence of NmeIPMS. The position of Arg371 in subdomain II is also highlighted. The residue numbers used are NmeIPMS 
numbering. 
 
The truncation of NmeIPMS was made by site-directed mutagenesis (SDM) to change the codon 
coding for Lys395 (AAA) to a stop codon (TAA), thus truncating the protein at residue Tyr394 
(Figure 4.2). This protein will be discussed as NmeIPMS K395Term. The construct used for SDM 
was the wild type Nme leuA gene cloned into pET151 by TOPO cloning as described and 
performed by Huisman64. The presence of the altered codon was assessed by DNA sequencing 




Figure 4.2: The homology model of NmeIPMS with residue Lys395 highlighted as spheres (left), and the same model with the 
residues beyond the point at which the truncation was made removed. 
 
4.1.2 Purification of NmeIPMS K395Term 
 
Purification was performed using the N-terminal polyhistidine (His6) tag, and immobilised metal 
affinity chromatography. The stability of the truncated protein appeared to be compromised, as 
activity was not maintained through the purification procedure if the His6 tag was removed. This 
instability does not appear to be related to the presence or absence of the His6 tag, as the small 
amount of un-tagged protein that was obtained was kinetically similar to tagged protein, but due 
to the excess handling of the protein through multiple purification steps, that caused soluble 
aggregates to form. Therefore, the His6 tag was not removed, and the protein underwent a gel 
filtration step to produce acceptably pure protein for further studies (Figure 4.3). When the 





Figure 4.3: Purification of NmeIPMS K395Term (left) and NmeIPMS wild type, demonstrating the difference in size 
 
4.1.3 Differential scanning fluorimetry  
 
Differential scanning fluorimetry (DSF) was used to explore the stability of the protein. Zhang et 
al.2 noted that truncations of LbIPMS2, LbIPMS2-R376 (equivalent to NmeIPMS Arg371) and 
LbIPMS2-S387 (equivalent to NmeIPMS Asp384), were unstable and suggested this was due to 
exposure of the hydrophobic core of subdomain II. Thermal shift assays were utilised to explore 
the thermal stability of the NmeIPMS truncation compared to the wild type protein. 
Thermal shift assays using the wild type protein compare well with previous results (Figure 4.4).64 
A single peak was seen in all thermal shift assays performed using NmeIPMS and NmeIPMS 
Lys395Term. There is a moderate increase in temperature when the substrate KIV is added to the 
wild-type protein, but a much larger increase was observed when leucine is added, suggesting that 
presence of 1 mM leucine stabilises the protein. The truncated NmeIPMS has a similar Tm to that 
of the wild type protein with no ligand added, suggesting that truncation of the regulatory domain 
has not substantially decreased thermal stability. However, unlike the wild type protein, an increase 
in thermal stability was not observed upon addition of KIV, suggesting that this substrate may not 
have the same stabilising effect on the truncated protein as it does on the wild type protein. 
Additionally, there is no increase in thermal stability upon addition of 1 mM L-leucine, 
demonstrating that the thermal stability provided to the wild type protein upon binding the 
allosteric inhibitor is not observed in the truncated protein, suggesting that it is not stabilised by 




Figure 4.4: Thermal melt temperatures determined by DSF for NmeIPMS (darker shades) and NmeIPMS K395Term (lighter 
shades) in the presence of different ligands. 
4.1.4 Analytical SEC of NmeIPMS K395Term 
 
Analytical size exclusion chromatography (analytical SEC) was used to explore the oligomeric 
structure of NmeIPMS K395Term. Previous work has demonstrated that wild type NmeIPMS is 
dimeric in the presence and absence of L-leucine.64 MtuIPMS also is dimeric in solution in the 
presence and absence of L-leucine.74 In a buffer containing 10 mM Tris, pH 8, NmeIPMS 
K395Term appeared to form two distinct species (Figure 4.5, left). Both species contained only 
the protein of interest, and both species showed similar specific activity when tested. When the 
salt concentration of the buffer used for analytical SEC increased to 300 mM KCl, only one, albeit 
broad, peak was present (Figure 4.5, right). 
 
Figure 4.5: Chromatograms of NmeIPMS K395Term during analytical SEC. (Left) Analytical SEC of NmeIPMS K395Term run 
in 10 mM Tris, pH 8, 50 mM NaCl. (Right) Analytical SEC run in 10 mM Tris, pH 8, 300 mM KCl. Note the volumes for the 
low salt buffer (left, blue) are inaccurate due to a computer recording issue. Analytical SEC was performed using a Superdex™ 
200 10/300 GL column (GE Healthcare). 
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This analysis suggests that the presence of salt has a major impact on the oligomeric state of the 
truncated protein.  Wulandari et al.94 noted that two peaks, thought to be monomer and dimer, of 
TthHCS were observed when analytical SEC was used to investigate the oligomeric state of 
TthHCS. Multiple peaks of HCS from Saccharomyces cerevisiae were also observed when analytical 
SEC were performed.152 Full length MtuIPMS was reported to be only dimeric in solution.74 The 
multiple peaks seen in analytical SEC of proteins without a regulatory domain that are not seen in 
proteins with a regulatory domain suggests that oligomeric stability may be affected by the removal 
of a regulatory domain even in proteins that have evolved further in the absence of a regulatory 
domain. Specifically, for NmeIPMS K395Term, the analytical SEC results suggest that the protein’s 
oligomeric state is not stable under some conditions, and this may contribute to the protein 
instability noted above.  
Under conditions where a single species was observable, the truncated protein eluted from the 
column at a volume that was consistent with a dimer. The molecular mass of the species was 
calculated to be 101 kDa, whereas the estimated molecular weight of a dimer was calculated to be 
93 kDa. This result suggests that truncation of the regulatory domain has not altered the oligomeric 
state in solution in the presence of higher salt concentrations. 
4.1.5 Kinetic characterisation of NmeIPMS K395Term  
 
4.1.5.1 The kinetics of His6-tagged NmeIPMS 
 
Due to the stability issues with the truncated form of NmeIPMS, the N-terminal His6 tag and TEV 
protease site, were retained for both the wild type protein and the truncated protein.  
Davies132 reported that the un-tagged NmeIPMS wild type protein had a kcat of 8.9 ± 0.1 s
-1 and 
that the tagged wild-type NmeIPMS protein had a kcat of 1.53 s
-1, 6-fold lower than that of the un-
tagged protein.  The kcat of tagged NmeIPMS determined in this study was 7.2 ± 0.1 s
-1 suggesting 
that there is a substantial change in kcat on a purification to purification basis and that the N-
terminal His6 tag may have an impact on the kinetics of the protein. In this study, the N-terminal 
His6 tag was retained on all proteins, including the alanine mutants discussed in Chapter 4.1.9, and 
the truncated form of the protein discussed in Chapter 4.1.5.2, and when the proteins are referred 




Figure 4.6: Plots of kinetic data of His6-tagged NmeIPMS wild typeshowing the variation in initial rate with change in KIV 
concentration (left) and AcCoA concentration (right). During these measurements, the other substrate was held at a saturating 
concentration of 250 µM. The apparent Km was obtained using the Michaelis-Menten fit from GraphPad Prism 7.00. 
  
 
Table 4.1: Kinetic parameters of the un-tagged NmeIPMS and the His6-tagged NmeIPMS. *The kinetic data for the un-tagged 
NmeIPMS was obtained from Huisman64. 
 




NmeIPMS un-tagged* 30 ± 2 35 ± 3 12.8 ± 0.3 
NmeIPMS His6-
tagged 
36 ± 3 35 ± 3 7.2 ± 0.1 
  
4.1.5.2 Michaelis-Menten kinetics of the His6-tagged truncated NmeIPMS 
 
Michaelis-Menten kinetic data of the His6-tagged truncated NmeIPMS were also obtained (Table 
4.2). The truncated variant had a similar Km for KIV to that of the wild type protein, suggesting 
that loss of the regulatory domain had not adversely impacted the residues involved in KIV 
interaction. Removal of the regulatory domain and part of subdomain II, although it led to inactive 
protein, did not adversely affect KIV binding in MtuIPMS or NmeIPMS as determined by ITC.64 
Although Km does not correlate directly with substrate binding, the lack of impact on KIV binding 
in the inactive truncation suggests that removal of the regulatory domain and subdomain II does 




Figure 4.7: Left: Plot showing the change in initial rate of NmeIPMS K395Term as the concentration of KIV increases.[AcCoA] 
was held at a saturating concentration of 250 µM. Right: Plot showing the change in initial rates of NmeIPMS K395Term as the 
concentration of AcCoA increases.  [KIV] was held at a saturating concentration of 250 µM.  
 
Unlike the Km for KIV, the apparent Km for AcCoA increased two-fold compared to that of the 
wild type protein, from 35 µM to 80 µM. An increase in the apparent Km for AcCoA but not one 
for the other substrate was also seen in a truncated variant of LbIPMS2, where a truncation was 
made into subdomain II and the protein retained the ability to catalyse the condensation of 
ketobutyrate and AcCoA although not the natural substrate.2   
As NmeIPMS has evolved to bear the burden of a regulatory domain, the dynamics of the 
subdomains may have been restrained to compensate for this. Removal of the regulatory domain 
could increase in the number of conformations the subdomains can form, as, following the 
truncation of the regulatory domain, the subdomains are only constrained at one end as opposed 
to two as in the full-length protein.  
As the subdomains are known to be important for the recruitment of AcCoA, there may only be 
certain conformations in which this is possible. An increase in the conformations sampled by the 
subdomains may lead to an increase in AcCoA Km, as there is less chance of the subdomains being 
in an AcCoA-interaction compatible conformation.  
Table 4.2: Kinetic parameters of NmeIPMS and NmeIPMS K395Term. Both of these proteins still contain a His6 tag. Kmapp 








NmeIPMS 36 ± 3 35 ± 3 7.2 ± 0.1 
NmeIPMS 
K395Term 





As mentioned above, the kcat can be dependent on the enzyme preparation used for the kinetic 
measurements, although the Km for either substrate did not change with different purifications. 
Determination of the kcat requires a known enzyme concentration but the method of determining 
protein concentration used in this experiment, that of absorbance at 280 nm, does not differentiate 
between active and inactive enzyme. It is plausible that the enzyme preparation of NmeIPMS 
K395Term and NmeIPMS wild-type included some amount of inactive enzyme, and this amount 
differed between preparations, causing the observed change in kcat. A method of determining the 
amount of active protein within a particular protein preparation would be advantageous in 
determining kcat values particularly for this protein.  
4.1.5.3 Inhibition of wild type NmeIPMS and truncated NmeIPMS by L-leucine  
 
The IC50 of NmeIPMS wild type for L-leucine was obtained (Figure 4.8, Table 4.4). This was 
comparable to prior results, suggesting that the presence of the His6 tag does not affect leucine 
inhibition.130 The absence of the regulatory domain in the truncated form, as indicted by site-
directed mutagenesis and SDS-PAGE, means that no regulation by L-leucine was observed with 
the truncated protein (Figure 4.8). 
 
Figure 4.8: The inhibition of wild-type NmeIPMS and NmeIPMS K395Term to L-leucine. The concentration of both substrates 
was held at 250 µM for both proteins as the concentration of L-leucine was increased. 
 
4.1.5.4 Cooperativity in NmeIPMS 
 
The potential cooperativity of NmeIPMS and the truncation were assessed using Hill plots (Figure 
4.9). The Hill coefficient, h, denotes negative cooperativity if it is less than one, or positive 
cooperativity if it is more than one. Neither KIV nor AcCoA showed cooperativity in the wild 
type protein although cooperativity has been reported in some examples of IPMS and related 




Figure 4.9: Hill plots of wild type NmeIPMS demonstrating the absence of cooperativity in substrate binding. h = Hill 
coefficient.   
 
Cooperativity was not seen in the truncated form of NmeIPMS with respect to either for KIV or 
AcCoA (Figure 4.10). This suggests that either the two active sites are truly independent, or that 
the cooperativity is being masked somehow. The positioning of the subdomains, particularly where 
subdomain I forms part of the active site of the opposite chain, suggests that cooperativity between 
the two chains may be important for catalytic function.  
A recent study using statistical mechanics models suggests that the absence of a sigmoidal steady-
state kinetics curve does not mean the absence of cooperativity.153 There can be weak cooperativity 
that does not result in a sigmoidal curve. Additionally, Moffitt et al.154 reconciles the lack of a 
sigmoidal binding curve when ATP binds a homomeric ring ATPase by suggesting that this arises 
because the binding events are separated by an irreversible transition. Plausibly, there may be 
cooperativity between the two active sites, it is simply not apparent using steady-state kinetics. 
 
Figure 4.10: Hill plot of NmeIPMS K395Term for AcCoA. 
 




Performing kinetics in the presence of a viscogen such as glycerol can provide information about 
conformational change and the dynamics of a protein. An example of this type of experiment was 
provided by Sekhar et al.155 who used glycerol to probe the viscosity-dependent kinetics of a 
conformational change in a four helix bundle FF domain. Kinetic analysis was performed in the 
presence of 30% glycerol to assess the impact of a viscogen on the kinetics and allosteric regulation 
of NmeIPMS, and the kinetics of truncated form of NmeIPMS (Table 4.3). 
Table 4.3: Kinetic parameters for the wild type NmeIPMS and the truncated NmeIPMS in the presence and absence of 30% 
glycerol in the kinetics buffer.*The Km for KIV was not determined for the truncated NmeIPMS. All kinetic analyses were 
performed at 25°C. 
 
Enzyme Km (KIV, µM) Km (AcCoA, µM) kcat (s-1) 
NmeIPMS 36 ± 3 35 ± 3 7.2 ± 0.1 
NmeIPMS 30% glycerol 57 ± 5 8.9 ± 0.6 1.95 ± 0.02 
NmeIPMS K395Term 30 ± 3 80 ± 7 4.1 ± 0.1 
NmeIPMS K395Term 30% glycerol Nd* 22 ± 2 1.2 ± 0.1 
 
There was a significant 1.6-fold increase in the Km value for KIV in the wild type protein when 
30% glycerol was present in the buffer, but a 3.8-fold decrease in the Km for AcCoA. The kcat has 
also decreased from 7 to 1.95 s-1. This implies that there has been a major change in how the 
protein is operating in the viscous buffer compared to the buffer with aqueous viscosity. The same 
experiment was conducted with the truncated form of the enzyme, and the Km for AcCoA also 
decreased 3.4-fold. The kcat had also decreased compared to the aqueous kinetics, but only 2-fold 
compared to 3.5-fold for the wild type protein.  
Although firm conclusions about the impact of viscosity on the kinetic cycle of NmeIPMS cannot 
be made from these preliminary experiments, as factors such as the size and charge of the viscogen 
must also be assessed, this data does suggest that viscosity does have a major impact on how the 
protein catalyses the reaction. To further clarify the impact of viscosity on the kinetic and allosteric 
behaviour of NmeIPMS and other proteins, the same experiments may be performed in the 
presence of a different viscogen or crowding agent such as bovine serum albumin (BSA). Further 
experiments, such as performing SAXS in the presence of 30% glycerol, may provide further 





Table 4.4: Inhibition data for the inhibition by L-leucine of the wild type NmeIPMS in the presence and absence of 30% glycerol. 
 IC50 (L-leu, µM) 
Activity remaining 
(%) 
NmeIPMS 55 ± 5 14 
NmeIPMS 30% 
glycerol 
29 ± 2 19 
 
As the kcat has decreased, this suggests that the product binding or release steps could have been 
adversely affected by increased viscosity, although it is noted that the rate-determining step under 
these conditions has not been determined. Most interesting, however, is the considerable impact 
of viscosity on the Km for AcCoA. One plausible explanation behind the substantial decrease in Km 
for AcCoA for both the wild type and the truncated protein is that the presence of the viscogen 
limits the conformations that the protein can access, especially the subdomains that are crucial for 
the binding of AcCoA and are highly mobile, meaning that it is more likely to be in a conformation 
that can interact with AcCoA.  
 
Figure 4.11: The change in the IC50 for L-leucine by NmeIPMS in the presence and absence of 30% glycerol. The concentration 
of both substrates was held at 250 µM while the concentration of L-leucine was increased. The response to L-leucine of the wild-
type protein in the standard buffer is shown in blue and the response to L-leucine of the wild-type protein in the same buffer 
containing 30% glycerol is shown in purple.  
 
The inhibition of the wild-type protein by L-leucine was also assessed in the presence of 30% 
glycerol. There was a small impact on L-leucine inhibition in that the IC50 decreased compared to 
the aqueous buffer, and the residual activity increased (Figure 4.11, Table 4.4). The decrease in 
IC50 suggests that the protein is allosterically inhibited at a lower inhibitor concentration in the 
presence of 30% glycerol. Inhibition by L-leucine in NmeIPMS is reported to be mixed non-
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competitive inhibition.64 The change in IC50 could plausibly be due to the restriction of the 
conformations that the protein can access, meaning that the protein is already limited in the 
conformational flexibility and thus in a more ‘inhibited-like’ form even in the absence of inhibitor. 
This correlates with the decrease in kcat and the decrease in Km for AcCoA in the presence of the 
viscogen.  
Using viscogens to alter the dynamics of NmeIPMS presents a plausible way to decrease the 
conformations available to the wild type protein and thus explore how this affects catalysis and 
allosteric regulation. Once the effect of other viscogens, and potentially macromolecular crowding 
agents such as Ficoll-70, has been explored, other techniques such as ITC could be used to explore 
the thermodynamics of inhibition in particular. Olsen et al.156 used BSA, a proteinaceous viscogen, 
as a macromolecular crowding agent in ITC experiments to assess the impact of a complex 
environment on the kinetics of hexokinase, which suggests a potential way to explore the 
thermodynamics of the NmeIPMS kinetic cycle.   
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4.1.6 Conformational dynamics in solution 
 
Small-angle X-ray scattering (SAXS) data was obtained for the apo truncated protein and the 
truncated protein in the presence of KIV (Figure 4.12). This was obtained to observe the structure 
of the truncated protein in solution, and any potential conformational change in the presence of 
the first substrate to bind, KIV. 
 
 
Figure 4.12: Small-angle X-ray scattering data for NmeIPMS K395Term in the absence (red) and presence (blue) of the substrate, 






Table 4.5: SAXS parameters of apo NmeIPMS K395Term and KIV-bound NmeIPMS K395Term 
 
 Truncated NmeIPMS (Apo) 
Truncated NmeIPMS (200 
µM KIV) 
I(0) (cm-1) 
from Guinier plot 






from Guinier plot 





I (Å) 140 140 










Figure 4.13: Guinier distributions of the SAXS data for apo NmeIPMS K395Term (red) and KIV-bound NmeIPMS K395Term 
(blue). 
Information obtained from SAXS is dependent on the sample being monodisperse, thus validation 
of the results obtained is of critical importance. The Guinier distribution was used to assess 
whether the samples showed significant aggregation. Neither the apo sample (Figure 4.13) or the 
sample containing KIV (Figure 4.13) showed substantial non-linearity at low q ranges, suggesting 
that the samples were not aggregating. The radius of gyration (Rg) was also determined from this 
plot for both samples (Table 4.5).  
 
 
Figure 4.14: Pairwise distributions of apo NmeIPMS K395Term (red), and KIV-bound NmeIPMS K395Term (blue). 
  
A pairwise distribution function, P(r), was generated for both the apo (Figure 4.14) and KIV bound 
(Figure 4.14) samples. From these, the Rg and the I(0) could be calculated (Table 4.5). The Rg from 
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this analysis was compared to the Rg obtained from the Guinier plot. The Dmax, the maximum 
dimension of the particle, was also obtained from the P(r) distribution, as was the Porod estimate 
of excluded volume that gives an indication of the molecular mass (Table 4.5). The Rg and I(0) 
calculated from the two different methods for both samples are similar, suggesting, as with the 
Guinier plots, that there is not significant aggregation in the samples.  
 
Figure 4.15: Kratky plot of apo NmeIPMS K395Term (red) and KIV-bound NmeIPMS K395Term (blue) 
 
Kratky plots (Figure 4.15) of both samples also suggest that there is substantial flexibility in both 
of the samples although there is a significant well folded component. The shape of the Kratky 
plots suggests that the truncated protein is more compact in the presence of KIV. This information 
corresponds well with the premise that, while unrestrained by the absence of a regulatory domain, 
the subdomains can form multiple conformations in solution. The presence of KIV appears to 
decrease the flexibility of the protein, suggesting that there is a change in dynamics in the presence 







4.1.6.1 Model fitting  
 
Crysol was used to fit homology models of the truncation that were made by Dr. Wanting Jiao 
(personal communication, November 2016). The models were constructed using molecular 
dynamics, having removed the regulatory domain. The starting conformation (“start” model) for 
the MD simulation included the position of the subdomains in the full length NmeIPMS homology 
model which was allowed to proceed until energy was minimised. The “start” model (Figure 4.16, 
top left), and “end” model (Figure 4.16, top right) were used as input in the Crysol programme to 
fit the theoretical scattering of these models to the scattering produced by the NmeIPMS truncation 
(Figure 4.16, middle and bottom). The theoretical scattering produced by either model does not 





Figure 4.16: Top: Models of the NmeIPMS K395Term truncation. NmeIPMS K395Term "Start" is shown on the left, and 
NmeIPMS K395Term “Final” is shown on the right. Chain A is shown in grey, the catalytic domain of chain B is shown in green, 
subdomain I in blue, the linker in orange, and subdomain II in red. Middle: The "start" model theoretical scattering (green) fitted 
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to the scattering produced by NmeIPMS K395Term (blue). Bottom: The "final" model theoretical scattering (green) fitted to the 
scattering produced by NmeIPMS K395Term (blue). 
 
 
Figure 4.17: The scattering of an ensemble of models of NmeIPMS K395Term compared to the SAXS scattering of NmeIPMS 
K395Term.Top: An ensemble of models of NmeIPMS K395Term generated from molecular dynamics simulations.  Bottom: The 
theoretical scattering of the above ensemble (green) fitted to the scattering produced by NmeIPMS K395Term (blue). 
 
Crysol was used to fit the theoretical scattering profiles of ensembles of models generated by 
molecular dynamics to the scattering profile of the samples (Figure 4.17).157 Neither the single 
conformations nor the ensemble fit the scattering profile, suggesting that the protein may access 
additional conformations that are not observed during this specific MD simulation. As the 
subdomains are un-restrained at one end, there is a considerable likelihood that, particularly in the 
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absence of ligand, the subdomains can sample conformational space to a large degree. Additionally, 
structural data for either the full length NmeIPMS or active truncated NmeIPMS has not been 
obtained, so the theoretical scattering profiles are generated from MD performed on a homology 
model that was constructed based on the MtuIPMS full length crystal structure that shows 
considerable difference from NmeIPMS in sequence and evolution. It is plausible that the models 
used to generate the theoretical scattering do not adequately describe the truncated form of 





4.1.7 SAXS of the wild type NmeIPMS 
 
Small-angle X-ray scattering data was obtained for the wild type NmeIPMS in its apo form at pH 
7.5 (Figure 4.18). Attempts were made to obtain SAXS data in the presence of L-leucine at several 
concentrations. However, under all conditions tested, there was significant aggregation in the 
sample. This problem has been noted in the past.64   
 
Figure 4.18: SAXS data for apo NmeIPMS WT (left) and a Kratky plot of the same data (right) 
 
The Guinier plot of the apo data shows that there is no substantial aggregation (Figure 4.19). The 
Rg calculated from the Guinier plot and that calculated from the pairwise distribution (Figure 4.19) 
correspond well, providing further evidence that there is no substantial aggregation in the sample. 
  
Figure 4.19: Guinier distribution and pairwise distribution of apo NmeIPMS WT 
 
The pairwise distribution function suggests that the wild type apo protein is primarily globular in 
solution. The Kratky plot (Figure 4.18) suggests that there are multiple domains in the protein and 
substantial flexibility. In the absence of leucine, it has been suggested that the subdomains and 
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regulatory domain form multiple conformations although these conformations have not been 
structurally assessed. The information obtained from SAXS also suggests this.  
Theoretical scattering of the NmeIPMS homology model, and of ensembles generated from 
molecular dynamics simulations, was also produced and fitted to the data using Crysol. The 
theoretical scattering of the homology model did not fit the scattering of the protein well, with a 
chi2 value of 15.01.  
 
Figure 4.20: The NmeIPMS homology model theoretical scattering (light green) fitted to the scattering produced by NmeIPMS  








Table 4.6: SAXS parameters of NmeIPMS wild type 
 NmeIPMS (Apo) 
I(0) (cm-1)  
from Guinier plot 
0.071 ± 0.00016 
I(0) (cm-1) 
 from pairwise 
distribution function 
0.07 
Rg (Ä)  
from Guinier plot 
40.96 ± 0.64 




Dmax (Ä) 133 
Porod volume estimate 
(Å3) 
237545 
Monomeric mass  
(Da) 
59208 








Crystallisation of NmeIPMS K395Term was attempted using both sitting-drop vapour diffusion 
and hanging-drop vapour diffusion under a variety of conditions. Sitting drop vapour diffusion 
conditions included commercial screens: JCSG+ (Molecular Dimensions), Clear Strategy 1 
(Molecular Dimensions), Clear Strategy 2 (Molecular Dimensions), and PACT (Molecular 
Dimensions). Protein concentrations of 5 mg/mL to 25 mg/mL were used, and screens were 
constructed with and without the ligand, KIV. A Mosquito® crystallisation robot (TTP LabTech) 
was used to put down the sitting drop vapour diffusion screens. A screen of conditions based 
around the crystallisation condition that produced crystals of NmeIPMS Glu365Term158 was also 
constructed. This screen varied protein concentration (10 mg/mL and 15 mg/mL), magnesium 
acetate concentration (0.1 M to 0.25 M), and PEG3350 (10% to 20%).  
Very little precipitation was seen at protein concentrations under 20 mg/mL, suggesting the 
protein is very soluble under these conditions. However, no lead crystals were seen under any 
conditions. The full-length protein has not been crystallised, although attempts have been made 
in the presence and absence of ligands including L-leucine. A crystal structure of the E365Term 
truncation of NmeIPMS has been solved158 but as the full length and active truncated proteins are 




4.1.9 Alanine mutants of NmeIPMS wild type and NmeIPMSK395Term  
 
Several residues in NmeIPMS, namely Tyr313, Lys332, and Arg371 have been identified as 
potentially important for catalytic activity in previous research.131, 132 Davies determined that the 
NmeIPMS Tyr313Phe and Lys332Ala mutants showed catalytic activity but further 
characterisation performed by Plowman-Holmes131 suggested that these mutants did not show 
catalytic activity although these assays were performed only with a limited amount of protein. 
When a large amount of protein was used in the kinetic assay, the mutant proteins did display 
some catalytic function. To explore the roles of these residues in providing catalytic function, 
kinetic parameters and whether the mutant proteins were inhibited by L-leucine were 
determined.  
Arg371, located in subdomain II, was identified as a residue that may be involved in the 
recruitment of AcCoA to the active site (Dr. Wanting Jiao, personal communication, May 2014). 
To investigate the role of this residue in the catalytic cycle, an alanine mutant, Arg371Ala, was 
made in both the full-length wild-type protein and the truncated K395Term protein.  
 
Table 4.7: Kinetic and inhibition parameters of NmeIPMS WT and NmeIPMS mutants. In this table, N/A stands for not 
applicable, and nd stands for not determined.  The IC50n for NmeIPMS K332A and NmeIPMS Y313F was not determined as the 
kcat of the protein was too low to obtain this data.
 











activity (%) at 
full inhibition 




70 ± 5 220 ± 20 
1.83 ± 
0.07 
No N/A N/A 
NmeIPMS 
K332A 
Nd 900 ± 100 
0.15 ± 
0.01 
Yes nd nd 
NmeIPMS 
R371A 
Nd 220 ± 20 3.8 ± 0.1 Yes 45 ± 5 12 
NmeIPMS 
Y313F 












4.1.9.1 NmeIPMS Tyr313Phe  
 
IPMS and related enzymes contain a conserved tyrosine in subdomain I that inserts into the active 
site of the opposite chain. In MtuIPMS, this tyrosine (Tyr410) stacks with His379, also in 
subdomain I, potentially to position this latter residue as the catalytic base (Figure 4.21).67 Glu218 
from the other chain is also in a position to act as the catalytic base. Alanine mutants of Glu218 
and His379, and a phenylalanine mutant of Tyr410, have been made in MtuIPMS.63 MtuIPMS 
Glu218Ala and MtuIPMS His379Ala both showed aberrant kinetics, and both displayed substrate 
activation towards KIV, whereas only Glu218Ala showed substrate activation towards AcCoA as 
well.63 Although the Tyr410Phe MtuIPMS mutant displayed a large decrease in kcat, there was also 
a corresponding decrease in the Km for both substrates, suggesting that this mutation allows the 
protein to bind substrates more tightly. Unlike the His379Ala or Glu218Ala mutants, MtuIPMS 
Tyr410Ala was insensitive to inhibition by L-leucine.63 
 
Figure 4.21: The location of Tyr410, His379, and Glu218 in the MtuIPMS structure (PDB: 1SR9). KIV is shown as black sticks 
and the metal ion as a black sphere. The stacking between His379 and Tyr410, and the interaction between Glu218 and Tyr410, 
that orients Tyr410 correctly in the active site can be seen. 
 
To explore the role of the conserved tyrosine residue, in a key location in subdomain I, in the 
catalytic cycle and allosteric regulation of NmeIPMS, a phenylalanine mutant of Tyr313, the 
corresponding residue in NmeIPMS, was made.132 The initial characterisation of this mutant was 
performed by Plowman-Holmes131.  
Michaelis-Menten kinetic data were obtained for this mutant (Figure 4.22, Table 4.7). NmeIPMS 
Tyr313Phe, similarly to MtuIPMS Tyr410Phe, showed a substantial decrease in kcat compared to 
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the wild type protein. The kcat was determined both from the experiment where the concentration 
of AcCoA was altered, where it was 0.0078 s-1 and when KIV was altered, where it was 0.11 s-1. As 
the apparent Km for KIV was so high, the concentration of KIV could not be held at a saturating 
level when the apparent Km for AcCoA was determined, and this may account for the difference 
in rates seen in Figure 4.22 and subsequently the difference in kcat between the two experiments. 
The extremely high Km for KIV also meant that the Vmax in the experiment where KIV 
concentration was varied could not be reliably determined. This problem also suggests that the kcat 
determined from the variation in AcCoA concentration is likely to be artificially low.  
 
Figure 4.22: Michaelis-Menten plots for NmeIPMS Tyr313Phe for the substrates KIV (left) and AcCoA (right).When the kinetic 
parameters of NmeIPMS Tyr313Phe were determined, the concentration of [AcCoA] was held at 230 µM while the concentration 
of KIV was altered, and when the concentration of AcCoA was altered, the concentration of KIV was held at 420 µM. 
 
Unlike MtuIPMS Tyr410Phe, the Km for AcCoA was similar to that of wild type NmeIPMS, 
suggesting that this mutation has not adversely affected interaction with AcCoA. Additionally, the 
Km for KIV for NmeIPMS Tyr313Phe had increased 14-fold compared to the wild type protein, 
suggesting that this mutation drastically decreases the ability of the protein to interact with KIV. 
As the Tyr410Phe mutation in MtuIPMS had the opposite effect on the Km for KIV, this suggests 
that the two proteins may have different interactions with the substrates in the active site.  
L-Leucine sensitivity of the mutant was also assessed, and unlike MtuIPMS Tyr410Phe, the 
NmeIPMS Tyr313Phe was sensitive to L-leucine (Table 4.7, Figure 4.23). This suggests, as 
discussed in Chapter 2, that there are different allosteric pathways conferring allosteric regulation 
by L-leucine in different members of the IPMS family. The mutant enzyme shows a considerably 
reduced response to L-leucine compared to the wild-type protein (Figure 4.23). However, this 
experiment was carried out under saturating conditions for the wild-type protein that are not 
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saturating, with respect to KIV, for the mutant enzyme. Under saturating conditions for KIV, the 
response to L-leucine may be different in the Tyr313Phe mutant.  
 
Figure 4.23: The response of NmeIPMS wild-type, NmeIPMS Tyr313Phe (Y313F), and NmeIPMS Lys332Ala (K332A) to L-
leucine. Due the low kcat of both Y313F and K332A, a complete IC50 plot for the mutant could not be completed. The 
concentration of AcCoA was held at 230 µM and the concentration of KIV was held at 210 µM in all analyses. The specific 
activity of NmeIPMS wild-type (blue) is plotted on the left axis and the specific activity of Y313F and K332A are plotted on the 
right axis.  
 
4.1.9.2 NmeIPMS Lys332Ala 
 
 
Figure 4.24: The location of residue Lys332 in the NmeIPMS homology model. Chain A is shown in grey, while chain B is 
shown in green (catalytic domain), blue (subdomain I), orange (linker), red (subdomain II), and teal (regulatory domain). The 
right-hand image shows Lys332 (spheres, coloured by element) in the linker and AcCoA obtained from the 3BLI structure of 






Molecular dynamics combined with docking of AcCoA performed by Dr. Wanting Jiao (personal 
communication, October 2015) identified several residues in the subdomains that may have a role 
in AcCoA recruitment. This set of residues includes residue Lys332 in NmeIPMS, which is located 
on the loop between subdomains I and II. This region has conserved positive charge, and in the 
RDP alignment, this residue is almost absolutely conserved. This suggests that this residue has a 
critical role in catalysis.  
 
 
Figure 4.25: Logo diagram of the regulatory-domain absent (RDA) (left) and regulatory domain present (RDP) (right) 
alignments from Chapter 3 showing the conservation of residue Lys332 (NmeIPMS numbering) in both alignments. The x-axis 
numbering refers to the residue number in the alignment.  
 
An alanine mutant, Lys332Ala, was made. The mutant was constructed by Davies132, and initial 
characterisation was performed by Plowman-Holmes131. This mutant displayed a large increase in 
the apparent Km for AcCoA; the wild-type protein has an apparent Km for AcCoA of 35 ± 3 µM 
while the Lys332Ala mutant has an apparent Km for AcCoA of 900 ± 100 µM. This enormous 
change in apparent Km demonstrates that this residue is critical for the interaction with AcCoA 
even though, in the homology model, it does not form part of the active site (Table 4.7, Figure 
4.26). The Km for KIV could not be determined as the Km for AcCoA was so high that the 






Figure 4.26: Plot of the kinetic data of NmeIPMS Lys332Ala where the concentration of AcCoA is varied. The substrate 
concentration of KIV was held at 250 µM 
 
The importance of positive charge in this location to catalytic activity may provide some 
understanding as to why subdomain II is essential for catalysis. The increase in Km for AcCoA in 
the Lys332Ala mutant suggests that this residue is involved in the recruitment of AcCoA. Lys332 
is located in the flexible loop between subdomains I and II, suggesting that the restriction on the 
conformations available to this region determined by the three-helix bundle of subdomain II 
allows the loop to be available to recruit AcCoA. In the absence of subdomain II, or when it has 
been partially truncated, this restriction has been abolished and the loop is not restrained 
sufficiently to allow for AcCoA recruitment to the active site. A kcat of 0.15 ± 0.01 s
-1 was estimated 
from the kinetic data obtained in Figure 4.26, although due to the high Km of this enzyme, this is 
likely to be considerably higher than the actual turnover number. This has significantly decreased 




Leucine sensitivity in this alanine mutant was also investigated (Figure 4.23, Table 4.7). This 
mutant, like Tyr313Phe, also shows sensitivity to leucine. As with the Tyr313Phe mutant, the IC50 
of the protein could not be obtained due to the extremely high Km for at least one of the substrates. 
Additionally, the very low kcat   for both the Tyr313Phe and Lys332Ala mutant made determining 
changes in rate especially in the presence of an inhibitor challenging as a large amount of protein 
was required. A true comparison between the residual activity of the mutant compared to wild 
type in the presence of inhibitor could also not be made, as the substrate concentrations used in 
the presence of the inhibitor were saturating for the wild-type protein but not for the mutant. 
However, the sensitivity of both these mutants to L-leucine even though they display extremely 
aberrant kinetic activity suggests that the allosteric network may utilise interactions beyond those 
that are important for catalytic function.  
4.1.9.3 NmeIPMS Arg371Ala and NmeIPMS K395Term Arg371Ala 
 
Figure 4.27: The location of Arg371 (spheres) in the NmeIPMS homology model. Chain A is shown in grey. Chain B is shown in 
green (catalytic domain), blue (subdomain I), orange (linker), red (subdomain II), and teal (regulatory domain). The right-hand 
image shows chain B of the NmeIPMS homology model with AcCoA (dots) from the LinCMS structure (PDB: 3BLI) 
superimposed onto it. The backbone of Arg371 in Chain B forms an interaction with the backbone of Lys369 and the sidechain 
of Arg371 also forms an interaction with the sidechain of Ser334. 
 
Arg371, like Lys332, was also identified as a residue that forms interactions with AcCoA in MD 
docking simulations performed by Dr. Wanting Jiao (personal communication, October 2015).  
Arg371 is found in subdomain II, and, like Lys332, is located in a loop, although Arg371 is located 
in a loop between helices of subdomain II, while Lys332 is located in a flexible loop between the 
subdomains. An alanine mutant of this residue was made in the full-length protein, and in the 
truncated protein, to determine the role of this residue in the recruitment of AcCoA in the presence 








Figure 4.28: Plots of kinetic data for NmeIPMS Arg371Ala Lys395Term, showing the change in initial rate when substrate 
concentration is increased.The data for KIV is shown on the left, and the data for AcCoA is shown on the right. The 
concentration of AcCoA was held at 300 µM while the concentration of KIV was varied, and the concentration of KIV was held 
at 230 µM while the concentration of AcCoA was varied.  
 
The full length Arg371Ala mutant showed a substantial increase in the Km for AcCoA, from 35 µM 
to 220 µM, although less than that seen in the Lys332Ala mutant which had a Km for AcCoA of 
~900 µM (Table 4.7, Figure 4.28). This increase suggests that this residue is important for the 
recruitment of AcCoA in the full-length protein. As with Lys332Ala and Tyr313Ala, this mutant 
is sensitive to leucine. The IC50 for leucine was determined, and was comparable to the wild type 
NmeIPMS, as the IC50 for wild-type NmeIPMS for L-leucine is 53 ± 5 µM and the full-length 
Arg371Ala mutant had an IC50 for L-leucine of 45 ± 5 µM. The lack of change to the IC50 value in the 
mutant protein compared to the wild-type protein suggests that this residue, and the interaction(s) it 
forms, are not involved in transmitting the allosteric signal to the active site.  
 
Figure 4.29: Plot of the kinetic data of NmeIPMS Arg371Ala in response to change in AcCoA concentration. The concentration 




The Km for AcCoA for the NmeIPMS Arg371Ala K395Term mutant was also increased compared 
to the wild type NmeIPMS, and also increased compared to the NmeIPMS truncation (Table 4.7, 
Figure 4.29). Interestingly, the Km for this mutant is the same as the Km for the full-length mutant, 
even though the Km for AcCoA for NmeIPMS K395Term is 2-fold higher than that of the full-
length protein, suggesting that this mutation affects the interaction with AcCoA but not the 
conformations that the subdomains can adopt. The apparent Km for KIV for this mutant was 
obtained, and it had increased compared to the wild type protein, although this may have been 
because the concentration of AcCoA was not saturating. In the future, the Km for KIV could be 
more accurately determined by determining the Km for KIV at different, non-saturating, AcCoA 
concentrations.   
 
Figure 4.30: Inhibition of NmeIPMS Arg371Ala by L-leucine.  The concentration of the substrates was held at 300 µM (AcCoA), 




Previous studies have shown that subdomain II is crucial for catalysis in IPMS from several 
organisms, even though it is located distant to the active site, and it has been have suggested that 
the role of subdomain II in catalysis is in the recruitment of AcCoA.2 It has also been suggested 
that the balance of stability and flexibility in the subdomains is important for catalysis, as sufficient 
stability is required to restrain the subdomains into conformations that allow for the recruitment 
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of AcCoA by the subdomains and linker to the active site, while allowing sufficient freedom to 
explore those conformations.  
A truncation in NmeIPMS was made to encompass all of subdomain II as a previous truncation, 
reported to be inactive, truncated the protein midway through subdomain II. This truncation was 
catalytically active yet insensitive to inhibition by leucine, although the Km for AcCoA had increased 
2-fold compared to the wild type protein. This increase in Km suggests that removal of the 
regulatory domain had adversely affected the interaction of the protein with the AcCoA substrate 
and thus affected catalysis.  
SAXS data suggested that the subdomains were highly mobile in solution, and kinetics performed 
in the presence of a viscogen showed a decreased apparent Km for AcCoA for both the full length 
and truncated proteins, suggesting that restraining the conformations that the subdomains can 
explore is crucial for the recruitment of AcCoA.  
Additionally, several alanine mutants of residues in the subdomains were constructed to further 
explore the role of particular residues in catalysis, and particularly, the recruitment of AcCoA to 
the active site. The results obtained from these mutations suggest that the dynamics of the 
subdomains, as well as particular chemistry within those subdomains, are crucially important for 
the recruitment of AcCoA in particular. The Tyr313Phe mutation in subdomain I suggests that 
this residue is important for interaction of KIV to the active site, and unlike the comparable 
mutation in MtuIPMS, mutation of this residue does not abolish sensitivity to leucine.  
The mutation of NmeIPMS Lys332Ala showed that positive charge in the linker region between 
subdomains I and II is particularly important for the recruitment of AcCoA, while the Arg371Ala 
mutant suggested that positive charge in the loop between helices in subdomain II may also be 
important for recruitment of AcCoA to the active site. A plausible theory based on these results 
suggests that the role of subdomain II in catalysis is to facilitate the recruitment of AcCoA to the 
active site, and the ability of the subdomains to move dynamically is crucially important for this 
function.    
The IPMS and IPMS-like proteins with and without a regulatory domain present an interesting 
conundrum: how can the similarly structured subdomains manage to provide sufficient stability 
yet flexibility to allow for the linker to recruit AcCoA to the active site in both the presence and 
absence of a regulatory domain? These results suggest that subdomain II provides sufficient 
restriction of conformations that the subdomains can form in the absence of a regulatory domain, 
even in a protein that has evolved to bear the burden of a regulatory domain, to facilitate catalysis. 
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Interestingly, the Km for AcCoA decreased substantially in the presence of a viscogen, suggesting 
that further restricting the subdomains by reducing the flexibility of the protein in solution allows 
for more efficient interaction with the substrate.  
Future work in this area could encompass the results of Chapters 3 and 4, and further explore the 
residues that demonstrate substantial coevolution in the subdomains in the presence or absence 
of a regulatory domain and that show differences between the regulatory domain presence and 
regulatory domain absent populations. One example of this is Phe363 (NmeIPMS numbering) that 
forms part of the hydrophobic core of the three-helix bundle of subdomain II. This residue is 
typically large and hydrophobic in the regulatory domain present alignment, yet smaller and 
hydrophobic in the regulatory domain absent population. By mutating the phenylalanine to a small 
hydrophobic residue in NmeIPMS and NmeIPMS K395Term, it may alter the stability of 
subdomain II and provide further information about the role of this subdomain in conferring 
catalysis in the presence and absence of a regulatory domain. The converse mutation, a small 
hydrophobic residue to a large one, could also be made in a protein that does not contain a 
regulatory domain, such as TthHCS, which has isoleucine present at this position and has been 
well characterised previously, to observe the difference altering the hydrophobic core of 
subdomain II makes to the catalytic cycle.  
It is obvious that complex interactions are involved in the catalytic cycle of this protein, and an 
intricate mix of flexibility and restriction is required to facilitate catalysis. The method by which 
catalysis is maintained through evolution in the presence and absence of a regulatory domain is 
not entirely clear, but these results provide further information about the mechanism by which 
AcCoA is recruited to the active site, and the fundamental importance of subdomain II in 






Chapter 5: Modular domain evolution in the IPMS and 




A domain can be defined as a functionally independent unit that shows conservation.159 The same 
protein domains recur over and over again through evolutionary heritage, appearing in vastly 
different proteins, performing diverse roles. A considerable number of protein domains have been 
found both independently, and as part of multi-domain proteins. Examples of these so-called 
modular domains include the ACT domain, a βαββαβ fold that binds small molecules and can be 
found through the genomes of a vast array of organisms both as a single domain, and in concert 
with other domains typically as a regulatory domain of an allosteric protein, and the Src homology 
2 (SH2) domain, commonly found in a wide variety of adapter proteins in receptor tyrosine kinase 
pathways as it binds phosphotyrosine.160, 161 
Modular domain evolution is critically important in processes such as cell signalling. Peisajovich et 
al.162 created a domain recombination library of 66 protein variants, mixing regulatory and catalytic 
domains, from 11 proteins that form part of a yeast mating pathway. The variant proteins were 
then added individually back to a strain containing the mating pathway, and the dynamics of the 
pathway were analysed by flow cytometry. The dynamics of the pathway were altered either 
positively or negatively by the addition of a recombinant variant protein, showing that modular 
domain evolution is critical to the maintenance and control of cell signalling pathways. Another 
similar example is the actin cytoskeleton of eukaryotic cells, where its morphology is controlled by 
guanine exchange factors (GEFs) that activate Rho family GTPases.163 Dbl family GEFs, that have 
a conserved Dbl homology (DH) domain but a wide variety of regulatory domains, were 
interchanged with different regulatory modules that are sensitive to other ligands, the actin 
cytoskeleton can be altered in predictable ways in response to the new regulatory ligands. This 
shows how cell signalling pathways can be altered in very wide-ranging ways by simply exchanging 
the regulatory modules in proteins that form part of the pathway.  
Modular domains are also important in the evolution of allosteric enzymes that form part of 
primary or secondary metabolic pathways. Many allosteric proteins contain multiple domains, and 
often, the same small-molecule binding domains, such as the aforementioned ACT domain, are 
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found on many allosteric enzymes with diverse functions. The ACT or ACT-like domain is found 
in E. coli 3-phosphoglycerate dehydrogenase (3-PGDH)164 as well as Thermatoga maritima DH7PS 
(TmaDH7PS)12, Campylobacter jejuni ATP PRTase, aspartate kinase, and chorismate mutase160, as 
well as other enzymes typically involved in amino acid metabolism. In these enzymes, the ACT 
domain functions as a regulatory domain and binds small molecules such as amino acids. 
Interestingly, the ACT domain can be found in many different configurations in the quaternary 
structure of various proteins.165 This modularity was exploited by Cross et al.35 where an ACT 
domain from TmaDAH7PS was attached to an unregulated DAH7PS from Pyroccocus furiosus. The 
addition of the regulatory domain provided regulation by tyrosine to PfuDAH7PS without 
adversely affecting catalysis, demonstrating the ease by which an unregulated protein may gain 
regulation throughout evolution.  
Like regulatory domains, catalytic domains can also be modular. One major example is the (β/α)8, 
or TIM, barrel. This domain is found in an enormous number of enzymatic contexts, such as 
alanine racemase, α-amylase, phosphotriesterase, and dihydropteroate (DHP) synthetase.70 The 
barrels can bind a diverse range of cofactors, such as divalent metals or pyridoxal-5’-phosphate, 
and can catalyse a truly spectacular number of reactions, acting as a lyase, hydrolase, transferase, 
oxidoreductase, and others.166 It was originally thought that the diversity of the barrel arose from 
convergent, rather than divergent evolution, but the similar location of catalytic residues at the C-
terminal end of the sheets of the barrel, even though the catalytic functions are incredibly diverse, 
suggest that, although sequence similarity between enzymes containing the TIM barrel is very low, 
it probably arose from divergent evolution from a catalytically promiscuous ancestral protein.70  
This fold also forms the catalytic domain of IPMS, CMS, and HCS, demonstrating the diverse 
range of substrates that the catalytic barrel can bind even in this small subset of enzymes. Like 
other examples, such as malyl-CoA lyase which also contains an insertion domain followed by a 
β-hairpin C-terminal to the barrel, the IPMS/CMS/HCS group of enzymes also contain extensions 
C-terminal to the barrel.167 In the case of IPMS and CMS, there is a C-terminal regulatory domain. 
Interestingly, this regulatory domain appears to be a novel fold as structural searches suggest that 
the closest similar structure is a double-stranded RNA binding domain.67  
The origin of the IPMS/CMS regulatory domain is of particular interest as it is a novel fold. It is 
not present on any characterised protein outside of IPMS and CMS. This could be due to some 
as-of-yet undiscovered role that is specific to the regulatory domain of these proteins and only this 
particular fold forming regulatory domain. However, this idea can be disputed with the discovery 
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that IPMS is functional without a regulatory domain, suggesting that the regulatory domain cannot 
perform a significant role in catalysis.2  
As homocitrate synthase does not have a regulatory domain, this suggests that the regulatory 
domain is a recent addition, after the divergence of the homocitrate synthases. It is presumed that 
the original, ancestral, promiscuous IPMS/CMS/HCS was not allosterically regulated, as allosteric 
and other types of regulation is a key step in increasing enzyme specificity throughout evolution.168 
This could also be important to explain why the regulatory domain has not spread throughout the 
genome – it is a relatively recent novel fold and thus has not had sufficient time to spread through 
the genome. There may also be genetic factors as to why this regulatory domain has not moved as 
a modular unit, for example, it may simply not be sufficiently near to a recombination ‘hot spot’ 
to allow for movement of the domain as a functional unit. 
Moore et al.113 suggest that ‘orphan domains’ such as the IPMS/CMS regulatory domain could be 
recent in evolutionary origin or could be derived from an ancestral protein fold yet sufficient 
evolutionary distance has occurred so the ‘novel fold’ and the original ancestral protein are not 
connected by existing methods of domain association. The authors also suggest that another way 
in which orphan domains can occur is through mutation of the stop codon and subsequent 
transcription and translation of formerly non-coding regions of DNA.113 However, these are 
typically disordered, whereas the IPMS/CMS regulatory domain has significant secondary 
structure. Hypothetically, the regulatory domain may formerly have been part of a significantly 
bigger domain, with a somewhat different fold, but most of the domain, and the original fold, was 
lost as it was extraneous to the functioning of the enzyme, and thus the ‘novel’ fold of the ligand-
binding portion of the domain remains.  
Another argument that could be made about the unique fold of the regulatory domain is that it 
cannot fold independently of the rest of the protein, and thus is selected against in the genomes 
of organisms as this may disrupt correct tertiary structure formation, and thus is not found as a 
modular domain.  
As IPMS, existing naturally without a regulatory domain, have been found and characterised, and 
the regulatory domain has been removed from both IPMS and CMS to produce catalytically active 
proteins, the regulatory domain cannot play an obligatory role in catalysis, yet, thus far, no IPMS 
or related protein with a different type of regulatory domain has been characterised. In a review of 
the ACT domain, Grant160 mentioned a LeuA protein from Sulfolobus solfataricus (Sso) that has a 
putative regulation of amino acids (RAM) domain C-terminal to the subdomains. The RAM 
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domain is structurally similar to an ACT domain, forming a β-β-α-β fold , but has a different 
effector binding site.169 
The ACT domain is a small-molecule binding domain (SMBD) that confers regulation to a protein 
upon ligand binding to the ACT domain. It is found in numerous different enzymes, often those 
involved in amino acid biosynthesis such as prephenate dehydrogenase and E. coli 3-
phosphoglycerate dehydrogenase where the ACT domain binds an allosteric inhibitor to regulate 
the protein.164 Like the ACT domain, the RAM domain can be found as a stand-alone small 
molecule binding domain, or fused to a catalytic domain or a DNA binding domain.169 One 
example is found in the thermophilic bacteria Thermus thermophilus (Tth), where a stand-alone RAM 
SMBD termed SraA, in the presence of tryptophan, forms a decamer and a complex with 
anthranilate phosphoribosyltransferase (AnPRT) to provide regulation by tryptophan to 
AnPRT.170 It has also been shown that lysine biosynthesis in Sso is controlled at a transcriptional 
level by LysM, a homologue of leucine responsive protein (Lrp), that contains a RAM domain that 
binds lysine and decreases the affinity of the DNA binding domain for the lysW promoter that 
controls the lys operon.171  
Kumar et al.69 explored a small group of proteins containing the ACT-like domain noted by Grant 
et al.160 further, showing that the proteins containing this structural motif are exclusively found in 
Archaea, and are likely to be HCS. Additionally, multiple sequence alignments suggested that, as 
an aspartate residue in the active site that is critical for competitive inhibition by lysine in canonical 
HCS is absent in the proteins containing the RAM domain, this group of HCS proteins may be 
allosterically regulated.69 Attempts were made to characterise the protein from Sso were 
unsuccessful.69 
To explore the potential for domain modularity in these proteins, the HCS from Sso (SsoHCS) 
discussed by Kumar et al.69 was cloned, expressed, and partially purified. Kinetic activity and 
inhibition of the partially purified protein were explored. Additionally, domain fusions were made 
with the NmeIPMS catalytic scaffold, where the NmeIPMS regulatory domain was replaced with 
the regulatory domain from SsoHCS, and the regulatory domain from LinCMS, to assess whether 
catalysis could be preserved, and inhibition by a different amino acid could be introduced by 
swapping the regulatory domain. Several fusions were also made between SpoHCS and NmeIPMS 
to investigate the interchangeability of the subdomains between allosterically regulated and 
competitively inhibited proteins.  
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5.2 Results  
 
5.2.1 Cloning and purification of SsoHCS  
 
The gene and protein sequences of SsoHCS were obtained from KEGG (ID: SSO0977).172-174 The 
genome sequence of Sso had previously been determined, and the gene coding for SsoHCS had 
been annotated as leuA-2.175 The proteome of Sso P2, one of the reference strains, has been 
explored, and the isoelectric point (pI) of SsoHCS was determined to be 7.2 while the molecular 
weight or SsoHCS was 50881 Da.176  
 
Figure 5.1: Agarose gel of the cloned SsoHCS gene (approx. size: 1350 bp) 
 
The gene coding for SsoHCS was cloned from Sso genomic DNA (Figure 5.1). The gene was then 
cloned into pET28a, a vector that contains a N-terminal His6 tag and provides kanamycin 
resistance, using the InFusion® HD cloning kit (Clontech). The vector contains a thrombin 
cleavage site between the N-terminal His6 tag and the gene sequence, and this was replaced with a 




Figure 5.2: IMAC purification of SsoHCS. S denotes the soluble fraction, IS the insoluble fraction, L the molecular weight 
ladder, FT the flow-through from the column, and Bound, the protein that bound to the IMAC column including SsoHCS (red 
box). 
 
The SsoHCS construct was insoluble under most conditions tested, including variations in type of 
buffer, salt concentration, type of salt, addition of additives such as metal ions or detergents, and 
different lysis methods such as chemical or physical lysis methods. Constructs were also made with 
GST and MBP solubility tags added using the Gateway system. The protein was not soluble with 
the GST tag added and showed some solubility, but no activity, with the MBP tag added.  
Using a lysis buffer of Tris, pH 8.5 with 100 mM NaCl, marginal solubility was achieved. The 
protein was partially purified using IMAC, although the low concentration of soluble protein in 
the lysate allowed for substantial non-specific binding to the IMAC column (Figure 5.2). To 
improve the purity of the protein would have reduced the already low yield, and further 
investigation into improving the purification protocol are on-going. Further purification, such as 
by SEC, was not attempted due to the small amount of protein obtained by this method, and the 
His6 tag was not removed.  
One way to improve purification may be to utilise the high thermal stability of the SsoHCS protein 
compared to E. coli proteins and use heat treatment followed by centrifugation to remove E. coli 
proteins. Ion exchange chromatography, namely cation exchange, could also be investigated 




5.2.2 Michaelis-Menten kinetics of SsoHCS 
 
Kinetic parameters of the partially purified His6 tagged SsoHCS were obtained. Activity was tested 
at a range of temperatures as Sso is a hyperthermophilic species. However, AcCoA is a heat labile 
substrate and produced substantial background activity at increased temperatures as the chemical 
couple that reacts with the free thiol of CoA reacted with CoA produced by AcCoA degradation 
as well as CoA produced by the enzymatic reaction. A temperature of 60°C was selected as this 
produced the best trade-off between background activity and catalytic activity of the thermophilic 
protein.  
 
Figure 5.3: The substrate preference of SsoHCS. The change in rate was determined using 17 µg of protein per experimental 
condition. The concentration of ketoglutarate (KG), ketoisovalerate (KIV), and pyruvate was 250 µM and the concentration of 
AcCoA was 250 µM.  
 
Ketoisovalerate (KIV), pyruvate, and ketoglutarate (KG) were all tested as potential substrates in 
combination with AcCoA (Figure 5.3). The highest level of activity was seen with ketoglutarate, 
suggesting that this protein acts primarily as a homocitrate synthase. Additionally, there was some 
activity observed with pyruvate, but none with ketoisovalerate, suggesting that the active site can 
accommodate other substrates, as seen in other members of the broad protein family. However, 
due to the low amount of soluble protein obtained, further exploration of other alternative 




Figure 5.4: Plot of the initial rate of SsoHCS in response to a change in substrate. The plot for increasing KG is on the left and 
increasing AcCoA is on the right. When KG was varied, AcCoA was held at 500 µM, and when AcCoA was varied, KG was held 
at 250 µM. 
 
Table 5.1: Kinetic parameters for SsoHCS 
 Km (KG, µM) Km (AcCoA, µM) 
kcat 
(s-1) 
SsoHCS 27 ± 5 78 ± 7 0.160 
 
Preliminary characterisation of the protein was performed using the substrates ketoglutarate and 
AcCoA in HEPES buffer at pH 7.5 with 20 mM MgCl2 and 20 mM KCl. Other buffers were 
tested, at a range of pH levels, but this buffer produced the most consistent activity. High pH can 
cause the reaction between DTP and CoA to become rate-limiting, so a larger range of buffers 
could be tested in the future using the direct as opposed to the indirect assay, where instead of 
using a chemical couple (DTP) that reacts with CoA to form a thio-pyridine that can be detected 
at 324nm, the loss of AcCoA at 232 nm can be directly measured. This was not performed due to 
time restraints.  
5.2.3 Testing of inhibitors  
 
Inhibition by three amino acids was tested (Figure 5.5). Due to the low amount of protein obtained, 
the activity at saturated substrate concentrations in the presence of 1 mM of L-lysine, L-leucine, or 
L-isoleucine, was tested and compared to the activity at the same concentration of substrates in 
the absence of inhibitor. The activity decreased to approximately half the maximal activity in the 
presence of 1 mM L-lysine, but not in the presence of either L-leucine or L-isoleucine. This suggests 
that the protein is inhibited only by L-lysine. In combination with evidence from multiple sequence 
alignments that the SsoHCS protein lacks a key aspartate residue in the active site to allow for 
competitive inhibition by lysine, it is plausible that this is the first evidence of an allosterically 




Figure 5.5: The response of SsoHCS to potential inhibitors. The concentration of both substrates was held at 500 µM when an 
inhibitor was tested. The concentration of all inhibitors tested was 1 mM.  
 
5.2.4 Summary and Discussion 
 
The putative HCS from Sso was cloned and partially purified. The problems with solubility outlined 
by Kumar et al.69 were partially overcome by the screening of different buffers, although further 
buffer screening may be necessary to obtain higher levels of protein, or a different growth strategy, 
such as changing the media in which E. coli is grown to increase the cell concentration, may be of 
use. Additionally, a method of purification such as heat treatment, as the protein is thermostable, 
may be more appropriate than purification using a His6 tag. Other additives such as different 
detergents may also improve solubility. The purified protein displayed maximal activity at increased 
temperatures, as expected of a protein from a thermophilic organism. The protein also showed 
inhibition by lysine, suggesting that it may be allosterically regulated. Further work is needed to 
establish the range of substrates that the protein can accommodate and to explore the mode of 




5.2.5 Fusion proteins 
 
To further explore the potential for modularity in IPMS and related proteins, several fusion 
proteins were made to investigate whether the subdomains of NmeIPMS and SpoHCS were 
interchangeable. A fusion was also made between SpoHCS and the regulatory domain of 
NmeIPMS, to investigate whether a HCS, which naturally does not have a regulatory domain, could 
still perform catalysis with a regulatory domain attached to its C-terminus.  
Additionally, two fusions were made where the regulatory domain of LinCMS or the putative 
regulatory domain of SsoHCS was fused to the end of subdomain II of NmeIPMS. This was done 
to explore whether the regulatory domains of IPMS and related proteins were interchangeable, 
and also to assess whether inhibition by isoleucine or lysine respectively could be transferred 
between the proteins by fusion of the regulatory domain.  
5.2.5.1 Construction of fusion proteins 
 
 
Figure 5.6: The strategy used to fuse genes together in the creation of the fusion construct.  The red and blue lines denote the 
two genes, while the purple and green lines denote the His6 tag and the TEV protease site that were also added. 
 
A series of pairwise, structural, and multiple sequence alignments was used to assess where to fuse 
the two fragments of the genes encoding the full-length protein together. The NmeIPMS/SpoHCS 
fusions were made at positions to maintain the entirety of both subdomains, thus preserving 
subdomain II as a single entity, as this is known to be essential for catalysis. All of the fusion 
proteins were constructed using multi-step PCR and the plasmid maps for the SpoHCS and SsoHCS 
constructs are located in Appendix IV. The protein sequences for the fusion constructs are located 
in Appendix IV. The SpoHCS construct was obtained from GeneArt and was sub-cloned into 
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pET28a for protein expression. The LinCMS construct was also a synthetic gene and was also sub-
cloned into pET28a. The NmeIPMS and SsoHCS constructs were described above. A table of the 
fusion proteins that were constructed is shown in Table 5.2.  
 
Figure 5.7: An example of the first two PCR stages, where regions of genes of interest are amplified and then fused using the 
overlapping region designed into the primer.  These gene fragments were generated during the construction of the NmeIPMS-
LinCMS fusion and show the gene fragment associated with NmeIPMS catalytic and subdomains in the lanes labelled NmeIPMS, 
and the gene fragment that codes for the regulatory domain of LinCMS in the lanes labelled LinCMS. The gene fragment in the 
right-hand image shows the fused gene construct where the gene fragment coding for the LinCMS regulatory domain has been 
fused to the gene fragment coding for the NmeIPMS catalytic domain and subdomains using overlapping primers.  
 
The cloning strategy used is described in Figure 5.6. The part of each gene of interest was amplified 
using PCR, then gel purified. An example of this is shown in Figure 5.7.  In the primer, a region 
of the other gene was included on the relevant end to allow for overlap of the two constructs in 
the second PCR step. A further two rounds of PCR were used to add an N-terminal His tag and 
a TEV protease site to the construct. InFusion cloning was then used to move the fused gene into 
pET21a for expression. 
5.2.5.2 Fusions of NmeIPMS and SpoHCS 
These fusions were constructed to assess the modularity of subdomain II in particular by 
determining whether a complete subdomain II from a different structural design, i.e. with or 







    NmeIPMS       LinCMS  
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Table 5.2: The fusion constructs, showing the regions of each protein that they contain. The residue numbers given are the 
residue number of that particular protein i.e. the residue numbers given for NmeIPMS are the residue numbers from NmeIPMS, 
the residue numbers for LinCMS are from LinCMS etc.  In the schematic diagrams of the single chain of the protein, parts of 
SpoHCS are shown in purple, parts of NmeIPMS are shown in blue, parts of LinCMS are shown in teal, and parts of SsoHCS are 












































































5.2.5.2.1 The fusion of the SpoHCS catalytic domain and subdomain I with the NmeIPMS 
subdomain II and regulatory domain (SpoHCSCat-SI – NmeIPMSSII-Reg) 
 
 
Figure 5.8: A schematic diagram of SpoHCSCat-SI – NmeIPMSSII-Reg. (left)  The catalytic barrel and subdomain I from SpoHCS are 
in purple, while subdomain II and the regulatory domain from NmeIPMS are shown in blue. The HisTrap purification of 
SpoHCSCat-SI – NmeIPMSSII-Reg (right).  
 
The SpoHCSCat-SI – NmeIPMSSII-Reg construct was made by fusing SpoHCS to residue Gly351 
(SpoHCS numbering) to NmeIPMS from residue Leu330 (NmeIPMS numbering). This 
encompasses SpoHCS to the C-terminal end of subdomain I, and NmeIPMS from the N-terminal 
end of subdomain II to the end of the regulatory domain. The aim of this fusion was to determine 
whether an HCS with no regulatory domain could be catalytically active with a regulatory domain 
attached. Subdomain II from NmeIPMS was included in the fusion to allow for potentially 
important connections between subdomain II and the regulatory domain to be maintained in the 
overall structure. 
Following the PCR steps detailed above, the purified plasmid was sequenced, and this showed that 
the correct fusion had been made and there were no other errors in the sequence. A HisTrap 
purification of this fusion protein was performed after it was determined that the protein was 
soluble and approximately the correct size (Figure 5.8). Further purification of the protein was not 
performed as only a small amount was obtained from the HisTrap purification step. There was 
some contamination in the HisTrap purification that could not be adequately resolved to 
determine whether the protein was correctly folded by circular dichroism nor whether the mass 
was consistent with the estimated mass using mass spectrometry. The protein also displayed no 
catalytic activity upon kinetic assay using ketoglutarate and AcCoA as substrates. The maximum 




Figure 5.9: The insolubility of the SpoHCScat-SDs – NmeIPMSReg fusion. This gel image shows the soluble (S) and insoluble (I) 
fractions after lysis of the SpoHCScat – NmeIPMSSDs-Reg fusion protein by sonication in a buffer containing 50 mM potassium 
phosphate pH 8, 300 mM KCl, 20 mM imidazole. L denotes the ladder. A significant amount of insoluble protein is observed in 
the insoluble fraction, although a small amount (red box) was soluble.  
 
A further fusion, where the regulatory domain from NmeIPMS was fused to the C-terminal end of 
subdomain II of SpoHCS was also constructed (SpoHCScat-SDs – NmeIPMSReg). However, this fusion 
was substantially less stable than the SpoHCSCat-SI – NmeIPMSSII-Reg fusion, and showed significant 
precipitation, and a very low yield, when an attempt was made to purify it using IMAC. When the 
partially purified protein was thawed after flash-freezing and storage in a -80°C freezer, more 
precipitation occurred, and no activity was observed by kinetic assay. Further investigation of 
buffer conditions that may stabilise this protein to enable purification and characterisation are on-
going.  
  





5.2.5.3 Fusions of NmeIPMS and LinCMS, and NmeIPMS and SsoHCS 
 
To further explore the plausibility of the modularity of the regulatory domain from these 
proteins, the regulatory domain was purified independently of the rest of the protein, and two 
fusion proteins were constructed where the regulatory domain from LinCMS, or the putative 
regulatory domain from SsoHCS, were fused to the catalytic unit, that is the catalytic domain and 
subdomains, of NmeIPMS to observe whether catalysis could be preserved, and whether allostery 
by the respective allosteric inhibitor could be introduced.  
5.2.5.3.1 The NmeIPMS regulatory domain (NmeIPMSreg) 
 
The NmeIPMS regulatory domain was cloned independently of the rest of the protein. The protein 
was soluble, but purification of the regulatory domain by the N-terminal His6 tag was difficult as 
there was a large amount of contamination in the purification that could not be adequately resolved 
(Figure 5.10). The regulatory domain appeared to be able to be purified as soluble protein, although 
whether the domain is properly folded, and whether it forms the correct oligomeric state and can 
bind leucine is yet to be established.  
 
Figure 5.10: HisTrap purification of the isolated NmeIPMS regulatory domain. The red box indicates the protein of 
approximately the size of the NmeIPMS regulatory domain. HisTrap purification was performed using an elution gradient from 0 






5.2.5.3.2 The NmeIPMS-SsoHCS fusion (NmeIPMSCat-SDs – SsoHCSReg) 
 
This fusion was made to explore the putative SsoHCS regulatory domain by fusion to the 
NmeIPMS catalytic unit to see whether it was able to provide allosteric regulation by L-lysine to 
NmeIPMS, and potentially, to observe whether lysine could bind this domain in this context as 
producing sufficient soluble SsoHCS for protein-intensive techniques such as ITC proved difficult. 
Additionally, this fusion was constructed to determine whether NmeIPMS was catalytically active 
with a different type of regulatory domain fused to the C-terminus.  
 
Figure 5.11: Purification of the NmeIPMSCat-SDs –SsoHCSReg fusion protein. The first lane shows the soluble fraction of the lysate, 
showing large amount of soluble fusion protein (red box). The second lane contains a molecular weight ladder. The third lane 
shows the fusion protein after HisTrap and SEC purification, showing that the fusion protein is relatively pure and is 
approximately the correct size that was calculated as 51700 kDa.  
 
As described above, this fusion was made using PCR where an overlap region with SsoHCS was 
introduced at the C-terminus of subdomain II of NmeIPMS, and the N-terminus of the putative 
regulatory domain of SsoHCS. As the absolute structure of SsoHCS is not known, the regulatory 
domain was defined by the residues identified by Pfam114 as an Asnc/Lrp ligand binding domain 
otherwise known as a RAM domain. The regulatory domain in this context was thus from residue 
399 (SsoHCS numbering) to the C-terminal end of the protein. The fusion point on NmeIPMS was 
made at residue Tyr394, as the active truncation of NmeIPMS was made at this position and 
therefore encompassed all of subdomain II. The protein sequence of this and the other fusions 
constructed are located in Appendix IV. 
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The protein was soluble, and purification by IMAC followed by SEC was performed. As discussed 
previously, removal of the His6 tag led to a substantial decrease in the amount of active protein 
obtained, so the His6 tag was also not removed from the fusion protein constructs.  
 
Figure 5.12: Michaelis-Menten kinetic data for the NmeIPMSCat-SDs –SsoHCSReg fusion protein. The concentration of KIV was 
varied in the left plot and the concentration of AcCoA was varied in the right plot. The other substrate was held at a saturating 
concentration of 250 µM (KIV) and 300 µM (AcCoA) 
 
Michaelis-Menten kinetics were obtained for the purified NmeIPMSCat-SDs –SsoHCSReg construct, 
using ketoisovalerate and AcCoA as substrates (Figure 5.12). The protein is catalytically active and 
has a Km for KIV similar to that of wild type NmeIPMS (Table 5.3). The Km for AcCoA of the 
NmeIPMSCat-SDs –SsoHCSReg fusion protein has increased compared to the wild type protein, to 
approximately a similar degree as the Km for AcCoA for the NmeIPMS K395Term truncated 
protein. This suggests that the fusion of the SsoHCS regulatory domain may somewhat adversely 
affect the interaction of subdomain II with AcCoA. Connections subdomain II may make with 
the regulatory domain in the wild-type protein have been broken in this construct, and the lack of 
these connections may increase the conformations that the subdomains may form, leading to a 
decrease in the ability of the subdomains to recruit AcCoA to the active site.  
The Km for KIV has decreased in the fusion protein compared to the wild type protein from 36 
µM to 21 µM. This decrease suggests that the addition of the regulatory domain from a more 
thermostable protein has increased the ability of the protein to interact with KIV.  
The kcat of the fusion protein has decreased substantially compared to the wild type protein, 
although as mentioned above, the kcat in these proteins can be variable due to the proportion of 
active to inactive protein as the proteins lack stability.  
The NmeIPMSCat-SDs –SsoHCSReg protein does not show inhibition by L-lysine, L-leucine, or L-
isoleucine up to concentrations of 10 mM, suggesting that inhibition via the regulatory domain has 
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not been introduced. Differential scanning fluorimetry (DSF) was used to investigate whether 
there was evidence of ligand binding. Typically, if thermal stabilisation is observed by DSF in the 
presence of a ligand, it suggests that the ligand is binding the protein, although the absence of 
thermal stabilisation does not preclude ligand binding. Thermal stabilisation by ligand binding was 
was demonstrated in Chapter 4.1.3 by L-leucine stabilisation of the wild type NmeIPMS protein.  
 
Figure 5.13: The melting temperature of NmeIPMSCat-SDs –SsoHCSReg as determined by DSF. 
The apo protein had a higher Tm than the NmeIPMS truncation or the NmeIPMS wild type protein. 
Stabilisation by leucine seen in the wild type NmeIPMS truncation was not observed in the NmeSso 
fusion as expected as the SsoHCS regulatory domain has been posited to bind lysine, although no 
stabilisation is seen with lysine either. There is a small amount of stabilisation seen when isoleucine 
is added, although the Tm is only 2 °C higher than that of the apo protein. This slight increase may 
be significant, but further examination such as by ITC would be required to investigate ligand 






Table 5.3: Kinetic parameters for NmeIPMS wild-type, the truncated NmeIPMS, and two fusion proteins 






36 ± 3 35 ± 3 7.2 ± 0.1 
NmeIPMS 
K395Term 








64 ± 3 21 ± 1 1.6 ± 0.1 
  
This fusion, although not allosterically regulated, does suggest that a different type of regulatory 
domain can be fused to the C-terminus of subdomain II of NmeIPMS and not significantly 
adversely affect catalysis. However, allostery was not preserved in this fusion.  
5.2.5.3.3  The NmeIPMS – LinCMS fusion (NmeIPMSCat-SDs –LinCMSReg) 
 
Another fusion, between the catalytic unit of NmeIPMS and the regulatory domain of LinCMS, 
was thus made to determine whether a canonically structured regulatory domain for this type of 
protein could be switched between proteins and confer both catalysis and allostery. 
This fusion was made to encompass the catalytic unit of NmeIPMS, encompassing the protein up 
to residue Ser388 (NmeIPMS numbering) and the regulatory domain of LinCMS from residue 
Gly388 (LinCMS numbering), and was constructed as described above. LinCMS was chosen as the 
source of the regulatory domain as, although the two proteins are phylogenetically distant, the 




Figure 5.14: Kinetic activity of the NmeIPMSCat-SDs –LinCMSReg fusion. In the left plot, AcCoA was held at 250 µM, and in the 
right plot, KIV was held at 250 µM, while the other substrate was varied.  
 
The fusion is catalytically active, and has kinetic parameters similar to those of the wild type 
protein, aside from an increase in Km for AcCoA and a decrease in kcat (Table 5.3, Figure 5.14). The 
Km for AcCoA of this fusion is comparable to the Km of the truncated NmeIPMS and the 
NmeIPMSCat-SDs –SsoHCSReg fusion, showing a 1.4-fold increase. Unlike the NmeIPMSCat-SDs –
SsoHCSReg fusion, the addition of the LinCMS regulatory domain did not cause a decrease in the Km 
for KIV. 
 As with NmeIPMSCat-SDs –SsoHCSReg, this fusion did not show regulation by L-leucine, L-isoleucine, 
or L-lysine. Ligand concentrations of the amino acids tested varied from 0 to 10 mM. Additionally, 
assays were performed, with L-lysine, L-leucine, and L-isoleucine present at varying concentrations 
(0 – 5 mM), at different concentrations of substrate ranging from low concentrations of either or 
both substrates (a concentration of 25 µM for AcCoA and/or KIV) to high concentrations of 
either or both substrates (a concentration of 150 µM for AcCoA and/or KIV). No inhibition was 




Figure 5.15: DSF denaturation of NmeIPMSCat-SDs –LinCMSReg without and with 1 mM Ile. The negative of the first derivative is 
shown in red (apo) and blue (1 mM Ile). This demonstrates the double peak seen in the apo but not the isoleucine-containing 
condition. 
 
DSF was also used with this fusion to investigate potential ligand binding to the fusion protein 
(Figure 5.16). NmeIPMSCat-SDs –LinCMSReg, as with other fusions described above, showed a 
substantial loss of stability compared to the wild type protein, and precipitated readily upon 
concentration, meaning that ITC was not a viable technique for exploring ligand binding under 
these conditions. Two peaks are visible in the graph of the thermal melt in the apo condition, one 
at 51°C and one at 56°C (Figure 5.15). Under conditions containing isoleucine, the profile had 
changed with only one main peak observed at 56°C. This suggests that addition of isoleucine has 
some effect on the stability of the protein.  
 
Figure 5.16: Melting temperature for the NmeIPMSCat-SDs –LinCMSReg fusion as determined by DSF. The temperature of the first 
peak in each condition is shown in a dark colour and the temperature of the second peak is shown in a light colour. The 
concentration of each ligand used was 1 mM. 
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5.3 Discussion  
 
These results show that the point at which a fusion is made is critically important to the 
maintenance of activity. The fusions made between NmeIPMS and SpoHCS did not show catalytic 
activity upon purification, suggesting that a complete catalytic unit, and the interactions that this 
unit forms within itself; is critical for catalysis. However, a different fusion point, or subsequent 
mutation, may improve stability in the case of the SpoHCScat – NmeIPMSSDs-Reg fusion or allow for 
catalytic activity to be maintained in the other NmeIPMS-SpoHCS fusions. The suitability of other 
fusion points may be investigated using large MSAs of NmeIPMS-like IPMS and SpoHCS-like HCS 
to assess regions of particular conservation in both large groups and when the two groups are 
aligned together. Another potential area to investigate would be to utilise a HCS from the bacterial 
HCS as these HCS are phylogenetically closer to NmeIPMS than SpoHCS are. As the bacterial HCS 
are from organisms in the Thermus-Deinococcus group, they are from extremophilic organisms. The 
fusion of an enzyme from a mesophilic organism (e.g. NmeIPMS) to one from an extremophilic 
organism (e.g. TthHCS) presents additional complications. Using an extremophilic IPMS, e.g. 
MjaIPMS to create fusions with an extremophilic HCS may also be a plausible solution.  
As discussed in Chapter 2, the allosteric network that controls subdomain II and catalytic activity 
appears to be phylogenetic in basis as opposed to conserved in all proteins of a particular 
structural type. For example, NmeIPMS and MtuIPMS catalyse the same reaction with the same 
overall structure but appear to have different allosteric networks that transfer the signal from the 
allosteric ligand binding site to the active site. This difference in network suggests that the 
transfer of allostery by domain fusion is difficult if the connections to the active site are broken, 
and, as the results in Chapter 2 show, single point mutations are sufficient to abolish allosteric 
regulation. However, the transfer of the allosteric signal could potentially be re-established in the 
fusion protein by subsequent mutations if the allosteric network in the subdomains is not 
disrupted.  
The positive charge of Arg470, located in the regulatory domain, is lost in the NmeIPMSSDs-
LinCMSReg fusion as there is not a comparable residue on the bottom of the LinCMS regulatory 
domain. An Arg470Ala mutation in NmeIPMS abolished leucine sensitivity, suggesting that this 
residue is crucial for the transmission of the allosteric signal to the active site. One way to assess 
whether this is the only factor in the lack of response to the allosteric ligand would be to mutate 
the comparable residue in the LinCMS domain in the fusion to arginine. 
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Additionally, the LinCMS is considerably more phylogenetically distinct from NmeIPMS than 
MjaCMS is, so the transfer of allostery by the transfer of a domain may be more accessible if the 
MjaCMS regulatory domain is transferred onto the NmeIPMS catalytic scaffold. These results 
suggest that, although catalytic activity can be readily preserved even when a foreign domain is 





Chapter 6: Discussion 
 
Determining how a protein fluctuates in a living cell is an immense task, although a deeper 
understanding of how proteins move, how that movement can be affected by allosteric regulation, 
and the evolutionary processes that have contributed to that movement, are crucially important to 
our understanding of proteins, their evolution, and ultimately, to our ability to design more 
effective antibiotics.  
In this study, a group of related enzymes have been explored as they share an interesting structural 
homology, namely a (αβ)8 barrel with a C-terminal extension, subdomains I and II, that is critical 
for catalysis. How the subdomains, and specifically how their movement, contribute to the catalytic 
activity even though they are some distance from the active site, has been of particular interest. A 
variety of techniques has been utilised to explore the role of the subdomains, how the enzymes 
have evolved to mediate catalysis both with and without the structural burden of a regulatory 
domain at the C-terminus of subdomain II, and how the allosteric signal can be transferred to the 
active site in the absence of an obvious conformational change.  
6.1 Residue networks in the subdomains facilitate catalysis in regulatory domain-
present and regulatory domain-absent structural populations  
 
In extant IPMS and related enzymes, it has been shown that removal of a regulatory domain, as 
long as subdomain II remains intact, does not abolish catalysis. This was shown in NmeIPMS, in 
which the information obtained from a previous truncation had suggested that removal of a 
regulatory domain abolished catalysis although this truncation encompassed only part of 
subdomain II.1, 158 There is a catalytic penalty to the removal of the regulatory domain, an increase 
particularly in the Km for AcCoA, which suggests that there is a change in the dynamics of the 
subdomains that recruit AcCoA in the absence of a regulatory domain restraining the 
conformations that the subdomains can adopt.   
In Chapter 3, covariance analyses were used to determine networks of coevolved residues in 
populations of sequences that possess a regulatory domain and that do not have a regulatory 
domain. These networks, spanning the catalytic domain and the subdomains, were different in the 
two populations, suggesting a mechanism by which the subdomains, that appear to have a similar 
structure in the presence and absence of a regulatory domain, can maintain sufficient freedom in 
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the presence of a regulatory domain, and sufficient restraint in the absence of one, to confer 
catalysis. As the truncated form of NmeIPMS still contained a network of residues that had evolved 
to bear the burden of a regulatory domain, there was a catalytic penalty to the removal of the 
regulatory domain that may have its roots in the increased freedom of the subdomains.  
As modern enzymes, such as NmeIPMS, can still be catalytically active even with a regulatory 
domain removed, it suggests that the ancestral protein did not have a regulatory domain, as, if the 
ancestral protein had a regulatory domain, the network of residues that have evolved to allow 
catalysis particularly in the subdomains may have encompassed the regulatory domain. Removal 
of the regulatory domain in modern proteins would thereby be less likely to result in a catalytically 
active truncated protein. Additionally, Liang et al.177 suggest that it is likely that allosteric proteins 
arise from non-allosteric proteins that can catalyse the same reaction. Additionally, domain fusions, 
where a regulatory domain has been transplanted from one enzyme to another, has been shown 
to confer allosteric regulation to unregulated proteins.35, 178  
In Chapter 3, the covariance analyses determined different networks of residues in the proteins 
that had regulatory domains compared to the proteins that did not, although these networks both 
included the subdomains and were in similar regions such as the hydrophobic interior of the three-
helix bundle of subdomain II. The Lys332Ala mutation made in the linker region of NmeIPMS 
showed a 25-fold increase in Km for AcCoA showing that the linker between subdomain I and 
subdomain II is important for catalysis due to its role in the recruitment of AcCoA. As networks 
identified by covariance analyses include the subdomains, it suggests that these networks are 
important for the control of the dynamics of the subdomains to facilitate recruitment of AcCoA 
and allow for catalysis. These networks also show one way these proteins have compensated for 
the burden of a regulatory domain, as the networks of residues in the regulatory domain present 
and regulatory domain absent populations are different, suggesting a mechanism by which the 
dynamics of the subdomains have been altered.  
In Chapter 5, it was shown that fusions between NmeIPMS and SpoHCS were not catalytically 
active. This suggests that, potentially, interactions between the subdomains, such as in the 
networks determined in Chapter 3, are important for catalysis and these were disrupted when 
fusions were made between the subdomains, leading to inactive protein. It also suggests that the 
catalytic unit in its entirety is the catalytic domain and the subdomains. However, the fusion 
proteins also showed limited stability which made purification difficult and sufficient amounts of 
purified fusion protein has not been obtained to allow for circular dichroism to assess whether 
these proteins are properly folded. With taxonomy in mind, future work could include fusions 
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between HCS from Thermus or Deinococcus species as these appear to share a closer phylogenetic 
relationship to NmeIPMS, although evolution towards extreme environments may have altered 
networks responsible for the control of the subdomains and catalytic activity.  
In summary, these results show that a network of residues that span from the catalytic domain to 
the subdomain are important for catalysis in these proteins both when a regulatory domain is 
present and when it is absent. This network appears to be important for maintaining the dynamics 
of the subdomains, allowing flexibility in the presence of a restraining regulatory domain and 
stability in the absence of one.  
6.2 Multiple gene duplication and horizontal gene transfer events have led to the 
modern taxonomic distribution of catalytic diversity 
 
Figure 6.1: A representation of the potential relationships between the different IPMS and IPMS-like enzymes of interest. HGT 
denotes a potential horizontal gene transfer event. 
 
Based on the pattern of evolution identified by the CLANS analysis in Chapter 3, and work done 
by Casey et al.68 and Kumar et al.69, both horizontal gene transfer, and gene duplication then 
diversification events are likely to have all played a role in the evolution of the different proteins 
(Figure 6.1). The LinCMS-like CMSs are evolutionarily distinct from the MjaCMS-like CMSs 
suggesting that this enzymatic activity has risen at least twice. The MjaCMS-like CMS are more 
closely related to the NmeIPMS-like IPMS, which are primarily found in Proteobacteria, than they 
are to the LinCMS-like CMS even though they do not catalyse the same reaction. Taxonomically, 
the species containing MjaCMS-like CMSs are eukaryotes, primarily Euryarchaetoa, but as the 
proteins show most similarity to IPMSs from Proteobacteria, it suggests there has been a relatively 
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recent gene transfer event from Proteobacteria that led to the diversification of the MjaCMS-like 
CMSs in those species.  Interestingly, there is also evidence of a HCS in methanogenic Archaea, 
although it appears to be involved in the biosynthesis of coenzyme-B and biotin as opposed to the 
biosynthesis of lysine.98 
The taxonomy of the LinCMS-like CMSs also suggests horizontal gene transfer events. The 
majority of the species that contain a LinCMS-like CMSs are bacteria from the superphylum FCB 
group, containing Chlorobi, Bacteroidetes, and Fibrobacteria, and bacteria from the Proteobacteria 
phylum. The phylum Spirochaetes that contains the Leptospira genus is quite distinct from these 
other phyla, suggesting that there has been a gene transfer event to the Leptospira genus as other 
genera in the Spirochaetes phylum do not contain a CMS sequence and many do not contain an 
IPMS sequence.  
The bacterial HCS, such as that observed in Thermus thermophilus, are more closely related to the 
NmeIPMS-like IPMSs than they are to the fungal HCSs, even though there is a significant 
difference in structure between IPMS and HCS. Nishida et al.179 analysed phylogenetic 
relationships inside the Deinococcus-Thermus phylum, in which lysine is synthesised primarily through 
a AAA pathway, and suggested that the entire lysine biosynthetic pathway in this phylum had been 
transferred to the ancestor of the phylum. Although numerous other phyla have annotated 
homocitrate synthases in their genomes, they do not have the rest of the aminoadipate pathway, 
and do have functioning DAP pathways, suggesting that lysine is not synthesised in the same way 




Figure 6.2: The AAA pathway from fungi, Deinococcus-Thermus, and Archaea. The coloured circles represent enzymatic steps in 
the pathway, with the same colour representing a homologous enzyme in the different organisms. The broken colour in steps 1-3 
of the Archaea pathway represents enzyme functionality that has not been identified in all species that have the second half of the 
pathway in their genomes.  
 
Parts of an AAA pathway is also present in some Archaea, such as Sulfolobus and Pyrococcus, 
suggesting another potential gene transfer event (Figure 6.2). The second half of the AAA pathway 
in bacteria and Archaea is different from that of fungi, as discussed previously, suggesting that the 
gene transfer event occurred between Deinococcus-Thermus and the Archaea that maintain a complete 
AAA pathway as opposed to a gene transfer event from fungi that utilise different enzymes to 
convert aminoadipate to lysine. It has also been shown that the small subunit from the 
homoaconitase from Pyrococcus horikoshii can form a functional heterodimer with the large subunit 
in Thermus thermophilus and complement the homoaconitase small subunit knockout in Thermus 
thermophilus, providing further evidence that the AAA pathways from Deinococcus-Thermus and 
Archaea have similar origins.180 Nishida et al.85 also argues that there may have been a horizontal 
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gene transfer event involving the AAA pathway between Thermus species and Pyrococcus horikoshii 
in particular, although the phylogenetic tree suggested that this event may have been close to the 
divergence of Archaea and Bacteria.  
The MtuIPMS-like IPMSs are also distinct from the NmeIPMS-like IPMSs, and the other proteins. 
The vast majority of the species containing MtuIPMS-like IPMSs are within the Actinobacteria 
phylum, while the species containing NmeIPMS-like IPMSs are found in other phyla such as 
Proteobacteria. This may be one of the earliest divisions from the ancestral IPMS. The ancestral 
protein was likely promiscuous, as this promiscuity is seen in extant enzymes where alternative 
substrates can be accommodated by the active site of the IPMS. Additionally, the ancestral protein 
was likely involved in leucine biosynthesis as no alternative pathway for leucine biosynthesis in 
prokaryotes has been discovered yet there are alternative pathways for both isoleucine and lysine 
biosynthesis that do not use proteins with the IPMS scaffold. It is also likely that the ancestral 
IPMS was allosterically regulated, as it appears unlikely that the same unique fold seen in the 
regulatory domain of both MtuIPMS-like and NmeIPMS-like IPMSs arose twice. It has been 
suggested that Actinobacteria diverged from other bacterial phyla so long ago that the last common 
ancestor of Actinobacteria and other bacterial phyla can no longer be identified.181 This substantial 
difference in sequence between the MtuIPMS-like and NmeIPMS-like IPMSs does suggest that 
divergence of these two groups was comparatively ancient. Therefore, care must be taken when 
comparing IPMS proteins from the two groups as, although they catalyse the same reaction, they 
appear to have diverged at the earliest point.  
Interestingly, a phylogenetic study was done to investigate the origin of IPMS in fungal species, 
and this showed that IPMS from fungi such as Schizosaccharyomyces pombe and Saccharomyces cerevisiae, 
i.e. fungi from the Dikarya subkingdom of fungi, appear to be more closely related to those IPMS 
present in Actinobacteria than IPMS from non-Dikarya fungi that appear to share a common 
origin with IPMS from plants and photosynthetic bacteria.90 It is not clear whether the origin of 
the fungal HCS was a different gene transfer event and thus has a different origin to that of the 
IPMS in the same genome or was the result of gene duplication and divergence from the IPMS 
pathway in the relevant species.  
6.3 Allostery in NmeIPMS in the absence of a conformational change 
 
The second question that this work focussed on was about how the allosteric signal was transferred 
from the regulatory domain to the active site in the apparent absence of a conformational change. 
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Along with utilising such techniques to explore the broader network that facilitates catalysis, a 
coevolution analysis was used to investigate the potential for an allosteric network in NmeIPMS-
like IPMS. Statistical coupling analysis suggested that there was a network of residues from the 
allosteric binding site to the catalytic barrel. There were significant differences in this network to 
a network of residues that have been identified as involved in allosteric regulation in MtuIPMS. 
One residue, Tyr410 (MtuIPMS numbering), was mutated to Phe and this mutant was insensitive 
to leucine.63 This residue is highly conserved in all of these proteins. However, the same mutation 
in NmeIPMS had very aberrant kinetics but showed sensitivity to leucine. This difference in the 
effect of a comparable mutation in MtuIPMS and NmeIPMS suggests that there is a phylogenetic 
basis to the network of residues that confer allostery. Based on phylogenetic and taxonomic 
information, it appears that the Actinobacteria, containing MtuIPMS-like IPMS, and 
Proteobacteria, containing NmeIPMS-like IPMS, diverged early in the evolution of bacteria, and 
suggests that the two populations have developed different networks to facilitate allosteric 
regulation using the same structural scaffold.  
6.4 The preservation of catalysis does not mean the preservation of allostery  
 
Alanine mutations in NmeIPMS of residues in the potential allosteric network have been made. 
The Arg470Ala and Arg32Ala mutants were insensitive to inhibition by leucine, although ITC 
showed that leucine was still bound by these proteins. Additionally, another mutant, Glu298Ala, 
was made, based on that residue’s presence in this network, which did not have substantial changes 
in kinetic parameters compared to the wild type protein yet showed a significant decrease in 
sensitivity to inhibition by leucine. This suggests that the network of residues determined by SCA 
may indeed be involved in allosteric signal transmission. Fusion proteins were constructed to 
determine whether allostery could be transferred by fusion of a regulatory domain to the catalytic 
unit of NmeIPMS. However, although these fusions were catalytically active, they did not show 
regulation by their respective amino acids. As the regulatory domains were obtained from proteins 
considerably evolutionarily distinct from NmeIPMS, it seems likely that there is a substantial 
difference in the network of residues that confer allosteric regulation between the two proteins, 
and therefore allosteric regulation was not able to be transferred.  
To explore these fusions further, different fusions could be made such as between MjaCMS and 
NmeIPMS, as these proteins share a much closer evolutionary relationship than between LinCMS 
and NmeIPMS, so the network may be maintained between the two proteins. Alternatively, or 
additionally, mutations could be made in the current fusions to attempt to re-establish allosteric 
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regulation once it had been determined by ITC whether the allosteric ligand is binding the fusion 
protein. To further explore the networks of residues identified in Chapter 3 as important for the 
maintenance of catalysis in the presence and absence of a regulatory domain, mutations could be 
made in NmeIPMS, the truncated form of NmeIPMS, or a modern IPMS that lacks a regulatory 
domain, to determine how changes to this network affect the catalytic activity of the protein, and 
the dynamics of the subdomains.  
6.5 Other avenues in the study of these proteins 
 
There are several additional ways by which the dynamics of NmeIPMS in particular could be 
explored more fully. These include using techniques such as single molecule FRET that would 
allow for direct detection of the dynamics of this protein. The dynamics could also be explored 
through a variety of NMR techniques such as H/D exchange as performed with MtuIPMS78, to 
determine whether the pathway identified by SCA is identifiable by this method. It could also be 
of considerable interest to perform a SCA on IPMS from Actinobacteria (i.e. the MtuIPMS-like 
IPMSs) and assess whether any network suggested by that technique is similar to the network 
identified by Frantom et al.78 using H/D exchange. 
Another technique that allow for further exploration of the evolution of these proteins is ancestral 
protein reconstruction. This technique takes modern sequences and, through the construction of 
a multiple sequence alignment, the construction of a phylogenetic tree, and reconstruction of 
ancestral sequences using algorithms. The resulting sequences can then be made into synthetic 
genes and the proteins expressed, purified, and analysed as modern proteins are. This technique 
could be the ultimate exploration into the evolution of these proteins and their dynamics. The 
putative leuA from Pyrococcus horikoshii has also been suggested to code for a bifunctional IPMS and 
HCS, and also lacks a regulatory domain.95 The characterisation of this protein may be a unique 
way to compare functionality with reconstructed ancestral proteins or with more specialised extant 
enzymes.  
6.6 Conclusion  
 
The evolution of protein dynamics is of interest currently as the change in dynamics in response 
to ligand binding is a comparatively unexplored way by which antibiotic resistance can develop.  
There are major challenges to investigating dynamics in extant proteins, and new technology may 
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enable further, deeper, study in the future. This project utilised several techniques to investigate 
how these very mobile proteins maintained the trade-off between flexibility and stability to 
confer catalysis, and allostery may alter the dynamics of the proteins in the absence of a 
conformational change. It is clear that the networks of residues involved in maintaining catalysis 
and allostery are intertwined and untangling these networks, and how they have evolved, is a 







Materials and methods 
Water 
All buffers and solutions were made up with water purified with a Millipore Milli-Q system prior 
to use.  
pH determination  
pH of solutions and buffers was determined using a Mettler Toledo™ S220 SevenCompact™ 
pH/Ion meter. The pH was altered as required using NaOH or HCl solutions.  
Structural images of proteins 
Structural representations of proteins were generated using the PyMOL Molecular Graphics 
System (version 1.8.2.1, Schrödinger, LLC)182. 
Media  
All E. coli cultures were grown in lysogeny broth (LB) at 20 gL-1 made up to volume with Milli-Q 
water and sterilised by autoclave prior to use. Antibiotics were added as required once the media 
had cooled and prior to use. Agar plates were made using LB media and agar (Miller’s, 37 gL-1) 
made up with Milli-Q and sterilised by autoclave. Following sterilisation, appropriate antibiotics 
were added once the media had cooled and prior to the plates being poured. SOC media used for 
transformation was made up of 2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 
mM KCl and 10 mM MgCl2 dissolved in Milli-Q and sterilised by autoclave. 20 mM of filter-
sterilised glucose was added once the media had cooled. SOC was stored at -20 °C in aliquots until 
required.  
Cloning  
The construct of NmeIPMS described by Huisman64 was used as the template for the construction 
of site-directed mutants and also for the construction of fusion proteins. The construction of 




Polymerase chain reaction 
PCR for cloning purposes was performed using Phusion® polymerase under standard reaction 
conditions unless otherwise specified. Colony PCR was performed using Taq polymerase (Roche) 
under standard reaction conditions. PCR was performed in a Veriti® 96-well Thermal Cycler 
(Applied Biosystems) or in an iCycler (BioRad).  
Lyophilised primers for PCR or site-directed mutagenesis were purchased from Invitrogen. The 
primers were dissolved to the desired concentration in sterile Milli-Q or TE buffer (10 mM Tris, 
0.1 mM EDTA, pH 8.0).  
InFusion cloning  
InFusion cloning was used for cloning genes into vectors in this project. This procedure utilises a 
proprietary enzyme mixture to clone inserts into vectors with directionality by fusing a 15 bp 
overlap on the ends of the linear insert to the corresponding sequence in a linearised vector. The 
vectors used were pET21a or pET28a and were linearised by digestion with restriction enzymes 
and the linear vector was gel purified using the Nucleospin® Gel and PCR Clean-up kit (Clontech). 
The ligation reaction was performed under conditions described in the InFusion HD Cloning Kit 
User Manual. The ligation mixture was then transformed as described below. 
Glycerol stock 
Glycerol stocks were made using cultures that had been grown overnight at 37°C. A stock solution 
of 50% glycerol and 50% Milli-Q water was sterilised by autoclave prior to use. 500 µl of overnight 
culture and 500 µl of the stock glycerol solution were mixed in a sterile Eppendorf tube and flash 
frozen. The glycerol stocks were stored at -80°C.  
Agarose gel electrophoresis 
Agarose gels were prepared by mixing 1% (w/v) powdered agarose (Seakem) with TAE buffer (50 
mM Tris, 20 mM acetic acid, and 1 mM EDTA), followed by heating until the agarose powder had 
dissolved. SYBR® Safe gel stain (Invitrogen) was then added at the standard concentration before 
the gel was cast. Samples were mixed with gel loading buffer (60 mM Tris-HCl, 60 mM EDTA, 
0.2% (w/v) Orange G, 0.05% (w/v) xylene cyanol FF, 60% (v/v) glycerol) prior to being loaded 
into the gel’s wells. Gels were typically run at 100 V for 30 minutes or until the dye front had 
reached a desired position.  
 
If the PCR product was to be used for further cloning, the E-Gel® Safe Imager™ 
Transilluminator was used to visualise the bands. The band(s) of interest were excised and 
purification of the DNA was performed using the Nucleospin® Gel and PCR Clean-up kit 
(Clontech). 
Synthetic genes 
The SpoHCS gene was obtained as a synthetic gene from GeneArt and was codon-optimised for 
expression in E. coli. PCR was used to amplify the gene in the initial generic GeneArt vector, using 
the primers specified in Materials Table 0.1. The gene was subsequently sub-cloned into pET28a 
using the InFusion® HD cloning kit (Clontech) at the NdeI and XhoI sites in the MCS of pET28a. 
Primers were designed with a 15 bp overlap to allow for use of this technique. The plasmid map 
of the SpoHCS construct is located in Appendix III. 
Genes cloned from genomic DNA 
The SsoHCS gene (Sso leuA-2) was amplified from Sso genomic DNA using standard Phusion® 
PCR techniques. As with the SpoHCS gene, primers used for PCR amplification included a 15 bp 
overlap to allow for use of the InFusion HD cloning kit. The SsoHCS gene was cloned into pET28a 
at the NheI and XhoI sites.  The plasmid map for the SsoHCS construct is located in Appendix 
III. 
Transformation  
Following the ligation reaction using the InFusion HD cloning kit or the site-directed mutagenesis 
reaction, part of the ligation/mutagenesis mixture was transformed into chemically competent 
Stellar™ E. coli cells. These cells were either provided as commercial chemically competent cells 
or were made chemically competent using the standard CaCl2 method.  The ligation mixture was 
added to a 100 µL aliquot of cells for 30 minutes on ice, followed by a 45 second heat shock at 
42°C. Following heat shock, 500 µl of SOC media was added, and the mixture was shaken at 37° 
for an hour. The mixture was then plated on solid agar plates with appropriate antibiotics added, 
and were incubated overnight at 37°C.  
  
 
Materials Table 0.1: Primers designed and used in this project. The complete protein sequences for the fusion constructs are 
located in Appendix IV, 
 
Enzyme Primer 5’ to 3’ 
NmeIPMS point mutations 
NmeIPMS Glu298Ala Forward CAATGCCTTTTCGCATGCATCGGGCATCCATCAG 
 
NmeIPMS Glu298Ala Reverse CTGATGGATGCCCGATGCATGCGAAAAGGCATTG 
 
NmeIPMS Arg371Ala Forward GAACTCGCCGACAAAAAAGCCGAAATCTTCGATGAAG 
NmeIPMS Arg371Ala Reverse CTTCATCGAAGATTTCGGCTTTTTTGTCGGCGAGTTC 
NmeIPMS truncation 
NmeIPMS K395Term Forward CATGAATGCCGAGAGCTACTAATTCATCTCCCAAAAAATC 
NmeIPMS K395Term Reverse GATTTTTTGGGAGATGAATTAGTAGCTCTCGGCATTCATG 
NmeIPMS fusions 
pET21a – His6 tag overlap 
primer for use with InFusion 
cloning 
AAGGAGATATACATACATCATCACCATCACCATG 
His6-tag and TEV site for 
cloning into pET21a 
CATCATCACCATCACCATGAAAACCTGTATTTTCAGGGCAGCGGCG
CG 
NmeIPMS Forward CAGGGCAGCGGCGCGATGACACAGACCAACCGCG 
































Colonies were screened to assess whether the insert had been ligated into the vector using a gene 
specific primer and a vector specific primer in a standard Taq polymerase PCR reaction. Part of a 
colony from an agar plate was used as the template for the reaction. Gel electrophoresis, using 
agarose gel stained with SYBR® Safe, was used to determine if the insert had been ligated into the 
vector correctly.  
Plasmid extraction and sequencing 
A single colony, or part of a colony if said colony had been determined to contain a plasmid with 
the insert correctly inserted into the vector, was selected from an agar plate and used to inoculate 
a 5 mL culture of liquid LB media. The culture was grown overnight at 37°C with shaking. A 
glycerol stock was then made from the overnight culture and was stored at -80°C. From the 
remaining culture, the plasmid was extracted using the ZR Plasmid Miniprep kit (Zymo Research) 
or the High Pure Plasmid Isolation Kit (Roche). Plasmid concentrations were determined by the 
absorbance at 260 nm using a NanoDrop® ND-1000 spectrophotometer. Plasmids were 
sequenced by Macrogen (Korea), the Canterbury Sequencing Facility (University of Canterbury), 
or the Massey Genome Service (Massey University).  
Protein expression and purification 
As the vectors used in this study were all pET-based vectors, BL21*(DE3) E. coli chemically 
competent cells were used for transformation of the purified plasmid after the mutation or insert 
had been confirmed as correct by sequencing. The pET vectors contain a T7 promotor that 
controls the expression of the gene of interest, while BL21*(DE3) E. coli cells contain a λDE3 
lysogen that has the gene for a T7 RNA polymerase under the control of a lac promoter. Upon 
induction by isopropyl β-D-1-thiogalactopyranoside (IPTG), the T7 RNA polymerase is expressed 
and allows the expression of the gene of interest under the control of the T7 promoter.   
Protein expression strain creation 
Chemically competent BL21*(DE3) cells were transformed with the plasmid of interested as 
detailed above. Following isolation of individual colonies on agar plates, an overnight or pre-





Pre-culture of 20 – 100 mL of LB media with appropriate antibiotics were inoculated with the 
expression cell strain of interest and was grown overnight at 37°C with shaking. A pre-culture was 
then added to a large culture (1 L of LB media with appropriate antibiotics in a 2 L baffled flask). 
Large cultures were then grown at 37°C with shaking until the optical density OD at 600 nm 
(OD600) had reached 0.4 – 0.8 AU.  IPTG was then added to the cultures to a final concentration 
of 0.5 mM.  Cultures were then grown overnight at 23°C with shaking, or for 4 hours at 37°C with 
shaking.  
Large cultures were harvested by centrifugation using 1 L bottles in a FiberliteTM F9-6x1000 LEX 
fixed-angle rotor (ThermoFisher Scientific). The cells were pelleted at 14000g for 30 mins at 4°C. 
The cell pellets were subsequently stored in sterile 50 mL tubes at -80°C until required.  
Cell lysis  
Cell lysis was performed using a Omni-Ruptor 4000 Ultrasonic Homogeniser sonicator with 4–6 
repeats of 5 minutes at 70% power with a pulse of 50%. The cell pellet was re-suspended in 20 – 
40 mL of cold lysis buffer and lysis was performed on ice. Benzonase® was added to the lysate 
prior to centrifugation at 40000 g for 45 minutes. The buffers used for purification of specific 
proteins are detailed in Materials Materials Table 0.2, Materials Materials Table 0.3, and Materials 
Materials Table 0.4. 
Fast protein liquid chromatography (FPLC) 
FPLC was performed at 4°C using a Bio-Rad Biologic Protein Chromatography system or an 
ÄKTApurifierTM (GE Healthcare). Buffers were filtered through a 0.2 µm filter and cooled to 4°C 
prior to use. Protein lysate was also filtered through a 0.2 µm filter prior to loading into a 
Superloop™(GE Healthcare).  
Immobilised metal affinity chromatography was performed as the first purification step. The 5 mL 
HisTrap column was equilibrated with equilibration buffer after the storage solution of 20% 
ethanol (v/v) had been removed. The sample was then loaded onto the column, the sample was 
washed with equilibration buffer to removed non-specific binding, and a gradient from 20 mM 
imidazole to 500 mM imidazole was used to elute the protein of interest from the column as 2 mL 
fractions. The purification was followed by tracking absorbance at 280 nm, and fractions that 
 
showed absorbance during elution were analysed by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE).  
Following IMAC, the protein was concentrated by centrifugation using a Vivaspin™ 20 mL 10 
kDa cut-off concentrator. Once the protein had reached the appropriate volume or concentration, 
the protein was loaded onto a HiLoadTM 26/60 SuperdexTM 200 prep grade size exclusion column 
that had been equilibrated into the appropriate SEC buffer. The protein was then eluted from the 
column with a column volume of SEC buffer and was collected as 2 mL aliquots. As with the 
IMAC, the progress of the purification was followed by tracking the absorbance at 280 nm, and 
fractions that showed substantial absorbance at 280 nm were analysed by SDS-PAGE.  
The purified protein was then stored as 50 – 500 µL aliquots at a concentration of 1 – 10 mg.mL-
1 at -80°C after being flash frozen in liquid nitrogen.  
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed using a precast Bolt® 10% Bis-Tris Plus gel (Invitrogen). All gels were 
run in MOPS and were run at 200 V for 30 minutes.  Protein samples were prepared as described 
in the product manual. Gels were stained using a heated solution of 10% (v/v) glacial acetic acid, 
and 40% (v/v) methanol and 0.1% (w/v) Coomassie Brilliant Blue R-250 until the gel was 
sufficiently stained. Gels were then de-stained using a heated solution of 10% (v/v) glacial acetic 
acid and 40% (v/v) methanol until bands of interest were appropriately visible.  
Determination of protein concentration 
The approximate extinction co-efficient of the protein of interest was determined using the 
ProtParam tool on the ExPASy server.183 Protein concentration was approximated using these 
values and the absorbance at 280 nm measured using a Nanodrop® ND-1000 spectrophotometer.  
Enzyme kinetic assays  
The assay used for determination of enzyme kinetics was the previously described assay using 4’-
4’-dithiopyridine (DTP) to detect the formation of CoA at 324 nm (ε = 1.98 x 104 M-1cm-1).1, 74, 79 
The assays were performed in stoppered quartz cuvettes with a path length of 1 cm, and the data 
was collected using a Varian Cary 100 UV-visible spectrophotometer at 25°C for all proteins aside 
from SsoHCS, where the temperature used was 60°C. Measurements were made in duplicate. 
 
The buffer used for kinetic experiments was 50 mM HEPES, pH 7.5, 20 mM KCl and 20 mM 
MgCl2. Stock solutions of substrates at 50 mM were used as required to achieve the concentration 
required. The stock solution of AcCoA was stored at -80°C. Typically, the buffer, AcCoA, DTP, 
and enzyme at the concentration required were added to the cuvette, and once the residual CoA 
had reacted with the DTP, the reaction was initiated with the addition of the other substrate 
(KIV/KG).  
Inhibition data was obtained using the standard enzyme assay with different concentrations of 
inhibitor. The concentration of substrates was held at saturating concentrations for the enzyme of 
interest.   
The concentration of substrates was also determined using this assay. A limiting amount of one 
substrate was added to the assay while the other substrate was held in excess. As with the enzyme 
assays, the buffer, DTP, AcCoA, and enzyme were added to the cuvette first and the reaction was 
initiated by the addition of the other substrate once there was no change in absorbance caused by 
excess CoA due to hydrolysis of AcCoA to CoA. The change in absorbance was measured, and 
this was used to calculate the concentration of the limiting substrate using the Beer-Lambert Law. 
The extinction coefficient of the reaction product is 1.98 x 104 M-1cm-1. 
Differential scanning fluorimetry (DSF) 
DSF was performed using a iCycler iQ5 Multicolor Real-Time PCR Detection System (Bio-Rad) 
to determine the melting temperatures (Tm) of proteins of interest. Protein samples (0.1 mg.mL
-1) 
were mixed with SEC buffer and SYPRO® Orange protein gel stain in the presence of substrate 
(250 µM KIV or KG) or inhibitor (1 mM L-Leu, L-Ile, or L-Lys). Controls that included buffer 
instead of the protein sample were also prepared. The temperature increased at a rate of 
1°C/minute from 20° to 98°C. Fluorescence was measured at 0.5°C intervals. The controls were 
subtracted from the protein samples to remove background fluorescence.  The Tm was derived 
from the inflection point of the sigmoidal graph on a plot of the fluorescence intensity as a function 
of temperature.  
Analytical size exclusion chromatography (analytical SEC) 
Analytical SEC was used to assess the oligomeric state of NmeIPMS K395Term. As detailed in 
Chapter 4.1.4, several different buffers were used as the oligomeric state of NmeIPMS 
K395Term was affected by the concentration of salt in the buffer. A Superdex™ 200 10/300 
GL column (GE Healthcare) was used to perform analytical SEC. The column was equilibrated 
 
in the buffer required, and protein samples or protein standards at 1 mg/mL-1 unless stated 
otherwise were injected onto the column in a volume of 500 µL. Blue dextran was used to 
calculate the void volume of the column. Bovine serum albumin (BSA, 66 kDa), apoferritin (443 
kDa), cytochrome c (12.4 kDa), β-amylase (200 kDa), and coalbumin (75 kDa) were used as 
known molecular weight standards. The elution volume for the protein of interest and the 
molecular weight standards were all recorded, and a linear graph of the log[protein standard mass 
(Da)] against the elution volume of the standard was obtained. From this, the oligomeric state of 
the protein of interest could be approximated.   
Small-angle X-ray scattering (SAXS) 
Small-angle X-ray scattering data was obtained for wild-type NmeIPMS and NmeIPMS 
K395Term. Measurements were obtained at the Australian Synchrotron SAXS/WAXS beamline 
equipped with a Pilatus detector. The wavelength of the X-rays was 1.0332 Å and the sample-
detector distance was 1.6 m.  
Scattering data for the proteins of interest was obtained following elution from a Superdex® 200 
Increase 5/150 size-exclusion column that had been equilibrated in the NmeIPMS SEC buffer. 
This buffer also had the addition of 250 µM KIV or 1 mM L-Leu or 200 µM L-Leu as 
appropriate for the experiment in particular. All buffers also had 5% glycerol added to limit 
radiation damage. 
Raw data was processed, and the background was subtracted, using Scatterbrain (Australian 
Synchrotron). The scattering from peaks that showed substantial absorbance at 280 nm were 
summed and averaged. Plots of scattering intensity (I) versus s and Guinier plots were generated 
using Primus.184 The plots were assessed for increasing intensity at low s that is indicative of 
aggregation. Indirect Fourier transform was performed using GNOM to generate the P(r) 
function.185 Crysol was used to generate theoretical scattering curves for the NmeIPMS homology 
model and other models produced by molecular dynamics simulations.157 
X-ray crystallography trials 
Attempts were made to crystallise NmeIPMS K395Term in the presence and absence of KIV. A 
Mosquito® Crystal robot (TTP Labtech) was used to screen for potential conditions in which 
the protein would crystallise using the sitting-drop vapour diffusion technique. The screen 
conditions tested were PACT premier™ HT-96, Clear Strategy™ I HT-96 and Clear Strategy™ 
II HT-96, and JCSG-plus™ HT-96 (Molecular Dimensions). Protein concentrations of 5 – 30 
 
mg.ml-1 were tested, and the ligand, if added, was added to the protein prior to the protein being 
mixed with the condition. 400 nL of protein sample was mixed with 400 nL of the condition of 
interest, and 40 nL of this was used as the reservoir.  
Isothermal titration calorimetry (ITC) 
ITC was performed using a Nano ITC Low Volume (TA Instruments). Experiments were 
performed at 25°C unless otherwise specified. Purified protein samples of 400 µL at 10 – 15 
mg.ml-1 were de-gassed and injected into the cell after the cell had been washed with de-gassed 
buffer from the same batch that the protein was purified in. The ligand solution was made up in 
the same buffer. The syringe was washed with de-gassed buffer and then de-gassed ligand 
solution before the ligand sample was loaded into the syringe. 2 µL of ligand was injected into 
the sample cell every 200 s. ITC parameters were determined using the NanoAnalyze software 
(TA Instruments). 
Multiple sequence alignments 
Sequence populations were obtained from KEGG172-174, Pfam114, 115, the NCBI Protein database, 
and PSI-BLAST101. CD-HIT or the CD-HIT online webserver was used to filter the sequence 
populations to remove redundancy.125, 186 Multiple sequence alignments were performed using the 
MAFFT online server.187 The choice in algorithm is detailed in Chapter 2.2.3. MSAs were 
visualised using Jalview and were manually edited to remove aberrant sequences from the 
alignments.188  
Cluster Analysis of Sequences (CLANS)  
CLANS was performed on different sequence populations.126 As described in Chapter 2.2.2, 
CLANS uses an all versus all BLAST search to calculate pairwise attraction values, and these 
values are then used to create a force-directed graph to observe clusters of sequences depending 
on their relationship to each other. The input is sequences in FASTA format and clustering can 
be performed using a variety of methods. Network-based clustering with a minimum of 10 
sequences per cluster was typically used to determine the clusters in the sequence population. 
The different clusters were then analysed to investigate which sequences were contained within 
the clusters to assign them to a known group within the sequence populations.  
Statistical coupling analysis (SCA) 
 
The SCA was performed in MATLAB using sca5.m. Trimming of the MSA and further steps 
were performed as described in Chapters 2 and 3.  
Mutual information (MIp) 
Covariance analysis using MIp was performed as described in Chapter 3, using Linux Ubuntu 
16.04 and The MIp Toolset.144 A coevolution network file was produced and visualised using 
Graphviz.189 The dist_pdb programme within the MIp toolset was used to obtain the distances 
between atoms in the NmeIPMS homology model PDB file. BioPython and code adapted from 
https://warwick.ac.uk/fac/sci/moac/people/students/peter_cock/python/protein_contact_ma
p/ was used to generate contact maps using these distances.190 The graphical images were 




Materials Table 0.2: Buffers used for the purification of NmeIPMS and variants 
 
Buffers used for the purification of NmeIPMS and variants 
 
Buffer Other components Uses 
50 mM potassium 
phosphate, pH 8.0 
300 mM KCl, 20 mM 
imidazole 
Lysis, and equilibration for HisTrap 
50 mM potassium 
phosphate, pH 8.0 
300 mM KCl, 500 mM 
imidazole 
HisTrap elution 
50 mM HEPES, pH 7.5 20 mM KCl, 20 mM 
MgCl2  
5% (v/v) glycerol (SAXS) 
0 – 30% (v/v) glycerol 
(viscosity-dependent 
kinetics) 
HiLoadTM 26/60 SuperdexTM 200 prep grade 
column size exclusion chromatography buffer.  
This buffer was also used for SAXS, kinetics, and 
ITC for NmeIPMS and mutants as detailed. 
 
10 mM Tris, pH 8.0 300 mM KCl SuperdexTM 200 10/300 GL column size 
exclusion buffer 
 Used for analytical SEC. 
 
Materials Table 0.3: Buffers used for the purification of SpoHCS and variants 
 
Buffers used for the purification of SpoHCS and variants 
 
Buffer Other components Uses 
50 mM sodium phosphate, 
pH 7.0 
500 mM NaCl, 20 mM 
imidazole 
Lysis, and equilibration for HisTrap 
50 mM sodium phosphate, 
pH 7.0 




Materials Table 0.4: Buffers used for the purification of SsoHCS 
 
Buffers used for the purification of SsoHCS 
 
Buffer Other components Uses 
50 mM Tris, pH 8.5 100 mM NaCl, 20 mM 
imidazole 
Lysis, and equilibration for HisTrap 
50 mM Tris, pH 8.5 100 mM NaCl, 500 mM 
imidazole 
HisTrap elution 






Appendix I  
Residues (NmeIPMS numbering) within the independent components identified in Chapter 3 






























































































































Appendix II  
Residues (NmeIPMS numbering) within the principal component of the RDA alignment 
identified in Chapter 3 
Principal component residues 


























































NmeIPMS and SpoHCS fusions 
 The part of the fusion protein that is from NmeIPMS is coloured blue, the part that is from 
SpoHCS is coloured in purple.  
SpoHCSCat-SI – NmeIPMS SII-Reg contains SpoHCS from residue 1 to 351 (SpoHCS numbering) and 













SpoHCScat – NmeIPMSSDs-Reg contains SpoHCS from residue 1 to 413 (SpoHCS numbering) and 
















NmeIPMS and LinCMS fusion  
The part of the fusion protein from NmeIPMS, from residue 1 to 388 (NmeIPMS numbering) is 
coloured blue. The part of the fusion protein from LinCMS, from residue 388 to 516 (LinCMS 















NmeIPMS and SsoHCS fusion 
 
The part of the fusion from NmeIPMS, from residues 1 to 394, is coloured in blue. The part of 
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